Method for reducing CST fluctuation in neovascular AMD by recombinant adeno-associated virus

By applying rAAV particles encoding anti-VEGF agents to the eyes, the problems of frequent injections of anti-VEGF agents and large fluctuations in retinal fluid are solved, and the retinal treatment effect with long-term stability and low side effects is achieved.

CN118946370APending Publication Date: 2024-11-12ADVERUM BIOTECHNOLOGIES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380031028.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-04
Filing Date
2023-02-14
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing anti-VEGF agent treatment methods require frequent intravitreal injections, resulting in low patient compliance, increased side effects and large fluctuations in retinal fluid, affecting visual acuity.

Method used

Single unit dose of recombinant adeno-associated virus (rAAV) particles carrying genes encoding anti-VEGF agents are used to reduce fluctuations in retinal fluid and central retinal thickness.

Benefits of technology

Long-term stability is achieved, reducing the accumulation of retinal fluid and fluctuations in visual acuity, reducing side effects, extending treatment intervals, and improving patient compliance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118946370A_ABST
    Figure CN118946370A_ABST
Patent Text Reader

Abstract

There is provided a method for treating an ocular neovascular disease in a subject by reducing fluctuations in central concave thickness (CST) or central retinal thickness (CRT), comprising administering to an eye of the subject a unit dose of a recombinant adeno-associated virus (rAAV) particle wherein the rAAV particle comprises: a) a nucleic acid encoding a polypeptide and flanking an AAV2 inverted terminal repeat (ITR), the present invention relates to a polypeptide comprising an amino acid sequence having at least about 95% identity to the amino acid sequence of SEQ ID NO: 35, and b) an AAV2 capsid protein comprising the amino acid sequence LGETTRP (SEQ ID NO: 14) interposed between positions 587 and 588 of the capsid protein wherein the amino acid residue number corresponds to the AAV2 VP1 capsid protein.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority under 35 USC §119(e) to U.S. Provisional Application No. 63 / 310,865, filed on February 16, 2022, and U.S. Provisional Application No. 63 / 316,705, filed on March 4, 2022, each of which is incorporated by reference in its entirety.

[0003] Statement regarding sequence listing

[0004] An official copy of the sequence listing is filed with this specification, the official copy being an XML file in WIPO standard ST.26 format, with the file name "17234-034WO1.xml", the creation date being February 6, 2023, and the size being 49 kilobytes. This sequence listing, filed via the USPTO Patent Center, is part of this specification and is incorporated herein by reference in its entirety. Technical Field

[0005] The present disclosure relates to methods of treating ocular neovascular diseases and conditions in an individual by reducing fluctuations in central subfield thickness (CST) or central retinal thickness (CRT), the methods comprising administering to the eye of the individual a single unit dose of recombinant adeno-associated viral (rAAV) particles encoding an anti-VEGF agent (e.g., aflibercept). Background Art

[0006] Age-related macular degeneration (AMD) is a degenerative eye disease that affects the macula, a small, light-sensitive area in the center of the retina that is responsible for reading and fine vision. Diseases affecting the macula reduce central vision while leaving peripheral vision intact. In severe cases, the disease can lead to central blindness. AMD is a significant cause of vision loss in the United States among people aged 65 and older, and the estimated prevalence of any AMD in people over 40 is approximately 6.5% (Klein et al., (2011) Arch Ophthalmol, 129(1):75-80). Neovascular or exudative or wet AMD (nAMD, wAMD or nwAMD) is a late form of AMD. The hallmark of wAMD is choroidal neovascularization (CNV), which is the infiltration of abnormal blood vessels from the underlying choroidal layer into the retina, leading to retinal cell damage and central blindness. This abnormal angiogenesis process is regulated by growth factors, particularly vascular endothelial growth factor (VEGF). The standard of care for wAMD is a class of molecules that bind to and sequester VEGF, such as ranibizumab (Lucentis) and aflibercept (Eylea).

[0007] Diabetic retinopathy (DR) is a major complication of diabetes and is the leading cause of vision loss in the working age population. DR can be non-proliferative DR (NPDR), with no new blood vessel growth, or proliferative DR (PDR), with new, abnormal blood vessel growth in the retina or choroid. Diabetic macular edema (DME) is a complication of DR and is an example of another eye disease that affects the macula. DME affects up to 10% of people with diabetes and is caused by a buildup of fluid in the macula. DME is the most common cause of vision loss in people with DR. Available therapies for treating DME include lasers and anti-vascular endothelial growth factor (anti-VEGF) drugs, such as aflibercept.

[0008] Aflibercept is a recombinant fusion protein that acts as a decoy receptor for vascular endothelial growth factor isoforms A and B (VEGF-A and VEGF-B) and placental growth factor (PGF). By binding to these ligands, aflibercept prevents them from binding to the vascular endothelial growth factor receptors (VEGFRs) VEGFR-1 and VEGFR-2, inhibiting neovascularization and reducing vascular permeability. Aflibercept consists of a fusion of domain 2 of VEGFR-1 and domain 3 of VEGFR-2 with the Fc fragment of IgG1.

[0009] Central subfield thickness (CST) is a measurement of the thickness of the macula, the central subfield area surrounding the fovea. In nAMD, fluid accumulation increases the CST. Previous studies and treatments have shown a correlation between CST fluctuations and visual acuity.

[0010] Previous studies based on clinical trial data have shown that greater retinal thickness fluctuations during intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for neovascular age-related macular degeneration (nAMD) are associated with poorer visual acuity results (Lai et al. J. Pers. Med. 2021, 11, 1024). Lai et al. confirmed that in intravitreal anti-VEGF therapy (bevacizumab, ranibizumab or aflibercept) for the treatment of nAMD, the variability of spectral domain optical coherence tomography (OCT) was used to calculate the central subfield thickness (CST), and a significant correlation was found between CST variability and visual acuity at 2 years, indicating that eyes with lower CST variability had better visual acuity at 2 years. Eyes with the least CST variability were associated with the highest mean visual acuity improvement at 2 years. These findings suggest that eyes that undergo anti-VEGF therapy for nAMD during follow-up and have the most stable OCT CST variability are associated with better visual outcomes. Thus, data from the Comparative AMD Treatment Trial (CATT) and the Inhibition of VEGF in Age-Related Choroidal Neovascularization (IVAN) trial suggest that larger CST fluctuations are associated with an increased risk of fibrosis and macular atrophy, which may contribute to worse visual acuity (VA).

[0011] Current standard-of-care anti-VEGF agents, such as aflibercept, require re-administration via intravitreal (IVT) injection every 4 to 8 weeks to achieve optimal treatment outcomes and maintain visual acuity. Adherence to this regimen is burdensome for patients, their caregivers, and the healthcare system, and most patients no longer adhere to the optimal regimen over time, which is associated with vision loss (Khanani AM et al.). In addition, there are complications, including endophthalmitis, retinal detachment, traumatic cataracts, and increased intraocular pressure (IOP); the risk of these complications may increase with repeated IVT injections (Falavarjani et al., (2013) Eye (Lond), 27(7):787-794).

[0012] There is a need in the art for therapies for ocular neovascular diseases such as wAMD, DR or DME that are effective, reduce the risk of side effects and are suitable for high long-term patient compliance. In this regard, there is also a need in the art for a more effective method of reducing CST variability. Summary of the Invention

[0013] In one aspect, provided herein is a method for treating an ocular neovascular disease in a subject by reducing fluctuations in subfoveal thickness (CST), the method comprising administering to one eye of the subject approximately 6×10 11In some embodiments, the method comprises reducing retinal fluid in an eye of the individual.

[0014] In one aspect, provided herein is a method for treating an ocular neovascular disease in a subject by reducing fluctuations in subfoveal thickness (CST), the method comprising administering to one eye of the subject approximately 6×10 11 In some embodiments, the method comprises reducing retinal fluid in an eye of the individual.

[0015] In another aspect, provided herein is a method for reducing fluctuations in the CST in an eye of an individual with an ocular neovascular disease, the method comprising administering a unit dose of rAAV particles to one eye of the individual, wherein the individual is a human, and wherein the rAAV particles comprise: (a) a nucleic acid encoding a polypeptide flanked by AAV2 inverted terminal repeats (ITRs), the polypeptide comprising an amino acid sequence having at least about 95% identity to the amino acid sequence of SEQ ID NO: 35, and (b) an AAV2 capsid protein comprising or consisting of the amino acid sequence LGETTRP (SEQ ID NO: 14) inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to that of the AAV2 VP1 capsid protein. In some embodiments, the individual has received at least one treatment with an anti-VEGF agent within about the last 2 to 12 weeks prior to administration of the unit dose of rAAV particles. In some embodiments, the amount or presence of retinal fluid in one eye of the individual is refractory to prior treatment with an anti-VEGF agent. In some embodiments, the anti-VEGF agent is aflibercept. In some embodiments, the retinal fluid in one eye is reduced by at least about 60%. In some embodiments, the retinal fluid in one eye is reduced by about 80% compared to the level of retinal fluid in the individual's eye before administration of rAAV to the individual. In some embodiments, the retinal fluid is subretinal fluid (SRF) or intraretinal fluid (IRF). In some embodiments, the unit dose of rAAV particles is about 6×10 11 vector genomes / eye (vg / eye) or less.

[0016] In another aspect, provided herein is a method for treating an ocular neovascular disease in a subject by reducing fluctuations in the CST, the method comprising: (a) administering an anti-VEGF agent to one eye of the subject; and (b) administering approximately 6×10 11A unit dose of recombinant adeno-associated virus (rAAV) particles containing 1 vector genome (vg) or less, wherein the individual is a human, and wherein the rAAV particles comprise: (i) a nucleic acid encoding a polypeptide flanked by AAV2 inverted terminal repeats (ITRs), the polypeptide comprising an amino acid sequence having at least about 95% identity to the amino acid sequence of SEQ ID NO: 35, and (ii) an AAV2 capsid protein comprising the amino acid sequence LGETTRP (SEQ ID NO: 14) inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to that of the AAV2 VP1 capsid protein. In some embodiments, the method comprises administering a unit dose of rAAV particles to one eye of the individual about 1 week or about 7 days after administration of the anti-VEGF agent. In some embodiments, the method comprises administering a unit dose of rAAV particles to one eye of the individual about 1 week to about 2 weeks after administration of the anti-VEGF agent. In some embodiments, the method comprises administering a unit dose of rAAV particles to one eye of the individual about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, about 14 days, or about 15 days after administration of the anti-VEGF agent. In some embodiments, the method comprises administering an anti-VEGF agent to one eye of the individual on day 1 and administering a unit dose of rAAV particles to one eye of the individual on day 8. In some embodiments, the anti-VEGF agent comprises aflibercept. In some embodiments, aflibercept is administered by intravitreal injection at a dose of about 2 mg. In some embodiments, the method further comprises administering a topical steroid treatment. In some embodiments, the topical steroid treatment is difluprednate treatment. In some embodiments, the topical steroid treatment comprises administering the topical steroid about four times a day for about four weeks, followed by administering the topical steroid about three times a day for about one week, followed by administering the topical steroid about twice a day for about one week, and then administering the topical steroid about once a day for about one week; the time is measured from the start of and after the administration of the anti-VEGF agent. In some embodiments, the topical steroid treatment comprises administering the topical steroid about four times a day for about one month, followed by administering the topical steroid about three times a day for about one month, followed by administering the topical steroid about twice a day for about one month, and then administering the topical steroid about once a day for about one month; the time is measured from the start of and after the administration of the anti-VEGF agent. In some embodiments, the topical steroid treatment comprises administering the topical steroid about four times a day for about one month, followed by administering the topical steroid about three times a day for about one month, followed by administering the topical steroid about twice a day for about one month, and then administering the topical steroid about once a day for about one month; the time is measured from the start of and after the administration of the rAAV particles.In some embodiments, the topical steroid comprises difluprednate 0.05% at a dose of about 1 μg to about 3 μg. In some embodiments, the topical steroid comprises difluprednate 0.05% at a dose of about 2.5 μg.

[0017] In some embodiments that may be combined with any of the preceding embodiments, the unit dose of rAAV particles is about 6×10 10 to about 2×10 11 In some embodiments, the unit dose of rAAV particles is about 2×10 11 or about 6×10 10 In some embodiments that may be combined with any of the preceding embodiments, the unit dose of rAAV particles is about 6×10 10 to about 6×10 11 In some embodiments that may be combined with any of the preceding embodiments, the unit dose of rAAV particles is between about 6×10 10 to about 2×10 11 In some embodiments that may be combined with any of the preceding embodiments, the unit dose of rAAV particles is between about 2×10 11 to about 6×10 11 In some embodiments, the unit dose of rAAV particles is about 2×10 11 or about 6×10 10 In some embodiments, the unit dose of rAAV particles is about 2×10 11 vg / eye. In some embodiments, the unit dose of rAAV particles is about 6×10 11 vg / eyes.

[0018] In some embodiments that may be combined with any of the preceding embodiments, the individual has one or more symptoms of an ocular neovascular disease in the fellow eye.

[0019] In some embodiments that can be combined with any of the foregoing embodiments, the methods provided herein also include administering a unit dose of rAAV particles to the contralateral eye of an individual. In some embodiments, administering a unit dose of rAAV particles to the contralateral eye is at most about 2 weeks after administering a unit dose of rAAV particles to one eye. In some embodiments, administering a unit dose of rAAV particles to the contralateral eye is on the same day as administering a unit dose of rAAV particles to one eye; or administering a unit dose of rAAV particles to the contralateral eye is between about 1 day and about 14 days after administering a unit dose of rAAV particles to one eye. In some embodiments, the unit dose of rAAV particles administered to the contralateral eye of an individual comprises the same or less vector genomes / eyes (vg / eyes) compared to the unit dose of rAAV particles administered to one eye of an individual. In some embodiments, administering a unit dose of rAAV particles to the contralateral eye is at least about 2 weeks after administering a unit dose of rAAV particles to one eye. In some embodiments, a unit dose of rAAV particles administered to the contralateral eye of an individual comprises more vector genomes / eye (vg / eye) than a unit dose of rAAV particles administered to one eye of the individual.

[0020] In some embodiments that may be combined with any of the preceding embodiments, the nucleic acid comprises the nucleic acid sequence of SEQ ID NO: 40, or a sequence at least 85% identical thereto.

[0021] In some embodiments that may be combined with any of the preceding embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 35. In some embodiments that may be combined with any of the preceding embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 41. In some embodiments, the polypeptide is aflibercept.

[0022] In some embodiments that may be combined with any of the preceding embodiments, the nucleic acid further comprises a first enhancer region, a promoter region, a 5'UTR region, a second enhancer region, and a polyadenylation site. In some embodiments, the nucleic acid comprises, in 5' to 3' order: (a) a first enhancer region; (b) a promoter region; (c) a 5'UTR region; (d) a nucleic acid encoding a polypeptide comprising an amino acid sequence having at least about 95% identity to the amino acid sequence of SEQ ID NO: 35; (e) a second enhancer region; and (f) a polyadenylation site; and flanked by AAV2 inverted terminal repeats (ITRs). In some embodiments, the first enhancer region comprises a CMV sequence comprising a sequence of SEQ ID NO: 22 or a sequence having at least 85% identity thereto. In some embodiments, the promoter region comprises a CMV sequence comprising a sequence of SEQ ID NO: 23 or a sequence having at least 85% identity thereto. In some embodiments, the nucleic acid encoding the polypeptide comprises a nucleic acid sequence of SEQ ID NO: 40 or a sequence having at least 85% identity thereto. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO:35, or a sequence at least 85% identical thereto. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO:41, or a sequence at least 85% identical thereto. In some embodiments, the polypeptide is aflibercept. In some embodiments, the 5'UTR region comprises, in 5' to 3' order, a TPL sequence comprising the sequence of SEQ ID NO:24, or a sequence at least 85% identical thereto, and an eMLP sequence comprising the sequence of SEQ ID NO:25, or a sequence at least 85% identical thereto. In some embodiments, the second enhancer region comprises an intact EES sequence comprising the sequence of SEQ ID NO:26, or a sequence at least 85% identical thereto. In some embodiments, the polyadenylation site comprises the HGH polyadenylation site comprising the sequence of SEQ ID NO:27, or a sequence at least 85% identical thereto.In some embodiments, the nucleic acid further comprises (a) a first enhancer region comprising a CMV sequence comprising a sequence of SEQ ID NO: 22, or a sequence at least 85% identical thereto; (b) a promoter region comprising a CMV sequence comprising a sequence of SEQ ID NO: 23, or a sequence at least 85% identical thereto; (c) a 5'UTR region comprising, in 5' to 3' order, a TPL sequence comprising a sequence of SEQ ID NO: 24, or a sequence at least 85% identical thereto, and an eMLP sequence comprising a sequence of SEQ ID NO: 25, or a sequence at least 85% identical thereto; (d) a second enhancer region comprising an entire EES sequence comprising a sequence of SEQ ID NO: 26, or a sequence at least 85% identical thereto; and (e) an HGH polyadenylation site comprising a sequence of SEQ ID NO: 27, or a sequence at least 85% identical thereto. In some embodiments, the nucleic acid comprises an AAV ITR flanked by elements.

[0023] In some embodiments that may be combined with any of the preceding embodiments, the nucleic acid comprises the sequence of SEQ ID NO: 39, or a sequence at least 85% identical thereto.

[0024] In some embodiments that may be combined with any of the preceding embodiments, the rAAV particle comprises an AAV2 VP1 capsid protein comprising a GH loop comprising the amino acid sequence of SEQ ID NO: 38, or an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 38. In some embodiments, the rAAV particle comprises an AAV2 VP1 capsid protein comprising a GH loop comprising an amino acid sequence having any of at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 38.

[0025] In some embodiments that may be combined with any of the preceding embodiments, the rAAV particle comprises an AAV2 VP1 capsid protein comprising the amino acid sequence of SEQ ID NO: 37, or an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 37. In some embodiments, the rAAV particle comprises an AAV2 VP1 capsid protein comprising an amino acid sequence having any of at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 37.

[0026] In some embodiments that may be combined with any of the preceding embodiments, the AAV2 capsid protein comprises or consists of the amino acid sequence LGETTRP (SEQ ID NO: 14) inserted between positions 587 and 588 of AAV2 VP1 comprising the sequence of SEQ ID NO: 13. In some embodiments, the AAV2 capsid protein comprises the amino acid sequence LALGETTRPA (SEQ ID NO: 1) inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to that of the AAV2 VP1 capsid protein. In some embodiments, the AAV2 capsid protein comprises the amino acid sequence LALGETTRPA (SEQ ID NO: 1) inserted between positions 587 and 588 of AAV2 VP1 comprising the sequence of SEQ ID NO: 13. In some embodiments, the AAV2 capsid protein comprises the amino acid sequence LALGETTRPA (SEQ ID NO: 1) inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to that of the AAV2 VP1 capsid protein. In some embodiments, the AAV2 capsid protein comprises the amino acid sequence LALGETTRPA (SEQ ID NO: 1) inserted between positions 587 and 588 of AAV2 VP1 comprising the sequence of SEQ ID NO: 13.

[0027] In some embodiments that may be combined with any of the preceding embodiments, administering the unit dose of rAAV particles to one eye and / or the contralateral eye is by intravitreal administration.

[0028] In some embodiments that may be combined with any of the preceding embodiments, the unit dose of rAAV particles is in a pharmaceutical formulation. In some embodiments, the pharmaceutical formulation comprises rAAV particles, sodium chloride, sodium phosphate, and a surfactant. In some embodiments, the pharmaceutical formulation comprises about 150 to about 200 mM sodium chloride, about 1 to about 10 mM sodium dihydrogen phosphate, about 1 to about 10 mM sodium dihydrogen phosphate, about 0.0005% (w / v) to about 0.005% (w / v) poloxamer 188, and about 6×10 13 to about 6×10 10 rAAV particles containing vector genomes (vg) / mL (vg / mL), wherein the pharmaceutical formulation has a pH of about 7.0 to about 7.5. In some embodiments, the pharmaceutical formulation comprises about 180 mM sodium chloride, about 5 mM sodium dihydrogen phosphate, about 5 mM sodium dihydrogen phosphate, about 6×10 12vg / mL of rAAV particles and about 0.001% (w / v) poloxamer 188, wherein the pharmaceutical formulation has a pH of about 7.3. In some embodiments, the pharmaceutical formulation comprises about 180 mM sodium chloride, about 5 mM sodium dihydrogen phosphate, about 5 mM sodium dihydrogen phosphate, about 2×10 12 vg / mL of rAAV particles and about 0.001% (w / v) poloxamer 188, wherein the pharmaceutical formulation has a pH of about 7.3. In some embodiments, the pharmaceutical formulation comprises about 180 mM sodium chloride, about 5 mM sodium dihydrogen phosphate, about 5 mM sodium dihydrogen phosphate, about 6×10 11 vg / mL of rAAV particles and about 0.001% (w / v) poloxamer 188, wherein the pharmaceutical formulation has a pH of about 7.3.

[0029] In some embodiments that may be combined with any of the preceding embodiments, the unit dose of rAAV particles comprises a volume of about 25 μL to about 250 μL. In some embodiments, the unit dose of rAAV particles comprises a volume of about 100 μL. In some embodiments, the unit dose of rAAV particles comprises a volume of about 30 μL. In some embodiments that may be combined with any of the preceding embodiments, the unit dose of rAAV particles administered to one eye and / or the contralateral eye comprises a volume of about 25 μL to about 250 μL. In some embodiments, the unit dose of rAAV particles administered to one eye and / or the contralateral eye comprises a volume of about 100 μL. In some embodiments, the unit dose of rAAV particles administered to one eye and / or the contralateral eye comprises a volume of about 30 μL.

[0030] In some embodiments that may be combined with any of the preceding embodiments, the individual has received prior treatment for an ocular neovascular disorder with an anti-VEGF agent. In some embodiments, the individual has received one or two injections of an anti-VEGF agent in one eye and / or the contralateral eye prior to administration of rAAV particles in the one eye and / or the contralateral eye. In some embodiments, the individual has not received prior treatment for an ocular neovascular disorder with an anti-VEGF agent. In some embodiments, the anti-VEGF agent is aflibercept.

[0031] In some embodiments that may be combined with any of the preceding embodiments, the ocular neovascular disease is wet age-related macular degeneration (AMD), retinal neovascularization, choroidal neovascularization diabetic retinopathy, proliferative diabetic retinopathy, retinal vein occlusion, central retinal vein occlusion, branch retinal vein occlusion, diabetic macular edema, diabetic retinal ischemia, ischemic retinopathy, diabetic retinal edema, or any combination thereof.

[0032] In some embodiments that can be combined with any of the foregoing embodiments, a unit dose of rAAV particles is administered in combination with a steroid therapy. In some embodiments, the steroid therapy is a corticosteroid therapy. In some embodiments, the steroid therapy is a systemic steroid therapy. In some embodiments, the steroid therapy is an oral steroid therapy. In some embodiments, the steroid therapy is a prednisone therapy. In some embodiments, the oral prednisone therapy includes administering prednisone at a dose of about 60 mg per day for 6 days starting 3 days before administering a unit dose of rAAV particles to one eye and / or the contralateral eye, followed by administering prednisone at a dose of about 40 mg per day for 3 days, followed by administering prednisone at a dose of about 20 mg per day for 2 days, and then administering prednisone at a dose of about 10 mg per day for 2 days. In some embodiments, the steroid therapy is a topical steroid therapy. In some embodiments, the steroid therapy is difluprednate therapy. In some embodiments, the steroid is administered before, during, and / or after administration of the unit dose of rAAV particles. In some embodiments, the steroid is administered before, during, and / or after administration of the unit dose of rAAV particles to one eye and / or the contralateral eye.

[0033] In some embodiments that may be combined with any of the preceding embodiments, the steroid treatment is a topical steroid treatment, and the topical steroid treatment is a daily steroid treatment that lasts up to about 4 weeks, up to about 6 weeks, or up to about 8 weeks from the administration of the unit dose of rAAV particles. In some embodiments, the topical steroid treatment comprises administering the topical steroid about four times in about week 1, administering the topical steroid about three times in about week 2, administering the topical steroid about twice in about week 3, and administering the topical steroid about once in about week 4; timing from and after the administration of the unit dose of rAAV particles. In some embodiments, the topical steroid treatment comprises administering the topical steroid about four times a day after the administration of the unit dose of rAAV particles for about 3 weeks, followed by administering the topical steroid about 3 times a day for about 1 week, followed by administering the topical steroid about 2 times a day for about 1 week, and then administering the topical steroid about once a day for about 1 week. In some embodiments, the topical steroid treatment comprises applying the topical steroid about four times a day for about four weeks, followed by applying the topical steroid about three times a day for about one week, followed by applying the topical steroid about twice a day for about one week, and then applying the topical steroid about once a day for about one week; the timer starts about one week before the administration of the unit dose of rAAV particles. In some embodiments, the topical steroid treatment comprises applying the topical steroid about four times a day for about one month, followed by applying the topical steroid about three times a day for about one month, followed by applying the topical steroid about twice a day for about one month, and then applying the topical steroid about once a day for about one month; the timer starts about when the unit dose of rAAV particles is administered. In some embodiments, the topical steroid treatment comprises applying the topical steroid about four times a day for about one month, followed by applying the topical steroid about three times a day for about one month, followed by applying the topical steroid about twice a day for about one month, and then applying the topical steroid about once a day for about one month; the timer starts about one week before the administration of the unit dose of rAAV particles. In some embodiments, the topical steroid comprises difluprednate 0.05% at a dose of about 1 μg to about 3 μg. In some embodiments, the topical steroid comprises difluprednate 0.05% at a dose of about 2.5 μg.

[0034] In some embodiments, the ocular neovascular disease is wet age-related macular degeneration (wAMD).

[0035] In some embodiments that can be combined with any of the foregoing embodiments, the administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in maintenance or reduction of retinal thickness compared to the retinal thickness before the administration of a unit dose of rAAV particles. In some embodiments, the maintenance or reduction of retinal thickness is about 30 weeks, about 34 weeks, about 44 weeks, about 6 months, about 1 year, about 1.5 years, about 2 years, about 3 years, about 5 years, about 10 years or more after the administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual. In some embodiments, the administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a reduction in retinal thickness compared to the retinal thickness before the administration of a unit dose of rAAV particles. In some embodiments, the retinal thickness is reduced by at least about 10% compared to the retinal thickness before the administration of a unit dose of rAAV particles. In some embodiments, the retinal thickness is central subfield thickness (CST) or central retinal thickness (CRT).

[0036] In some embodiments that may be combined with any of the preceding embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in maintenance or reduction of macular volume compared to the macular volume before administration of the unit dose of rAAV particles. In some embodiments, maintenance or reduction of macular volume compared to the macular volume before administration of the unit dose of rAAV particles exists for about 30 weeks, about 34 weeks, about 44 weeks, about 6 months, about 1 year, about 1.5 years, about 2 years, about 3 years, about 5 years, about 10 years or more after administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a reduction in macular volume compared to the macular volume before administration of the unit dose of rAAV particles. In some embodiments, macular volume is reduced by at least about 10% compared to the macular volume before administration of the unit dose of rAAV particles.

[0037] In some embodiments that may be combined with any of the foregoing embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in maintenance or improvement of visual acuity compared to the visual acuity before administration of the unit dose of rAAV particles. In some embodiments, maintenance or improvement of visual acuity is present for about 30 weeks, about 34 weeks, about 44 weeks, about 6 months, about 1 year, about 1.5 years, about 2 years, about 3 years, about 5 years, about 10 years or longer after administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in improvement of visual acuity compared to the visual acuity before administration of the unit dose of rAAV particles. In some embodiments, visual acuity is best corrected visual acuity (BCVA).

[0038] In some embodiments that may be combined with any of the preceding embodiments, administration of a single unit dose of rAAV particles to one eye and / or the contralateral eye of an individual provides a therapeutic benefit (e.g., treating an ocular neovascular disease, reducing retinal fluid, maintaining or reducing retinal thickness, maintaining or reducing macular volume, and / or maintaining or improving visual acuity). In some embodiments, administration of a single unit dose of rAAV particles to one eye and / or the contralateral eye of an individual provides a therapeutic benefit that persists for about 30 weeks or more, about 34 weeks or more, about 44 weeks or more, about 6 months or more, about 1 year or more, about 1.5 years or more, or about 2 years, about 3 years, about 5 years, about 10 years or more after administration of the unit dose of rAAV particles to one eye and / or the contralateral eye of the individual.

[0039] In some embodiments that may be combined with any of the preceding embodiments, administration of the unit dose of rAAV particles to one eye and / or the contralateral eye of a plurality of individuals results in at least about 50% of the individuals in the plurality not requiring anti-VEGF rescue therapy. In some embodiments, at least about 50% of the individuals in the plurality do not require anti-VEGF rescue therapy for at least about 20 weeks, at least about 36 weeks, at least about 52 weeks, at least about 56 weeks, or longer after administration of the unit dose of rAAV particles.

[0040] In some embodiments that may be combined with any of the preceding embodiments, administration of a single unit dose of rAAV particles to one eye and / or the contralateral eye of a plurality of individuals results in at least about 67% of the individuals in the plurality of individuals not requiring anti-VEGF rescue therapy. In some embodiments, at least about 67% of the individuals in the plurality of individuals do not require anti-VEGF rescue therapy for at least about 20 weeks, at least about 36 weeks, at least about 52 weeks, at least about 60 weeks, at least about 64 weeks, or at least about 66 weeks after administration of the unit dose of rAAV particles.

[0041] In some embodiments that may be combined with any of the preceding embodiments, administration of the unit dose of rAAV particles to one eye and / or the contralateral eye of a plurality of individuals results in at least about 78% of the individuals in the plurality of individuals not requiring anti-VEGF rescue therapy. In some embodiments, at least about 78% of the individuals in the plurality of individuals do not require anti-VEGF rescue therapy for at least about 20 weeks, at least about 36 weeks, or longer following administration of the unit dose of rAAV particles.

[0042] In some embodiments that may be combined with any of the preceding embodiments, administration of the unit dose of rAAV particles to one eye and / or the contralateral eye of a plurality of individuals results in 100% of the individuals in the plurality not requiring anti-VEGF rescue therapy. In some embodiments, 100% of the individuals in the plurality do not require anti-VEGF rescue therapy for at least about 64 weeks, at least about 68 weeks, at least about 72 weeks, at least about 76 weeks, at least about 80 weeks, at least about 84 weeks, or more after administration of the unit dose of rAAV particles.

[0043] In some embodiments that may be combined with any of the preceding embodiments, administration of the unit dose of rAAV particles to one eye and / or the contralateral eye of a plurality of individuals results in a reduction in the annualized anti-VEGF injection rate by at least about 80%, at least about 85%, at least about 87%, at least about 90%, at least about 95%, at least about 99%, or 100%, compared to the annualized anti-VEGF injection rate before administration of the unit dose of rAAV particles.

[0044] In some embodiments, the ocular neovascular disease is diabetic macular edema (DME). In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a 2-step or 3-step improvement on the Diabetic Retinopathy Severity Scale (DRSS). In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a 2-step improvement on the Diabetic Retinopathy Severity Scale (DRSS). In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a 3-step improvement on the Diabetic Retinopathy Severity Scale (DRSS).

[0045] Incorporated by reference

[0046] All references cited herein, including patent applications and publications, are incorporated by reference in their entirety. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] The novel features of the present invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description and accompanying drawings which set forth illustrative embodiments in which the principles of the invention are utilized, in which:

[0048] Figures 1A to 1B A schematic diagram of the investigational drug product and Phase I studies described in Examples 1 and 2 is provided. Figure 1A Figure 2 is a schematic diagram of AAV mm8-Aflibercept. AAV2.7m8-Aflibercept is a recombinant, replication-defective adeno-associated viral (rAAV) vector containing an AAV2.7m8 protein capsid and a vector genome containing an expression cassette for a codon-optimized version of the aflibercept cDNA under the control of a ubiquitous chimeric promoter (C11). The AAV2.7m8-Aflibercept vector genome also contains two AAV2 inverted terminal repeats (ITRs) flanking the aflibercept cDNA expression cassette. Figure 1B is a figure summarizing the study design of the Phase I study described in Examples 1 and 2.

[0049] Figure 1CA map of the AAV2.7m8-aflibercept vector genome (SEQ ID NO: 39) is provided. The vector genome comprises two inverted terminal repeats (ITRs) of AAV serotype 2 (at positions 1-145 and 3772-3916 of SEQ ID NO: 39), an expression cassette comprising a CMV promoter (at positions 180-693 of SEQ ID NO: 39), a 5' untranslated region (UTR) comprising an adenoviral tripartite leader sequence and a synthetic intron (at positions 694-1314 of SEQ ID NO: 39), a Kozak sequence (at positions 1329-1340 of SEQ ID NO: 39), a codon-optimized aflibercept cDNA (at positions 1338-2714 of SEQ ID NO: 39), a 3' UTR comprising a human scaffold attachment region (at positions 2717-3527 of SEQ ID NO: 39), and a human growth hormone polyadenylation / transcription termination signal (at positions 3546-3748 of SEQ ID NO: 39). AAV = adeno-associated virus; CMV = cytomegalovirus; GH = growth hormone; ITR = inverted terminal repeat; polyA = polyadenylation; SAR = scaffold attachment region; TPL = tripartite leader sequence.

[0050] Figures 2A to 2L Shown are optical coherence tomography (OCT) images and retinal thickness maps derived from the OCT images taken from subjects in Cohort 1 of the study described in Example 1. OCT images were taken at the indicated times before and after administration of AAV2.7m8-aflibercept (Day 1). The anti-VEGF IVT treatment interval applied to all subjects. Figure 2A OCT images and retinal thickness maps derived from the OCT images were obtained from Subject 1 at five clinic visits at designated times prior to the screening aflibercept injection. The OCT images were obtained immediately prior to standard-of-care treatment with aflibercept. Subject 1 required aflibercept IVT every 5-7 weeks and presented with refractory subretinal fluid and pigment epithelial detachment (PED) despite standard-of-care treatment with aflibercept. Figure 2B OCT images and retinal thickness maps derived from OCT images were taken from Subject 1 at the time of screening aflibercept injection (Day -7), AAV2.7m8-aflibercept injection (Day 1), and visits at the indicated times. Subject 1 did not require any rescue injections after AAV2.7m8-aflibercept injection. Subject 1 demonstrated resolution of subretinal fluid starting at Week 4 and remained free of subretinal fluid and intraretinal fluid (remained dry). Figure 2COCT images and retinal thickness maps derived from these OCT images were obtained from Subject 2 at five clinic visits at designated times prior to the screening aflibercept injection. OCT images were obtained immediately prior to standard-of-care treatment with aflibercept. Subject 2 required six aflibercept IVT treatments within 8 months prior to AAV2.7m8-aflibercept treatment to maintain retinal anatomy. Figure 2D OCT images and retinal thickness maps derived from OCT images were obtained from Subject 2 at the time of screening aflibercept injection (Day -7), AAV2.7m8-aflibercept injection (Day 1), and visits at the indicated times. Subject 2 did not require any rescue injections after AAV2.7m8-aflibercept injection. Subject 2 demonstrated stable retinal anatomy with no subretinal or intraretinal fluid through Week 24. Figure 2E OCT images and retinal thickness maps derived from the OCT images are provided for Subject 3, taken at four clinic visits at designated times prior to the screening aflibercept injection. OCT images taken at Week -27 are not shown. OCT images were taken just prior to standard-of-care treatment with aflibercept. Subject 3 exhibited subretinal fluid, which increased as the interval between aflibercept IVTs increased from 5 to 7 weeks. Figure 2F OCT images and retinal thickness maps derived from OCT images were taken from Subject 3 at the time of screening aflibercept injection (Day -7), AAV2.7m8-aflibercept injection (Day 1), and visits at the indicated times. Subject 3 did not require any rescue injections after AAV2.7m8-aflibercept injection. Subject 3 demonstrated refractory subretinal fluid resolution through Week 8 and stable retinal anatomy through Week 24. Figure 2G OCT images and retinal thickness maps derived from the OCT images were obtained from Subject 4 at five clinic visits at designated times prior to the screening aflibercept injection. The OCT images were obtained immediately prior to standard of care treatment with ranibizumab 0.5 mg IVT. Subject 4 presented with subretinal fluid that was refractory to the ranibizumab IVT injection. Figure 2H OCT images and retinal thickness maps derived from OCT images were taken from Subject 4 at the time of screening aflibercept injection (Day -14), AAV2.7m8-aflibercept injection (Day 1), and visits at the indicated times. Subject 4 did not require any rescue injections after AAV2.7m8-aflibercept injection. Subject 4 demonstrated refractory subretinal fluid resolution through Week 8 and stable retinal anatomy through Week 24. Figure 2IProvided are OCT images and retinal thickness maps derived from the OCT images taken from Subject 5 at five clinic visits at designated times prior to the screening aflibercept injection. The OCT images were taken just prior to standard of care treatment with aflibercept. Figure 2J OCT images and retinal thickness maps derived from OCT images were obtained from Subject 5 at the time of screening aflibercept injection (Day -14), AAV2.7m8-aflibercept injection (Day 1), and visits at the indicated times. Subject 5 did not require any rescue injections after AAV2.7m8-aflibercept injection. Subretinal fluid and PED present during AAV2.7m8-aflibercept treatment resolved over time, and retinal anatomy remained stable with no subretinal fluid or intraretinal fluid until Week 24. Figure 2K OCT images and retinal thickness maps derived from the OCT images were obtained from Subject 6 at five clinic visits at designated times prior to the screening aflibercept injection. OCT images were obtained just prior to treatment with either standard of care bevacizumab 1.5 mg IVT or standard of care ranibizumab 0.5 mg IVT, as indicated. The retinal appearance of Subject 6 was consistent with polypoidal choroidal vasculopathy (PCV). Figure 2L OCT images and retinal thickness maps derived from the OCT images were obtained from Subject 6 at the time of screening aflibercept injection (Day -10), AAV2.7m8-aflibercept injection (Day 1), and visits at the indicated times. Subject 6 did not require any rescue injections after AAV2.7m8-aflibercept injection. Subject 6 did not demonstrate any increase in subretinal fluid and achieved some anatomical improvement up to Week 24. Subject 6's fellow eye received standard-of-care aflibercept injections every 4 weeks during the trial and demonstrated retinal morphology similar to that of the AAV2.7m8-aflibercept-treated eye.

[0051] Figure 3 Shown are the changes in mean central retinal thickness (CST) at the indicated time points for subjects in cohort 1 of the study described in Example 1. Error bars indicate 90% confidence intervals calculated using a T distribution. Baseline (BL) indicates measurements taken 7 to 15 days (e.g., 7-14 days) prior to the screening aflibercept injection, prior to AAV2.7m8-aflibercept treatment on Day 1. At 24 weeks after AAV2.7m8-aflibercept treatment, subjects demonstrated an average CRT change of -52.7 μm (90% CI -86.5, -18.8). BL = Baseline; D = Day; W = Week. The Day 1 visit occurred 7-14 days after the baseline visit.

[0052] Figure 4Shown are the mean best-corrected visual acuity (BCVA) measurements of subjects in Cohort 1 of the study described in Example 1 based on the Early Treatment Diabetic Retinopathy Study (ETDRS) letter assessment at the indicated time points. Error bars indicate 90% confidence intervals calculated using a T distribution. Baseline (BL) indicates a measurement taken 7 to 15 days (e.g., 7-14 days) prior to AAV2.7m8-aflibercept treatment on Day 1, prior to the screening aflibercept injection. At 24 weeks after AAV2.7m8-aflibercept treatment, subjects demonstrated an average BCVA change of -2 letters (90% CI -9.1, 5.1). BL = Baseline; D = Day; W = Week. The Day 1 visit occurred 7-14 days after the baseline visit.

[0053] Figure 5 The nucleic acid sequence of aflibercept (SEQ ID NO: 36) is provided.

[0054] Figure 6 Figures are shown of anterior chamber cell and vitreous cell counts for subjects 1-6 of the study described in Example 1 after treatment with AAV2.7m8-aflibercept. The steroid treatment administered to each patient is indicated below each graph. The aqueous humor cell count categories are standardized based on the Uveitis Nomenclature (SUN) criteria (Jabs, DA et al., JOphthalmol. 2005; 140: 509–516). The vitreous humor cell count categories are based on the National Institutes of Health (NIH) guidelines. For aqueous humor cells, a cell count value of 0.5+ indicates 1-5 cells; a cell count value of 1+ indicates 6-15 cells; a cell count value of 2+ indicates 16-25 cells; a cell count value of 3+ indicates 26-50 cells; and a cell count value of 4+ indicates> 50 cells. For vitreous cells, a cell count value of 0.5+ indicates 1-10 cells; a cell count value of 1+ indicates 11-20 cells; a cell count value of 2+ indicates 21-30 cells; a cell count value of 3+ indicates 31-100 cells; and a cell count value of 4+ indicates >100 cells. For the analysis shown in this figure, rare cells were captured as 0.5+.

[0055] Figures 7A to 7BOptical coherence tomography (OCT) images and retinal thickness maps derived from the OCT images are shown for subjects 1-6 in cohort 1 of the study described in Example 1 at a median follow-up of 34 weeks. In addition, the change from baseline in BCVA, the number of anti-VEGF IVT injections within the 8 months prior to administration of AAV2.7m8-aflibercept, and the number of rescue anti-VEGF IVT injections administered during the study are provided for each of subjects 1-6. The actual week at which the OCT image and retinal thickness map were obtained for each subject is specified (Subject 1 = Week 44; Subject 2 = Week 40; Subject 3 = Week 36; Subject 4 = Week 32; Subject 5 = Week 28; and Subject 6 = Week 28). During the study, no subject required a rescue anti-VEGF IVT injection and did not meet retreatment criteria at any time point during the follow-up period of up to 44 weeks. No subject demonstrated signs of disease reactivation on OCT imaging.

[0056] Figure 8 Graphs are shown of aqueous humor and vitreous cell counts for subjects 1-6 in cohort 1 of the study described in Example 1 at a median follow-up time of 44 weeks (40-52 weeks) after treatment with AAV2.7m8-aflibercept. The steroid treatment administered to each subject is indicated below each graph. Aqueous humor cell grade categories are standardized based on the Uveitis Nomenclature (SUN) criteria (Jabs, DA et al. J Ophthalmol. 2005; 140: 509–516). Vitreous humor cell grade categories are based on National Institutes of Health (NIH) guidelines. For aqueous humor cells, a cell grade of 0.5+ indicates 1-5 cells; a cell grade of 1+ indicates 6-15 cells; a cell grade of 2+ indicates 16-25 cells; a cell grade of 3+ indicates 26-50 cells; and a cell grade of 4+ indicates >50 cells. For vitreous cells, a cell grade of 0.5+ indicates 1-10 cells; a cell grade of 1+ indicates 11-20 cells; a cell grade of 2+ indicates 21-30 cells; a cell grade of 3+ indicates 31-100 cells; and a cell grade of 4+ indicates >100 cells. Rare cells are captured as a cell grade of 0.5+.

[0057] Figures 9A to 9BOptical coherence tomography (OCT) images and retinal thickness maps derived from the OCT images taken from subjects 1-6 in cohort 1 of the study described in Example 1 at a median follow-up of 44 weeks are shown. The change in BCVA ETDRS letters and CST from baseline are also provided. The actual week that the OCT images and retinal thickness maps were obtained for each subject is indicated. The asterisk indicates that subject 4 underwent retinal detachment repair using bubble injection to repair spontaneous pseudophakic inferior macula ( Figure 9B Subject 4 is still under follow-up; the OCT images and BCVA values ​​of subject 4 correspond to the last observations before retinal detachment.

[0058] Figure 10 Shown are the mean best-corrected visual acuity (BCVA) measurements of subjects in Cohort 2 based on the Early Treatment Diabetic Retinopathy Study (ETDRS) letter assessment at the indicated time points from the studies described in Examples 2 and 3. Error bars indicate the 90% confidence interval for the mean absolute BCVA calculated using the T distribution. Baseline (BL) indicates a measurement taken 7 to 15 days (e.g., 7-14 days) prior to AAV2.7m8-aflibercept treatment on Day 1, prior to the screening aflibercept injection. At 24 weeks after AAV2.7m8-aflibercept treatment, subjects demonstrated a mean change in BCVA of -4.8 letters. BL = Baseline; D = Day; W = Week. The Day 1 visit occurred 7-15 days after the baseline visit.

[0059] Figure 11 The mean central retinal thickness (CST) at the indicated time points is shown for subjects in cohort 2 of the studies described in Examples 2 and 3. Error bars indicate 90% confidence intervals for the mean absolute CST calculated using a T-distribution. Baseline (BL) indicates measurements taken 7 to 15 days (e.g., 7-14 days) prior to AAV2.7m8-aflibercept treatment on Day 1, prior to the screening aflibercept injection. At 24 weeks after AAV2.7m8-aflibercept treatment, subjects demonstrated a mean change in CST of -27.8 μm. BL = Baseline; D = Day; W = Week. The Day 1 visit occurred 7-15 days after the baseline visit.

[0060] Figure 12Graphs are shown of aqueous humor and vitreous cell counts for subjects in cohort 2 of the studies described in Examples 2 and 3 after treatment with AAV2.7m8-aflibercept up to 24 weeks of follow-up. The steroid treatment administered to each subject is indicated below each graph; the frequency of topical steroid (difluprednate) eye drops administration is indicated (e.g., 1x = once daily; 2x = twice daily; 3x = 3 times daily; 4x = 4 times daily). Aqueous humor cell grade categories are standardized based on the Uveitis Nomenclature (SUN) criteria (Jabs, DA et al. J. Ophthalmol. 2005; 140: 509–516). Vitreous humor cell grade categories are based on the National Institutes of Health (NIH) guidelines. For aqueous humor cells, a cell grade of 0.5+ indicates 1-5 cells; a cell grade of 1+ indicates 6-15 cells; a cell grade of 2+ indicates 16-25 cells; a cell grade of 3+ indicates 26-50 cells; and a cell grade of 4+ indicates >50 cells. For vitreous cells, a cell grade of 0.5+ indicates 1-10 cells; a cell grade of 1+ indicates 11-20 cells; a cell grade of 2+ indicates 21-30 cells; a cell grade of 3+ indicates 31-100 cells; and a cell grade of 4+ indicates >100 cells. For this analysis, rare cells were captured as a cell grade of 0.5+.

[0061] Figures 13A to 13B Optical coherence tomography (OCT) images and retinal thickness maps derived from the OCT images are shown for subjects 1-6 from cohort 2 of the study described in Examples 2 and 3, up to 24 weeks of follow-up. Also provided are the change from baseline in BCVA, the change from baseline in CST, and the number of rescue anti-VEGF injections administered during the 24-week follow-up period. Figure 13A In the , asterisks indicate that subject 3 received 3 rescue anti-VEGF injections, including at week 24, all due to a BCVA loss of ≥10 letters relative to baseline. This was attributed to intraretinal or subretinal fluid. Figure 13B In the figure, asterisks indicate that subject 5 received three rescue anti-VEGF injections, the last of which occurred at week 20 due to an increase in central subfield thickness of >75 μm relative to baseline.

[0062] Figure 14Figure 1 is a Swimmer's Lane Plot showing the number of anti-VEGF injections for subjects in Cohorts 1 and 2 of the studies described in Examples 1 to 3. The x-axis represents time (in weeks) relative to the time AAV2.7m8-aflibercept was administered. The y-axis shows each individual subject in Cohorts 1 and 2. The circles represent anti-VEGF IVT injections administered before and after treatment with AAV2.7m8-aflibercept. The asterisk indicates that Subject 6 of Cohort 2 was diagnosed with nAMD 6.4 months prior to the administration of AAV2.7m8-aflibercept. The vertical line bisecting the graph indicates Day 1, the time AAV2.7m8-aflibercept was administered. To the right of the vertical line are each of the 61 subsequent study visits.

[0063] Figures 15A to 15C Graphs showing aqueous humor cell and vitreous cell counts measured by slit lamp examination following treatment with AAV2.7m8-aflibercept in subjects in Cohorts 1, 2, and 3 of the studies described in Examples 1 to 5. Figure 15A Graph showing aqueous humor cell and vitreous cell counts for subjects in Cohort 1 up to 64 weeks of follow-up (median = 60 weeks; range = 52-64 weeks). Figure 15B Graph showing aqueous humor cell and vitreous cell counts for subjects in Cohort 2 up to 40 weeks of follow-up (median = 36 weeks; range = 32-40 weeks). Figure 15C Graph showing aqueous humor cell and vitreous cell counts for subjects in Cohort 3 up to 20 weeks of follow-up. Figures 15A to 15C The steroid treatment administered to each subject is indicated below each graph; aqueous humor cell grade categories are standardized based on the Uveitis Nomenclature (SUN) criteria: Jabs DA et al. J Ophthalmol 2005;140:509–516; vitreous cell grade categories are based on the National Institutes of Health (NIH) guidelines; aqueous humor cells: 0.5+ = 1-5 cells; 1+ = 6-15 cells; 2+ = 16-25 cells; 3+ = 26-50 cells; 4+ = >50 cells; vitreous cells: 0.5+ = 1-10 cells; 1+ = 11-20 cells; 2+ = 21-30 cells; 3+ = 31-100 cells; 4+ = >100 cells; for this analysis, rare cells were captured as 0.5+. QID = four times a day; TID = three times a day; BID = twice a day; QD = once a day; QOD = every other day; "QD>>" indicates that the subject continues to receive topical steroids once a day; "BID>>" indicates that the subject continues to receive topical steroids twice a day; and "QID>>" indicates that the subject continues to receive topical steroids four times a day.

[0064] Figures 16A to 16B Mean BCVA and mean CST relative to baseline through Week 52 are provided for subjects in Cohort 1 (n=6) of the studies described in Examples 1 to 5. Figure 16A Mean BCVA (ETDRS letters) relative to baseline are shown through Week 52. Asterisks indicate one subject with low BCVA scores at Weeks 44 and 48 due to retinal detachment. Figure 16B Mean CST (μm) relative to baseline is shown up to Week 52. Asterisks indicate one subject for whom CST data were not available at Weeks 44 and 48 due to retinal detachment. Figures 16A to 16B In , error bars indicate 90% confidence intervals for mean absolute BCVA and CST values ​​using T distribution; BL = baseline; D = day; W = week.

[0065] Figures 17A to 17B Mean BCVA and mean CST relative to baseline through Week 36 are presented for subjects in Cohort 2 (n=6) of the studies described in Examples 1 to 5. Figure 17A Mean BCVA (ETDRS letters) relative to baseline through Week 36 are shown. Figure 17B Mean CST (μm) relative to baseline up to Week 36 is shown. Figures 17A to 17B In , error bars indicate 90% confidence intervals for mean absolute BCVA and CST values ​​using T distribution; BL = baseline; D = day; W = week; one subject missed the Week 36 visit.

[0066] Figures 18A to 18B Mean BCVA and mean CST relative to baseline through Week 20 are provided for the five subjects in Cohort 3 of the study described in Examples 1 to 5. Figure 18A Mean BCVA (ETDRS letters) relative to baseline up to Week 20 are shown. Figure 18B Mean CST (μm) relative to baseline up to Week 20 is shown. Figures 18A to 18B In , error bars indicate 90% confidence intervals for mean absolute BCVA and CST values ​​using T distribution; BL = baseline; D = day; W = week; one subject missed the Week 36 visit.

[0067] Figure 19Figure 5 is a swimmer's lane graph showing the number of anti-VEGF injections administered to subjects in Cohorts 1, 2, and 3 of the studies described in Examples 1 to 5. The x-axis represents time (in weeks) relative to the time AAV2.7m8-aflibercept was administered. The y-axis shows each individual subject in Cohorts 1 to 3. The circles represent anti-VEGF IVT injections administered before and after treatment with AAV2.7m8-aflibercept. The vertical line bisecting the graph indicates Day 1, when AAV2.7m8-aflibercept was administered. To the right of the bisecting vertical line are each of the subsequent study visits.

[0068] Figures 20A to 20B Shown are optical coherence tomography (OCT) images taken from subject 4 in cohort 1 of the studies described in Examples 1 to 5 at the indicated times before and after administration of AAV2.7m8-aflibercept and retinal thickness maps derived from the OCT images. Figure 20A Shown are OCT images and retinal thickness maps of subject 4 in cohort 1 at the indicated times (weeks) before administration of AAV2.7m8-aflibercept, during which time the subject was administered an anti-VEGF IVT injection (ranibizumab). Figure 20B OCT images and retinal thickness maps are shown for Subject 4 in Cohort 1 at the indicated times (weeks) before and after administration of AAV2.7m8-aflibercept. The times of administration of the screening anti-VEGF IVT injection ("Screening anti-VEGF IVT") and AAV2.7m8-aflibercept ("AAV2.7m8-aflibercept") are indicated. BCVA (ETDRS letter) and CST (μm) are provided for each indicated time before and after administration of AAV2.7m8-aflibercept. Asterisks indicate subjects who experienced a retinal detachment event unrelated to AAV2.7m8-aflibercept.

[0069] Figures 21A to 21B Shown are optical coherence tomography (OCT) images and retinal thickness maps derived from the OCT images taken from subject 5 in cohort 3 of the studies described in Examples 1 to 5 at the indicated times before and after administration of AAV2.7m8-aflibercept. Figure 21A Shown are OCT images and retinal thickness maps of subject 5 in cohort 3 at the indicated times (weeks) before administration of AAV2.7m8-aflibercept, during which time the subject was administered an anti-VEGF IVT injection (aflibercept). Figure 21BOCT images and retinal thickness are shown for Subject 5 in Cohort 3 at the indicated times (weeks) before and after administration of AAV2.7m8-aflibercept. The times of administration of the screening anti-VEGF IVT injection ("Screening Anti-VEGF IVT") and AAV2.7m8-aflibercept ("AAV2.7m8-aflibercept") are indicated. BCVA (ETDRS letters) and CST (μm) are provided for each indicated time before and after administration of AAV2.7m8-aflibercept.

[0070] Figures 22A to 22D Graphs showing aqueous humor cell and vitreous cell counts measured by slit lamp examination following treatment with AAV2.7m8-aflibercept in subjects in Cohorts 1, 2, 3, and 4 of the studies described in Examples 1 to 5 and 7. Figure 22A Graph showing aqueous humor cell and vitreous cell counts for subjects in Cohort 1 up to 80 weeks of follow-up. Figure 22B Graph showing aqueous humor cell and vitreous cell counts for subjects in Cohort 2 up to 56 weeks of follow-up. Figure 22C Graph showing aqueous humor cell and vitreous cell counts for subjects in Cohort 3 up to 36 weeks of follow-up. Figure 22D Graph showing aqueous humor cell and vitreous cell counts for subjects in Cohort 4 up to 8 weeks of follow-up. Figures 22A to 22D The steroid treatment administered to each subject is indicated below each graph; aqueous humor cell grade categories are standardized based on the Uveitis Nomenclature (SUN) criteria: Jabs DA et al. J Ophthalmol 2005;140:509–516; vitreous cell grade categories are based on the National Institutes of Health (NIH) guidelines; aqueous humor cells: 0.5+ = 1-5 cells; 1+ = 6-15 cells; 2+ = 16-25 cells; 3+ = 26-50 cells; 4+ = >50 cells; vitreous cells: 0.5+ = 1-10 cells; 1+ = 11-20 cells; 2+ = 21-30 cells; 3+ = 31-100 cells; 4+ = >100 cells; for this analysis, rare cells were captured as 0.5+. QID = four times a day; TID = three times a day; BID = twice a day; QD = once a day; QOD = every other day; "QD>>" indicates that the subject continues to receive topical steroids once a day; "BID>>" indicates that the subject continues to receive topical steroids twice a day; "TID>>" indicates that the subject continues to receive topical steroids three times a day; and "QID>>" indicates that the subject continues to receive topical steroids four times a day.

[0071] Figures 23A to 23BMean BCVA and mean CST relative to baseline through Week 72 are presented for subjects in Cohort 1 of the studies described in Examples 1 to 5 and 7 (n=6). Figure 23A Mean BCVA (ETDRS letters) relative to baseline are shown through Week 72. One subject had low BCVA scores at Weeks 44 and 48 due to retinal detachment. *From Week 56 to Week 72, n=5. Figure 23B Mean CST (μm) relative to baseline is shown up to Week 72. One subject had no CST data at Weeks 44 and 48 due to retinal detachment. * From Week 56 to Week 72, n=5. Figures 23A to 23B In , error bars indicate 90% confidence intervals for mean absolute BCVA and CST values ​​using T distribution; BL = baseline; D = day; W = week.

[0072] Figures 24A to 24B Mean BCVA and mean CST relative to baseline through Week 52 are presented for subjects in Cohort 2 (n=6) of the studies described in Examples 1 to 5 and 7. Figure 24A Mean BCVA (ETDRS letters) relative to baseline are shown through Week 52. *Weeks 36 and 40, n=5. Figure 24B Mean CST (μm) relative to baseline up to Week 52 is shown. * Week 36 and Week 40, n=5. Figures 24A to 24B In , error bars indicate 90% confidence intervals for mean absolute BCVA and CST values ​​using T distribution; BL = baseline; D = day; W = week.

[0073] Figures 25A to 25B Mean BCVA and mean CST relative to baseline up to Week 20 are presented for subjects in Cohort 3 (n=9) of the studies described in Examples 1 to 5 and 7. Figure 25A Mean BCVA (ETDRS letters) relative to baseline are shown through Week 20. *Weeks 4, 16, and 20, n=8. Figure 25B Mean CST (μm) relative to baseline up to Week 20 is shown. * Weeks 4, 16, and 20, n=8. Figures 25A to 25B In , error bars indicate 90% confidence intervals for mean absolute BCVA and CST values ​​using T distribution; BL = baseline; D = day; W = week.

[0074] Figure 26Figure 1 is a swimmer's lane graph showing the number of anti-VEGF injections administered to subjects in Cohorts 1, 2, 3, and 4 of the studies described in Examples 1 to 5 and 7. The x-axis represents time (in weeks) relative to the time of AAV2.7m8-aflibercept administration. The y-axis shows each individual subject in Cohorts 1 to 4. The circles represent anti-VEGF IVT injections administered before and after treatment with AAV2.7m8-aflibercept. The vertical line bisecting the graph indicates Day 1, the time of AAV2.7m8-aflibercept administration. To the right of the vertical line are each of the subsequent study visits. Five subjects were diagnosed <1 year before AAV2.7m8-aflibercept injection (1 subject each in Cohorts 2 and 3, and 3 subjects in Cohort 4). In Cohort 4, data prior to Day 1 were incomplete for Subject 2 due to relocation, and data prior to Day 1 were incomplete for Subject 5 because the subject participated in a clinical trial using an unknown drug after diagnosis.

[0075] Figures 27A to 27B Shown are the mean annualized anti-VEGF injection rates for subjects in Cohorts 1-3 of the studies described in Examples 1-5 and 7. Figure 27A The subjects in group 1 (administered 6×10 11 vg / eye "high dose"; n=6) and subjects in Cohorts 2 and 3 (administered 2×10 11 vg / eye "low dose"; n=15). Figure 27B A comparison of the mean annualized anti-VEGF injection rates for subjects in each of Cohorts 1 (n=6), 2 (n=6), and 3 (n=9) is provided. Figures 27A to 27B In the study, annualized rate (before) = (number of anti-VEGF IVT injections in the 12 months before AAV2.7m8-aflibercept) / (number of days from the first anti-VEGF IVT injection in the past 12 months to the AAV2.7m8-aflibercept injection / 365.25); and annualized rate (after) = (number of anti-VEGF IVT injections since AAV2.7m8-aflibercept) / (number of days from AAV2.7m8-aflibercept to the last study follow-up / 365.25).

[0076] Figures 28A to 28B Shown are optical coherence tomography (OCT) images and retinal thickness maps derived from the OCT images taken from subject 5 in cohort 3 of the studies described in Examples 1 to 5 and 7 at the indicated times before and after administration of AAV2.7m8-aflibercept. Figure 28AShown are OCT images and retinal thickness maps of subject 5 in cohort 3 at the indicated times (weeks) before administration of AAV2.7m8-aflibercept, during which time the subject was administered an anti-VEGF IVT injection (aflibercept). Figure 28B OCT images and retinal thickness are shown for Subject 5 in Cohort 3 at the indicated times (weeks) before and after administration of AAV2.7m8-aflibercept. The times of administration of the screening anti-VEGF IVT injection ("aflibercept IVT") and AAV2.7m8-aflibercept are indicated. BCVA (ETDRS letters) and CST (μm) are provided for each indicated time before and after administration of AAV2.7m8-aflibercept.

[0077] Figure 29 A diagram shows the design of the study described in Example 6, which evaluated the persistence of a single intravitreal (IVT) injection of AAV2.7m8-aflibercept in subjects with diabetic macular edema (DME). DRSS = Diabetic Retinopathy Severity Score; OCT = Optical Coherence Tomography; CST = Central Subfield Thickness. *All subjects received a 7-week course of difluprednate eye drops, starting every day and tapering to every day. **PE = Primary Endpoint Evaluation. ***EOS = End-of-Study Evaluation.

[0078] Figure 30 Two views of CST measured using four different treatment groups are shown: (1) monthly ranibizumab 0.5 mg (Rq4); monthly intravitreal aflibercept injection (IAI) 0.5 mg (0.5q4); monthly IAI 2 mg (2q4); and after 3 initial monthly doses, IAI 2 mg every 2 months (2q8).

[0079] Figure 31 A single intravitreal (IVT) injection of AAV2.7m8 2x10 11 A case study of the results of vg / eyes in eliminating fluid and CST fluctuations. The patient was a 90-year-old woman who had received 21 IVTs prior to the study and 9 IVTs in the 12 months prior to AAV2.7m8 administration. OCT images and graphs showing CST fluctuations before and after AAV2.7m8 administration are shown.

[0080] Figure 32Annualized CST volatility (+ or - 50 μm) is shown. "Volatility" is defined as a change from one planned study week (Week A) to the following planned study week (Week B) that meets the following criteria: 1. The magnitude of the change equals or exceeds the volatility criterion. 2. The direction of the change from the first planned week (Week A) remains the same for any intervening planned study weeks between the first and second planned weeks (Weeks A and B). 3. The direction of the change from the first planned week (Week A) changes in the planned study week immediately following the second planned week (Week B). Annualized volatility before AAV2.7m8 = (number of fluctuations since the first historical observation) / (number of days from the first historical observation to the last historical observation / 365.25). Annualized volatility after AAV2.7m8 = (number of fluctuations since AAV2.7m8 injection) / (number of days from AAV2.7m8 to the last study visit / 365.25). Figure 32 Also shown is a reduction in CST fluctuations in subjects with documented baseline anti-AAV2.7m8 neutralizing antibody (NAb) titer levels <1:125.

[0081] Figure 33 Annualized positive CST volatility (+50 μm) is shown. A "volatility" is defined as a change from one planned study week (Week A) to the following planned study week (Week B) that meets the following criteria: 1. The magnitude of the change equals or exceeds the volatility criterion. 2. The direction of the change from the first planned week (Week A) is positive and remains the same for any intervening planned study weeks between the first and second planned weeks (Weeks A and B). 3. The direction of the change from the first planned week (Week A) changes in the planned study week immediately following the second planned week (Week B). Annualized volatility before AAV2.7m8 = (number of fluctuations since the first historical observation) / (number of days from the first historical observation to the last historical observation / 365.25). Annualized volatility after AAV2.7m8 = (number of fluctuations since AAV2.7m8 injection) / (number of days from AAV2.7m8 to the last study visit / 365.25). Figure 33 Also shown is a reduction in CST fluctuations in subjects with documented baseline anti-AAV2.7m8 neutralizing antibody (NAb) titer levels <1:125.

[0082] Figure 34 Shows the ratio Figure 32 Annualized CST volatility (+ or - 50 μm) over a period of approximately six months is shown. Maintaining a reduction in CST volatility. Figure 34 Also shown is a reduction in CST fluctuations in subjects with documented baseline anti-AAV2.7m8 neutralizing antibody (NAb) titer levels <1:125. DETAILED DESCRIPTION

[0083] Several aspects are described below with reference to the application of the embodiments for illustration. It should be understood that many specific details, relationships and methods have been set forth to provide a comprehensive understanding of the features described herein. However, those skilled in the relevant art will readily recognize that features described herein can be put into practice without one or more specific details or using other methods. Features described herein are not subject to the restriction of the actions shown or the sequence of events, because some actions can occur in different orders and / or simultaneously with other actions or events. In addition, not all shown actions or events are required for implementation according to the method for the features described herein.

[0084] definition

[0085] Unless defined otherwise, all technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.

[0086] The terms used herein are for the purpose of describing specific examples only and are not intended to be limiting. As used herein, the singular forms "a / an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. In addition, to the extent that the terms "including / include," "having / has / with," or variations thereof are used in the specific embodiments and / or claims, such terms are intended to be inclusive in a manner similar to the term "comprising." As used herein, the term "comprising" is synonymous with "including" or "containing," and is inclusive or open-ended.

[0087] Unless otherwise indicated, any reference to "or" herein is intended to encompass "and / or." As used herein, the term "about" a number refers to the number plus or minus 10% of the number. The term "about" a range refers to the range minus 10% of the lowest value and plus 10% of the highest value. References herein to "about" a value or parameter include (and describe) embodiments for that value or parameter itself.

[0088] The term "subject," "patient," or "individual" refers to primates, such as humans and non-human primates, for example, African green monkeys and rhesus monkeys. In some embodiments, the subject is a human.

[0089] As used herein, the terms "treat / treating / treatment" or "ameliorate / ameliorating" and other grammatical equivalents refer to alleviating, reducing or ameliorating an ocular neovascular disease or condition or a symptom of an ocular neovascular disease or condition, preventing other symptoms of an ocular neovascular disease or condition, improving or preventing the underlying metabolic causes of symptoms, inhibiting an ocular neovascular disease or condition, such as preventing the development of an ocular neovascular disease or condition, alleviating an ocular neovascular disease or condition, causing regression of an ocular neovascular disease or condition, or stopping the symptoms of an ocular neovascular disease or condition, and are intended to include prevention. The terms also include achieving a therapeutic benefit and / or a prophylactic benefit. The term "therapeutic benefit" refers to eradicating or ameliorating the ocular neovascular disease or condition being treated. Moreover, a therapeutic benefit is achieved with eradication or amelioration of one or more physiological symptoms associated with an ocular neovascular disease or condition, such that an improvement is observed in the subject, although in some embodiments, the subject still suffers from the ocular neovascular disease or condition. For prophylactic benefit, the pharmaceutical compositions are administered to a subject at risk of developing an ocular neovascular disease or disorder, or a subject reporting one or more physiological symptoms of an ocular neovascular disease or disorder, even if a diagnosis of the disease or disorder has not yet been made.

[0090] As used herein, the term "administer" refers to a method for delivering a therapeutic agent or pharmaceutical composition to a desired biological site of action, such as by intravitreal or subretinal injection into the eye.

[0091] As used herein, the terms "effective amount," "therapeutically effective amount," or "pharmaceutically effective amount" may refer to a sufficient amount of at least one administered pharmaceutical composition or compound to provide some relief from one or more symptoms of the ocular disease or condition being treated. An "effective amount," "therapeutically effective amount," or "pharmaceutically effective amount" of a pharmaceutical composition may be administered to a subject in need thereof as a unit dose (as described in further detail elsewhere herein).

[0092] As used herein, the term "pharmaceutically acceptable" may refer to a substance, such as a carrier or diluent, that does not abrogate the biological activity or properties of the compounds disclosed herein and is relatively non-toxic (i.e., it does not cause undesirable biological effects when administered to a subject, nor does it interact in a deleterious manner with any component of the composition in which it is contained).

[0093] As used herein, the term "pharmaceutical composition" or simply "composition" may refer to a biologically active compound optionally mixed with at least one pharmaceutically acceptable chemical component, such as but not limited to a carrier, stabilizer, diluent, dispersant, suspending agent, thickener, excipient, etc.

[0094] As used herein, "AAV vector" or "rAAV vector" refers to an adeno-associated virus (AAV) vector or a recombinant AAV (rAAV) vector that comprises a polynucleotide sequence of non-AAV origin (e.g., a polynucleotide heterologous to AAV, such as a nucleic acid sequence encoding a therapeutic transgene (e.g., aflibercept)) for transduction into target cells or target tissues. Typically, the heterologous polynucleotide is flanked by at least one and typically two AAV inverted terminal repeats (ITRs). The term rAAV vector encompasses rAAV vector particles and rAAV vector plasmids. rAAV vectors can be single-stranded (ssAAV) or self-complementary (scAAV).

[0095] "AAV virus" or "AAV virus particle" or "rAAV vector particle" or "rAAV particle" refers to a virus particle comprising at least one AAV capsid protein and a polynucleotide rAAV vector. In some cases, the at least one AAV capsid protein is from wild-type AAV or a variant AAV capsid protein (e.g., an AAV capsid protein with an insertion, e.g., of a 7m8 amino sequence as described below). If the particle contains a heterologous polynucleotide (e.g., a polynucleotide other than a wild-type AAV genome, such as a transgene to be delivered to a target cell or target tissue), it is referred to as a "rAAV particle", "rAAV vector particle" or "rAAV vector". Therefore, the production of rAAV particles necessarily includes the production of rAAV vectors, e.g., vectors contained within rAAV particles.

[0096] As used herein, the term "packaging" may refer to the series of intracellular events that may lead to the assembly and encapsidation of rAAV particles.

[0097] The AAV "rep" and "cap" genes refer to polynucleotide sequences encoding the replication and encapsidation proteins of the adeno-associated virus. AAV rep and cap are referred to herein as AAV "packaging genes."

[0098] The term "polypeptide" may encompass naturally occurring and non-naturally occurring proteins (e.g., fusion proteins), peptides, fragments, mutants, derivatives, and analogs thereof. A polypeptide may be a monomer, dimer, trimer, or multimer. In addition, a polypeptide may comprise a number of different domains, each of which has one or more different activities. For the avoidance of doubt, a "polypeptide" may be any length greater than two amino acids.

[0099] As used herein, "polypeptide variant" or simply "variant" refers to a polypeptide whose sequence contains an amino acid modification. In some embodiments, the modification is an insertion, duplication, deletion, rearrangement or substitution of one or more amino acids compared to the amino acid sequence of a reference protein or polypeptide, such as a native or wild-type protein. The variant may have one or more amino acid point substitutions (wherein a single amino acid at one position has been changed to another amino acid), one or more insertions and / or deletions (wherein one or more amino acids are inserted or deleted, respectively, in the sequence of the reference protein), and / or truncation of the amino acid sequence at one or both of the amino or carboxyl termini. Variants may have the same or different biological activities compared to a reference protein or unmodified protein.

[0100] In some embodiments, a variant may have, for example, at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% overall sequence identity with its corresponding reference protein. In some embodiments, a variant may have at least about 90% overall sequence identity with the wild-type protein. In some embodiments, a variant exhibits at least about 95%, at least about 98%, at least about 99%, at least about 99.5%, or at least about 99.9% overall sequence identity.

[0101] As used herein, "recombinant" can refer to a biological molecule, such as a gene or protein, that (1) has been removed from its naturally occurring environment, (2) is not associated with all or a portion of a polynucleotide to which the gene is found in nature, (3) is operably linked to a polynucleotide to which it is not linked in nature, or (4) does not occur in nature. The term "recombinant" can be used to refer to cloned DNA isolates, chemically synthesized polynucleotide analogs, or polynucleotide analogs biologically synthesized by heterologous systems, as well as proteins and / or mRNA encoded by such nucleic acids. Thus, for example, a protein synthesized by a microorganism is recombinant if it is synthesized from mRNA synthesized by a recombinant gene present in a cell.

[0102] The term "anti-VEGF agent" includes any therapeutic agent, including a protein, polypeptide, peptide, fusion protein, multimeric protein, gene product, antibody, human monoclonal antibody, antibody fragment, aptamer, small molecule, kinase inhibitor, receptor or receptor fragment or nucleic acid molecule, which can reduce, interfere with, disrupt, block and / or inhibit the activity or function of endogenous VEGF and / or endogenous VEGF receptor (VEGFR), or VEGF-VEGFR interaction or pathway in vivo. The anti-VEGF agent can be any known therapeutic agent that can reduce new blood vessel growth or formation and / or edema or swelling when delivered to cells, tissues or subjects in vivo, such as ranibizumab, brolucizumab or bevacizumab. In some embodiments, the anti-VEGF agent can be naturally occurring, non-naturally occurring or synthetic. In some embodiments, the anti-VEGF agent can be derived from a naturally occurring molecule that is subsequently modified or mutated to confer anti-VEGF activity. In some embodiments, the anti-VEGF agent is a fusion protein or chimeric protein. In such proteins, functional domains or polypeptides are artificially fused to moieties or polypeptides to prepare fusion proteins or chimeric proteins that can sequester VEGF in vivo or act as a VEGFR decoy. In some embodiments, the anti-VEGF agent is a fusion protein or chimeric protein that blocks the interaction of endogenous VEGFR with its ligand.

[0103] As used herein, "VEGF" may refer to any isoform of VEGF, including, but not limited to, VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F, or any combination or functional fragment or variant thereof, unless otherwise required. Unless otherwise required, "VEGF" may refer to any member of the VEGF family, including members: VEGF-A, placental growth factor (PGF), VEGF-B, VEGF-C, and VEGF-D, or any combination, functional fragment or variant thereof. As used herein, "VEGF receptor" or "VEGFR" or "VEGF-R" may be used to refer to any of the VEGF receptors, including, but not limited to, VEGFR-1 (or Flt-1), VEGFR-2 (or Flk-1 / KDR), and VEGFR-3 (or Flt-4). VEGFR may be membrane-bound or soluble, or a functional fragment or truncated form of the receptor. Examples of anti-VEGF agents include, but are not limited to, ranibizumab, bevacizumab, brucella, or any combination, variant, or functional fragment thereof.

[0104] "Operably linked" or "coupled" can refer to the juxtaposition of genetic elements in which the elements are in a relationship that allows them to operate in their intended manner. For example, a promoter can be operably linked to a coding region if the promoter helps initiate transcription of the coding sequence. Intervening residues can exist between the promoter and the coding region as long as this functional relationship is maintained.

[0105] The term "expression vector" or "expression construct" or "cassette" or "plasmid" or simply "vector" can include any type of genetic construct, including AAV or rAAV vectors, which contain a nucleic acid or polynucleotide encoding a gene product, wherein part or all of the nucleic acid coding sequence is capable of being transcribed and is suitable for gene therapy. The transcript can be translated into protein. In some embodiments, the transcript is partially translated or not translated. In certain aspects, expression includes transcription of the gene and translation of mRNA into a gene product. In other aspects, expression includes only transcription of the nucleic acid encoding the target gene. The expression vector may also contain control elements operably linked to the coding region to promote expression of the protein in the target cell. The combination of control elements and one or more genes to which they are operably linked for expression is sometimes referred to as an "expression cassette," a large number of which are known and available in the art, or can be readily constructed from components available in the art.

[0106] The term "heterologous" may refer to an entity that is genotypically different from the rest of the entity to which it is being compared. For example, a polynucleotide introduced by genetic engineering techniques into a plasmid or vector derived from a different species may be a heterologous polynucleotide. A promoter that is removed from its native coding sequence and operably linked to a coding sequence to which it is not naturally found linked may be a heterologous promoter.

[0107] As used herein, "7m8" refers to the amino acid sequence LALGETTRPA (SEQ ID NO: 1).

[0108] "7m8 variant" refers to rAAV, of any serotype, having the amino acid sequence LALGETTRPA (SEQ ID NO: 1) inserted into the solvent-exposed GH loop of the capsid protein.

[0109] When 7m8 is inserted into rAAV2 (also referred to as AAV2.7m8), the amino acid sequence LALGETTRPA (SEQ ID NO: 1) is inserted into the GH loop within amino acids 570-611 of the AAV2 capsid protein, e.g., between positions 587 and 588 of AAV2 capsid protein VP1. In some cases, when 7m8 is inserted into rAAV2 (also referred to as AAV2.7m8), the amino acid sequence LALGETTRPA (SEQ ID NO: 1) is inserted into the GH loop of the AAV2 capsid protein, e.g., between positions 587 and 588 of AAV2 VP1 comprising the sequence of SEQ ID NO: 13. When 7m8 is inserted into rAAV1 (also referred to as AAV1.7m8), the amino acid sequence LALGETTRPA (SEQ ID NO: 1) is inserted into the GH loop within amino acids 571-612 of the AAV1 capsid protein, e.g., between amino acids 590 and 591 of the AAV1 capsid protein. When 7m8 is inserted into rAAV5 (also known as AAV5.7m8), the amino acid sequence LALGETTRPA (SEQ ID NO: 1) is inserted into the GH loop within amino acids 560-601 of the AAV5 capsid protein, for example, between amino acids 575 and 576 of the AAV5 capsid protein. When 7m8 is inserted into rAAV6 (also known as AAV6.7m8), the amino acid sequence LALGETTRPA (SEQ ID NO: 1) is inserted into the GH loop within amino acids 571 to 612 of the AAV6 capsid protein, for example, between amino acids 590 and 591 of the AAV6 capsid protein. When 7m8 is inserted into rAAV7 (also known as AAV7.7m8), the amino acid sequence LALGETTRPA (SEQ ID NO: 1) is inserted into the GH loop within amino acids 572 to 613 of the AAV7 capsid protein, for example, between amino acids 589 and 590 of the AAV7 capsid protein. When 7m8 is inserted into rAAV8 (also known as AAV8.7m8), the amino acid sequence LALGETTRPA (SEQ ID NO: 1) is inserted into the GH loop within amino acids 573 to 614 of the AAV8 capsid protein, for example, between amino acids 590 and 591 of the AAV8 capsid protein. When 7m8 is inserted into rAAV9 (also known as AAV9.7m8), the amino acid sequence LALGETTRPA (SEQ ID NO: 1) is inserted into the GH loop of the AAV9 capsid protein, for example, between amino acids 588 and 589 of the AAV9 capsid protein. When 7m8 is inserted into rAAV10 (also known as AAV10.7m8), the amino acid sequence LALGETTRPA (SEQ ID NO: 1) is inserted into the GH loop within amino acids 573 to 614 of the AAV10 capsid protein, for example, between amino acids 589 and 590 of the AAV10 capsid protein.

[0110] As used herein, the term "fluctuation" refers to a change in subfoveal thickness or central retinal thickness from one planned study week (Week A) to a subsequent planned study week (Week B) that satisfies the following criteria: 1. The magnitude of the change equals or exceeds the fluctuation criterion. 2. The direction of the change from the first planned study week (Week A) remains the same for any intervening planned study weeks between the first and second planned weeks (Weeks A and B). 3. The direction of the change from the first planned week (Week A) changes in the planned study week immediately following the second planned week (Week B).

[0111] As used herein, "annualized volatility" is categorized and described as the "pre-AAV2.7m8 injection" time period, which is calculated as (number of fluctuations since the first historical observation) / (number of days from the first historical observation to the last historical observation / 365.25); and the "post-AAV2.7m8 injection" time period, which is calculated as (number of fluctuations since AAV2.7m8 injection) / (number of days from AAV2.7m8 to the last study follow-up / 365.25).

[0112] Overview

[0113] Current therapies for ocular neovascular diseases such as wAMD (e.g., aflibercept recombinant protein, ranibizumab recombinant protein) require lifelong IVT administration approximately every 4-8 weeks. This increases the risk of inflammation, infection, and other side effects in some patients. In addition, current therapies present compliance challenges, particularly for elderly patients who are most affected by wAMD, due to repeated and / or frequent visits to the doctor's office to administer the therapy. A reduction in the frequency of administration is associated with vision loss and worsening of the ocular disease or disorder. The ability of AAV vectors to effectively transduce target retinal cells after IVT injection has been used to successfully transfer therapeutic genes into photoreceptors, retinal pigment epithelium, and inner retina to treat a variety of retinal diseases. Therefore, administration of rAAV particles encoding an anti-VEGF agent (e.g., aflibercept) can provide extended and / or sustained release of the anti-VEGF agent in vivo.

[0114] Surprisingly, administration of a single low unit dose of 6 × 10 11 rAAV particles encoding aflibercept at 10 vector genomes (vg) / eye resulted in stable disease and strong anatomical responses in all treated individuals (see Example 1). 11After administration of aflibercept-encoding rAAV particles to each eye, visual acuity remained stable in all treated individuals, and no individual required rescue anti-VEGF therapy (e.g., aflibercept IVT injection). In addition, administration of a single unit dose of aflibercept-encoding rAAV particles to the eyes of individuals with ocular neovascular disease unexpectedly resulted in a reduction (e.g., regression) of symptoms including intraretinal and subretinal fluid that were refractory to previous anti-VEGF therapy (e.g., chronic IVT injections of aflibercept, ranibizumab, or bevacizumab).

[0115] Thus, the present disclosure provides for the administration of a single unit dose of 6×10 11 vg / eye or less of rAAV particles encoding an anti-VEGF agent (e.g., aflibercept). In addition, the present disclosure provides methods for reducing retinal fluid in the eye of an individual suffering from an ocular neovascular disease by administering a single unit dose of rAAV particles encoding an anti-VEGF agent (e.g., aflibercept). The methods disclosed herein reduce or eliminate the need for repeated IVT injections while providing long-term efficacy, thereby addressing non-compliance and non-adherence issues. In addition, the methods provided herein reduce the side effects associated with multiple IVT injections.

[0116] Treatment

[0117] Provided herein is a method for treating an ocular neovascular disease in a subject, the method comprising administering a unit dose of recombinant adeno-associated virus (rAAV) particles to an eye of the subject.

[0118] Also provided herein is a method for reducing retinal fluid in an eye of an individual suffering from an ocular neovascular disease, the method comprising administering a unit dose of rAAV particles to the eye of the individual.

[0119] Also provided herein is a method for treating an ocular neovascular disease in a subject, the method comprising administering an anti-VEGF agent (e.g., aflibercept) to an eye of the subject, and administering a unit dose of recombinant adeno-associated virus (rAAV) particles to the eye of the subject after administering the anti-VEGF agent.

[0120] In some embodiments, the ocular neovascular disease is wet age-related macular degeneration (wAMD), retinal neovascularization, choroidal neovascularization diabetic retinopathy, proliferative diabetic retinopathy, retinal vein occlusion, central retinal vein occlusion, branch retinal vein occlusion, diabetic macular edema, diabetic retinal ischemia, ischemic retinopathy, diabetic retinal edema, or any combination thereof.

[0121] In some embodiments, the term ocular neovascular disease also encompasses VEGF-driven pre-neovascular diseases that, if left untreated, progress to a neovascular form. In some embodiments, the ocular neovascular disease is pre-neovascular disease, non-proliferative diabetic retinopathy.

[0122] In some embodiments, the individual is a human. In some embodiments, the individual received at least one prior treatment (e.g., at least one, at least two, at least three, at least four, at least five, or more treatments) for an ocular neovascular disease with an anti-VEGF agent (e.g., bevacizumab, brolucizumab, ranibizumab, farecximab, abicipar pegol, conbercept, OPT-302, KSI-301, injectable sunitinib maleate (GB-102), PAN-90806 (PanOptica), and / or aflibercept) within about the last 8 weeks, about the last 9 weeks, about the last 10 weeks, about the last 11 weeks, about the last 12 weeks, about the last 13 weeks, about the last 14 weeks, about the last 15 weeks, or about the last 16 weeks prior to administration of the unit dose of rAAV particles. In some embodiments, the individual has demonstrated a meaningful response to prior treatment with an anti-VEGF agent (e.g., bevacizumab, brolucizumab, ranibizumab, farximab, abispiracept, conbercept, OPT-302, KSI-301, injectable sunitinib malate (GB-102), PAN-90806 (PanOptica), and / or aflibercept). In some embodiments, the anti-VEGF agent is aflibercept, a functional variant thereof, or a functional fragment thereof. In some embodiments, the anti-VEGF agent comprises a polypeptide comprising an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO: 35. In some embodiments, the retinal fluid in the eye of the individual is intraretinal fluid (IRF) and / or subretinal fluid (SRF). In some embodiments, the amount or presence of retinal fluid in the eye of the individual is refractory to prior treatment with an anti-VEGF agent (e.g., bevacizumab, brolucizumab, ranibizumab, farecoxib, abispiracept, conbercept, OPT-302, KSI-301, injectable sunitinib maleate (GB-102), PAN-90806 (PanOptica), and / or aflibercept). In some embodiments, the anti-VEGF agent is aflibercept, a functional variant thereof, or a functional fragment thereof. In some embodiments, the anti-VEGF agent comprises a polypeptide comprising an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO: 35.

[0123] In some embodiments, the ocular neovascular disease is diabetic macular edema (DME). In some embodiments, the individual is a human. In some embodiments, the individual suffers from type 1 or type 2 diabetes. In some embodiments, the individual suffers from visual impairment caused by central involvement of diabetic macular edema. In some embodiments, before administering a unit dose of rAAV particles, the eye of the individual administering rAAV particles has a visual acuity (BCVA) of about 78 to 50 ETDRS letters (e.g., 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77 or any one of 78 ETDRS letters). In some embodiments, prior to administration of the unit dose of rAAV particles, the individual's eye to which the rAAV particles were administered has a visual acuity (Snellen equivalent) between about 20 / 32 and about 20 / 100. In some embodiments, prior to administration of the unit dose of rAAV particles, the individual's eye to which the rAAV particles were administered has a visual acuity (Snellen equivalent) of ≥ 325 μm (using a Heidelberg with an IRF involving the center (center 1 mm)). ) of the central subfield thickness (CST). In some embodiments, prior to the administration of the unit dose of rAAV particles, the individual's eye to which the rAAV particles are administered has reduced visual acuity, primarily due to diabetic macular edema. In some embodiments, the individual's eye to which the rAAV particles are administered is diagnosed with diabetic macular edema about 6 months or less prior to the administration of the unit dose of rAAV particles, for example, any of about 6 months, about 5 months, about 4 months, about 3 months, about 2 months, about 1 month or less prior to the administration of the unit dose of rAAV particles. In some embodiments, prior to the administration of the unit dose of rAAV particles, the individual's eye to which the rAAV particles are administered has received 0, 1 or 2 prior treatments for DME, for example, 0, 1 or 2 intravitreal injections of an anti-VEGF agent (e.g., aflibercept). In some embodiments, at least about 60 days (i.e., about 2 months) prior to the administration of the unit dose of rAAV particles, the individual's eye to which the rAAV particles are administered has received a prior treatment with an anti-VEGF agent. In some embodiments, prior to administration of the unit dose of rAAV particles, the individual's eye to which the rAAV particles were administered exhibited a meaningful response in central subfield thickness to prior treatment with an anti-VEGF agent, e.g., a decrease in central subfield thickness of at least 10%. In some embodiments, prior to administration of the unit dose of rAAV particles, the individual had not experienced an adverse reaction to prior treatment with an anti-VEGF agent. In some embodiments, prior to administration of the unit dose of rAAV particles, the individual did not have neutralizing antibodies against AAV2.7m8. In some embodiments, prior to administration of the unit dose of rAAV particles, e.g., within about 6 months prior to administration of the unit dose of rAAV particles, the individual did not have an anti-AAV2.7m8 neutralizing antibody titer greater than 1:125. In some embodiments, prior to administration of the unit dose of rAAV particles, the individual did not have a history of allergy to aflibercept, corticosteroids, or fluorescein dye or fluorescein sodium (e.g., for angiography). In some embodiments, prior to the administration of the unit dose of rAAV particles, the individual has a history of mild allergy to aflibercept, corticosteroids, or fluorescein dye or fluorescein sodium (e.g., for angiography), where the allergy is treatable. In some embodiments, prior to the administration of the unit dose of rAAV particles, the individual does not have uncontrolled diabetes, e.g., an HbA1C greater than 10%. In some embodiments, the individual does not have a history of diabetic ketoacidosis within about 3 months prior to the administration of the unit dose of rAAV particles. In some embodiments, prior to the administration of the unit dose of rAAV particles, the individual does not start intensive insulin therapy, e.g., with an insulin pump or multiple daily insulin injections. In some embodiments, within about 3 months after the administration of the unit dose of rAAV particles, the individual does not plan to start intensive insulin therapy, e.g., with an insulin pump or multiple daily insulin injections.In some embodiments, prior to administering a unit dose of rAAV particles, the individual does not have a history of systemic autoimmune diseases that require systemic steroid therapy or immunosuppressive therapy (e.g., methotrexate or adalimumab) for treatment. In some embodiments, prior to administering a unit dose of rAAV particles, systemic drugs known to cause macular edema, such as fingolimod, tamoxifen, chloroquine, or hydroxychloroquine, are not administered to the individual. In some embodiments, prior to administering a unit dose of rAAV particles, systemic anti-VEGF therapy is not administered to the individual. In some embodiments, prior to administering a unit dose of rAAV particles, the individual's eyes administering rAAV particles do not have high-risk proliferative diabetic retinopathy (PDR). In some embodiments, PDR is defined as any vitreous or preretinal hemorrhage, neovascularization of >1 / 2-optic disc area elsewhere in an area equivalent to the standard ETDRS 7-field of clinical examination, or neovascularization of >1 / 3-optic disc area of ​​clinical examination. In some embodiments, prior to administration of the unit dose of rAAV particles, the individual's eye to which the rAAV particles were administered had not undergone focal or grid laser photocoagulation. In some embodiments, prior to administration of the unit dose of rAAV particles, the individual's eye to which the rAAV particles were administered had not undergone any prior panretinal photocoagulation (PRP). In some embodiments, prior to administration of the unit dose of rAAV particles, the individual's eye to which the rAAV particles were administered had not received anti-VEGF therapy (e.g., aflibercept IVT injection) in the individual's eye to which the rAAV particles were administered. In some embodiments, prior to administration of the unit dose of rAAV particles, the individual's eye to which the rAAV particles were administered had not received anti-VEGF therapy (e.g., aflibercept IVT injection) for at least 60 days in the individual's eye to which the rAAV particles were administered. In some embodiments, prior to administration of the unit dose of rAAV particles, the individual's eye to which the rAAV particles were administered had not received more than two prior anti-VEGF therapies (e.g., aflibercept IVT injections). In some embodiments, prior to administration of the unit dose of rAAV particles, the individual's eye to which the rAAV particles are administered does not have a history of any of anterior segment neovascularization (e.g., iris neovascularization [NVI] or neovascular glaucoma [NVG]), significant vitreous hemorrhage, fibrovascular proliferation, or tractional retinal detachment. In some embodiments, prior to administration of the unit dose of rAAV particles, the individual's eye to which the rAAV particles are administered does not have a structural abnormality (e.g., any of dense hard exudates, pigment abnormalities, foveal atrophy, vitreomacular traction, or epiretinal membrane) at the fovea that results in macular edema or visual impairment. In some embodiments, structural abnormalities at the fovea are assessed based on clinical examination or OCT.In some embodiments, prior to administration of the unit dose of rAAV particles, the individual's eye to which the rAAV particles are administered does not have a history of retinal disease other than diabetic retinopathy (e.g., age-related macular degeneration (in either eye), retinal vein occlusion, retinal artery occlusion, or pathological myopia). In some embodiments, prior to administration of the unit dose of rAAV particles, the individual's eye to which the rAAV particles are administered does not have a history of ocular disease other than diabetic macular edema (e.g., significant cataract or macular traction), or signs of posterior subcapsular cataract. In some embodiments, within at least about 3 months prior to administration of the unit dose of rAAV particles, the individual's eye to which the rAAV particles are administered does not have a history of cataract extraction or yttrium aluminum garnet (YAG) capsulotomy. In some embodiments, prior to administration of the unit dose of rAAV particles, the individual's eye to which the rAAV particles are administered does not have a history of retinal detachment (repaired or unrepaired). In some embodiments, prior to administration of the unit dose of rAAV particles, the individual's eye to which the rAAV particles are administered does not have a history of any of trabeculectomy, glaucoma shunt, or minimally invasive glaucoma surgery (MIGS). In some embodiments, prior to administration of the unit dose of rAAV particles, the individual's eye to which the rAAV particles are administered does not have a history of vitrectomy or other filtering surgery. In some embodiments, prior to administration of the unit dose of rAAV particles, the individual's eye to which the rAAV particles are administered does not have the presence of aphakia or anterior chamber intraocular lens. In some embodiments, prior to administration of the unit dose of rAAV particles, the individual's eye to which the rAAV particles are administered does not have uncontrolled ocular hypertension or glaucoma, e.g., IOP>22 mmHg despite treatment with anti-glaucoma medication, or currently using>2 IOP-lowering medications. In some embodiments, prior to the administration of the unit dose of rAAV particles, the individual's eye to which the rAAV particles are administered does not have a history of intraocular or periocular steroid treatment (e.g., IVT Triesence, Iluvien, or Ozurdex) for any ocular condition. In some embodiments, the individual's eye to which the rAAV particles are administered has not undergone refractive surgery within at least about 90 days prior to the administration of the unit dose of rAAV particles. In some embodiments, prior to the administration of the unit dose of rAAV particles, the individual's eye to which the rAAV particles are administered has not undergone prior penetrating keratoplasty, endothelial keratoplasty, or ocular radiation. In some embodiments, prior to the administration of the unit dose of rAAV particles, the individual's eye to which the rAAV particles are administered has not undergone any prior vitreoretinal surgery. In some embodiments, prior to the administration of the unit dose of rAAV particles, the individual's eye to which the rAAV particles are administered has not undergone any prior vitreoretinal surgery. In some embodiments, prior to the administration of the unit dose of rAAV particles, the individual does not have a history of uveitis or intraocular inflammation (e.g., mild or higher grade other than mild expected post-operative inflammation that has resolved).In some embodiments, prior to administration of the unit dose of rAAV particles, the individual does not have a history of elevated IOP associated with topical steroid administration. In some embodiments, prior to administration of the unit dose of rAAV particles, the individual does not have a history of ocular herpes simplex virus (HSV), varicella-zoster virus (VZV), or cytomegalovirus (CMV) (including viral uveitis, retinitis, or keratitis). In some embodiments, prior to administration of the unit dose of rAAV particles, the individual does not have any signs of external ocular infection (including conjunctivitis, chalazion, or severe blepharitis). In some embodiments, prior to administration of the unit dose of rAAV particles, the individual does not have a history of ocular toxoplasmosis.

[0124] In some embodiments, the unit dose is expressed as the number of vector genomes (vg). In some embodiments, the unit dose is about 6×10 11 In some embodiments, the unit dose is expressed as the number of vector genomes (vg) per eye (vg / eye). In some embodiments, the unit dose is about 6×10 11 vg / eye or less of rAAV particles. In some embodiments, the unit dose of rAAV particles is about 6×10 10 to about 2×10 11 vg / eye. In some embodiments, the unit dose of rAAV particles is about 2×10 11 or about 6×10 10 vg / eyes.

[0125] In some embodiments, a unit dose of rAAV particles is administered to one eye of an individual. In some embodiments, the one eye of an individual is a right eye or a left eye. In some embodiments, the one eye of an individual is a right eye. In some embodiments, the one eye of an individual is a left eye. In some embodiments, the methods provided herein further comprise administering a unit dose of rAAV particles to the contralateral eye of an individual. In some embodiments, the one eye of an individual is a right eye, and the contralateral eye is a left eye. In some embodiments, the one eye of an individual is a left eye, and the contralateral eye is a right eye.

[0126] In some embodiments, the unit dose of rAAV particles is administered to the contralateral eye of the individual up to about 2 weeks (e.g., about 0 days, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, or 14 days) after the unit dose of rAAV particles is administered to one eye. In some embodiments, the unit dose of rAAV particles administered to the contralateral eye of the individual is about the same (e.g., less than 1% higher or lower, less than 5% higher or lower, less than 10% higher or lower, or less than 20% higher or lower) or lower (e.g., about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% lower) as compared to the unit dose of rAAV particles administered to one eye of the individual.

[0127] In some embodiments, administration of the unit dose of rAAV particles to the contralateral eye is at least about 2 weeks (e.g., at least about 2 weeks, at least about 3 weeks, at least about 4 weeks, at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 1 year, at least about 2 years, at least about 3 years, at least about 4 years, at least about 5 years, or longer) after administration of the unit dose of rAAV particles to one eye. In some embodiments, the unit dose of rAAV particles administered to the contralateral eye of an individual is higher (e.g., any of about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 125%, about 150%, about 175%, about 200%, about 225%, about 250%, about 275%, about 300% or more higher) than the unit dose of rAAV particles administered to one eye of the individual.

[0128] In some embodiments, the rAAV particle comprises a) a nucleic acid encoding a polypeptide flanked by AAV2 inverted terminal repeats (ITRs), the polypeptide comprising an amino acid sequence that is at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.99%, or 100% identical to the amino acid sequence of SEQ ID NO: 35, and b) an AAV2 capsid protein comprising the amino acid sequence LGETTRP (SEQ ID NO: 14) inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to that of the AAV2 VP1 capsid protein. The sequence of SEQ ID NO: 35 is provided below:

[0129] SDTGPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSP SHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAP ELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG(SEQ ID NO:35)

[0130] In some embodiments, the rAAV particle comprises a) a nucleic acid encoding a polypeptide flanked by AAV2 inverted terminal repeats (ITRs), the polypeptide comprising an amino acid sequence at least about 95% identical to the amino acid sequence of SEQ ID NO: 35, and b) an AAV2 capsid protein comprising the amino acid sequence LGETTRP (SEQ ID NO: 14) inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to that of the AAV2 VP1 capsid protein.

[0131] In some embodiments, the rAAV particle comprises a nucleic acid encoding a polypeptide flanked by AAV2 inverted terminal repeats (ITRs), the polypeptide comprising an amino acid sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.99%, or 100% identical to the amino acid sequence of SEQ ID NO: 35. In some embodiments, the rAAV particle comprises a nucleic acid encoding a polypeptide flanked by AAV2 inverted terminal repeats (ITRs), the polypeptide comprising an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO: 35. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 35. In some embodiments, the polypeptide is aflibercept or a functional variant or functional fragment thereof.

[0132] In some embodiments, the rAAV particle comprises a nucleic acid comprising a codon-optimized sequence flanked by AAV2 inverted terminal repeats (ITRs), the codon-optimized sequence encoding an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.99%, or 100% identity to the amino acid sequence of SEQ ID NO: 35. In some embodiments, the rAAV particle comprises a nucleic acid comprising a codon-optimized sequence flanked by AAV2 inverted terminal repeats (ITRs), the codon-optimized sequence encoding an amino acid sequence having at least about 95% identity to the amino acid sequence of SEQ ID NO: 35. In some embodiments, the rAAV particle comprises a nucleic acid comprising a codon-optimized sequence flanked by AAV2 inverted terminal repeats (ITRs), the codon-optimized sequence encoding an amino acid sequence having 100% identity to the amino acid sequence of SEQ ID NO: 35.

[0133] In some embodiments, the rAAV particle comprises a nucleic acid comprising a cDNA sequence of aflibercept or a functional variant thereof or a functional fragment thereof and flanked by AAV2 inverted terminal repeats (ITRs). In some embodiments, the rAAV particle comprises a nucleic acid comprising a codon-optimized cDNA sequence of aflibercept or a functional variant thereof or a functional fragment thereof and flanked by AAV2 inverted terminal repeats (ITRs). In some embodiments, the rAAV particle comprises a nucleic acid comprising the nucleic acid sequence of SEQ ID NO: 36.

[0134] In some embodiments, the nucleic acid further comprises (a) a first enhancer region comprising a CMV sequence; (b) a promoter region comprising a CMV sequence; (c) a 5'UTR region comprising a TPL sequence and an eMLP sequence in 5' to 3' order; (d) a second enhancer region comprising an entire EES sequence; and (e) an HGH polyadenylation site. In some embodiments, the enhancer region comprising the CMV sequence comprises the sequence of SEQ ID NO: 22. In some embodiments, the promoter region comprising the CMV sequence comprises the sequence of SEQ ID NO: 23. In some embodiments, the TPL sequence comprises the sequence of SEQ ID NO: 24. In some embodiments, the eMLP sequence comprises the sequence of SEQ ID NO: 25. In some embodiments, the second enhancer region comprising the entire EES sequence comprises the sequence of SEQ ID NO: 26. In some embodiments, the HGH polyadenylation site comprises the sequence of SEQ ID NO: 27.

[0135] In some embodiments, the rAAV particle comprises an AAV2 capsid protein comprising the amino acid sequence LGETTRP (SEQ ID NO: 14) inserted between positions 587 and 588 of AAV2 VP1 comprising the sequence of SEQ ID NO: 13. The sequence of SEQ ID NO: 13 is provided below:

[0136] (SEQ ID NO: 13)

[0137] In some embodiments, the rAAV particle comprises an AAV2 capsid protein comprising the amino acid sequence LALGETTRPA (SEQ ID NO: 1) inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to that of the AAV2 VP1 capsid protein. In some embodiments, the rAAV particle comprises an AAV2 capsid protein comprising the amino acid sequence LALGETTRPA (SEQ ID NO: 1) inserted between positions 587 and 588 of AAV2 VP1 comprising the sequence of SEQ ID NO: 13.

[0138] In some embodiments, the rAAV particle comprises an AAV2 capsid protein comprising any of the following amino acid sequences inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to that of the AAV2 VP1 capsid protein: LALGETTRPA (SEQ ID NO: 1); LANETITRPA (SEQ ID NO: 2), LAKAGQANNA (SEQ ID NO: 3), LAKDPKTTNA (SEQ ID NO: 4), KDTDTTR (SEQ ID NO: 5), RAGGSVG (SEQ ID NO: 6), AVDTTKF (SEQ ID NO: 7), STGKVPN (SEQ ID NO: 8), LAKDTDTTRA (SEQ ID NO: 9), LARAGGSVGA (SEQ ID NO: 10), LAAVDTTKFA (SEQ ID NO: 11), LASTGKVPNA (SEQ ID NO: 12), LGETTRP (SEQ ID NO: 14), NETITRP (SEQ ID NO: 15), KAGQANN (SEQ ID NO: 16), KDPKTTN (SEQ ID NO: 17). NO: 17), KDTDTTR (SEQ ID NO: 18), RAGGSVG (SEQ ID NO: 19), AVDTTKF (SEQ ID NO: 20), and STGKVPN (SEQ ID NO: 21).In some embodiments, the rAAV particle comprises an AAV2 capsid protein comprising any of the following amino acid sequences inserted between positions 587 and 588 of AAV2 VP1 comprising the sequence of SEQ ID NO: 13: LALGETTRPA (SEQ ID NO: 1); LANETITRPA (SEQ ID NO: 2), LAKAGQANNA (SEQ ID NO: 3), LAKDPKTTNA (SEQ ID NO: 4), KDTDTTR (SEQ ID NO: 5), RAGGSVG (SEQ ID NO: 6), AVDTTKF (SEQ ID NO: 7), STGKVPN (SEQ ID NO: 8), LAKDTDTTRA (SEQ ID NO: 9), LARAGGSVGA (SEQ ID NO: 10), LAAVDTTKFA (SEQ ID NO: 11), LASTGKVPNA (SEQ ID NO: 12), LGETTRP (SEQ ID NO: 14), NETITRP (SEQ ID NO: 15), KAGQANN (SEQ ID NO: 16), KDPKTTN (SEQ ID NO: 17). NO: 17), KDTDTTR (SEQ ID NO: 18), RAGGSVG (SEQ ID NO: 19), AVDTTKF (SEQ ID NO: 20), and STGKVPN (SEQ ID NO: 21).

[0139] In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual is performed by intravitreal (IVT) injection, intraocular administration, or intraretinal injection. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual is performed by intravitreal (IVT) injection.

[0140] In some embodiments, a unit dose of rAAV particles is in a pharmaceutical formulation. In some embodiments, the pharmaceutical formulation comprises rAAV particles, one or more osmotic agents or ionic strength agents, one or more buffers, one or more surfactants, and one or more solvents. In some embodiments, the osmotic agent or ionic strength agent is sodium chloride. In some embodiments, the one or more buffers are sodium dihydrogen phosphate and / or sodium dihydrogen phosphate. In some embodiments, the surfactant is poloxamer 188. In some embodiments, the solvent is water. In some embodiments, the pharmaceutical formulation comprises rAAV particles, sodium chloride, sodium phosphate, and a surfactant. In some embodiments, the pharmaceutical formulation comprises approximately 1×10 10 vg / mL to about 1×10 13vg / mL of rAAV particles. In some embodiments, the pharmaceutical formulation comprises about 6×10 11 vg / mL to about 6×10 12 vg / mL of rAAV particles. In some embodiments, the pharmaceutical preparation comprises about 150mM to about 200mM sodium chloride (e.g., any one of about 150mM, about 160mM, about 170mM, about 180mM, about 190mM, or about 200mM). In some embodiments, the pharmaceutical preparation comprises about 1mM to about 10mM sodium dihydrogen phosphate (e.g., about 1mM, about 2mM, about 3mM, about 4mM, about 5mM, about 6mM, about 7mM, about 8mM, about 9mM, or about 10mM). In some embodiments, the pharmaceutical preparation comprises about 1mM to about 10mM sodium dihydrogen phosphate (e.g., about 1mM, about 2mM, about 3mM, about 4mM, about 5mM, about 6mM, about 7mM, about 8mM, about 9mM, or about 10mM). In some embodiments, the pharmaceutical formulation comprises about 0.0005% (w / v) to about 0.005% (w / v) poloxamer 188 (e.g., any of about 0.0005% (w / v), 0.0006% (w / v), 0.0007% (w / v), 0.0008% (w / v), 0.0009% (w / v), 0.001% (w / v), 0.002% (w / v), 0.003% (w / v), 0.004% (w / v), or about 0.005% (w / v). In some embodiments, the pharmaceutical formulation has a pH of about 7.0 to about 7.5 (e.g., any of about 7.0, about 7.1, about 7.2, about 7.3, about 7.4, or about 7.5). In some embodiments, the pharmaceutical formulation comprises about 6×10 12 vg / mL of rAAV particles, about 180 mM sodium chloride, about 5 mM sodium dihydrogen phosphate, about 5 mM sodium dihydrogen phosphate, and about 0.001% (w / v) poloxamer 188, wherein the pharmaceutical formulation has a pH of about 7.3. In some embodiments, the pharmaceutical formulation comprises about 6×10 11 vg / mL of rAAV particles, about 180 mM sodium chloride, about 5 mM sodium dihydrogen phosphate, about 5 mM sodium dihydrogen phosphate, and about 0.001% (w / v) poloxamer 188, wherein the pharmaceutical formulation has a pH of about 7.3.

[0141] In some embodiments, a unit dose of rAAV particles comprises a volume between about 25 μL and about 250 μL (e.g., any of about 25 μL, about 30 μL, about 40 μL, about 50 μL, about 60 μL, about 70 μL, about 80 μL, about 90 μL, about 100 μL, about 110 μL, about 120 μL, about 130 μL, about 140 μL, about 150 μL, about 160 μL, about 170 μL, about 180 μL, about 190 μL, about 200 μL, about 210 μL, about 220 μL, about 230 μL, about 240 μL, or about 250 μL). In some embodiments, the concentration of rAAV particles in the pharmaceutical formulation is adjusted so that the volume of the unit dose of rAAV particles administered to the eye of an individual is between about 25 μL and about 250 μL. In some embodiments, a unit dose of rAAV particles comprises a volume of about 100 μL. In some embodiments, a unit dose of rAAV particles comprises a volume of about 30 μL.

[0142] In some embodiments, a unit dose of rAAV particles is administered in combination with a steroid treatment. In some embodiments, the steroid treatment is a corticosteroid treatment. In some embodiments, the steroid treatment is a systemic steroid treatment. In some embodiments, the steroid treatment is an oral steroid treatment. In some embodiments, the steroid treatment is a prednisone treatment. In some embodiments, the steroid treatment is an ophthalmic steroid treatment. In some embodiments, the ophthalmic steroid treatment is a topical steroid treatment (e.g., drops), a periocular steroid treatment (e.g., under the Tenon's fascia capsule, under the conjunctiva), an intravitreal steroid treatment, or a suprachoroidal steroid treatment. In some embodiments, the topical steroid treatment is difluprednate treatment, medrysone treatment, loteprednol treatment, prednisolone treatment, fluocinolone treatment, triamcinolone treatment, rimexolone treatment, dexamethasone treatment, fluorometholone treatment, fluocinolone treatment, rimexolone treatment, or prednisone treatment. In some embodiments, the topical steroid treatment is difluprednate treatment. In some embodiments, steroid therapy is administered before, during, and / or after administration of a unit dose of rAAV particles. In some embodiments, steroid therapy is administered before administration of a unit dose of rAAV particles. In some embodiments, steroid therapy is administered during administration of a unit dose of rAAV particles. In some embodiments, steroid therapy is administered after administration of a unit dose of rAAV particles. In some embodiments, steroid therapy is administered before and during administration of a unit dose of rAAV particles. In some embodiments, steroid therapy is administered before and after administration of a unit dose of rAAV particles. In some embodiments, steroid therapy is administered during and after administration of a unit dose of rAAV particles. In some embodiments, steroid therapy is administered before, during, and after administration of a unit dose of rAAV particles.

[0143] In some embodiments, the steroid treatment is an ophthalmic steroid treatment (e.g., difluprednate). In some embodiments, the ophthalmic steroid treatment (e.g., difluprednate) is a daily steroid treatment that lasts up to about 4 weeks, about 6 weeks, or about 8 weeks from the administration of a unit dose of rAAV particles. In some embodiments, the ophthalmic steroid treatment includes administering ophthalmic steroids about four times in about week 1, about three times in about week 2, about twice in about week 3, and about once in about week 4; starting from and after the administration of a unit dose of rAAV particles. In some embodiments, the ophthalmic steroid is about 0.005% to about 0.5% difluprednate. In some embodiments, the ophthalmic steroid is about 0.005%, about 0.006%, about 0.007%, about 0.008%, about 0.009%, about 0.01%, about 0.02%, about 0.03%, about 0.4%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, or about 0.1% difluprednate. In some embodiments, the ophthalmic steroid is difluprednate 0.05%. In some embodiments, the dose of difluprednate 0.05% is one drop of ophthalmic solution. In some embodiments, one drop is about 50 μl (e.g., about 25 μl to about 50 μl, about 50 μl to about 100 μl). In some embodiments, the dose of difluprednate comprises about 1 μg to about 5 μg, or about 2 μg to about 3 μg, or about 2.5 μg difluprednate. In some embodiments, the dose of difluprednate comprises about 2.5 μg difluprednate.

[0144] In some embodiments, a unit dose of rAAV particles is administered in combination with a steroid therapy. In some embodiments, the steroid therapy is a corticosteroid therapy. In some embodiments, the steroid therapy is a systemic steroid therapy. In some embodiments, the steroid therapy is an oral steroid therapy. In some embodiments, the steroid therapy is a prednisone therapy. In some embodiments, the steroid therapy is an ophthalmic steroid therapy. In some embodiments, the ophthalmic steroid therapy is a topical steroid therapy (e.g., drops), a periocular steroid therapy (e.g., under the Tenon's capsule, under the conjunctiva), an intravitreal steroid therapy, or a suprachoroidal steroid therapy. In some embodiments, the ophthalmic steroid therapy is a glucocorticoid, including but not limited to an anti-inflammatory glucocorticoid. In some embodiments, the topical steroid therapy is a glucocorticoid, including but not limited to an anti-inflammatory glucocorticoid. In some embodiments, the topical steroid treatment is difluprednate treatment, medrysone treatment, loteprednol treatment, prednisolone treatment, fluocinolone treatment, triamcinolone treatment, rimexolone treatment, dexamethasone treatment, fluorometholone treatment, fluocinolone treatment, rimexolone treatment, or prednisone treatment. Anti-inflammatory glucocorticoids may include but are not limited to difluprednate, dexamethasone, prednisolone, triamcinolone, fluorometholone, rimexolone, fluocinolone, loteprednol, and generics thereof. In some embodiments, the topical steroid treatment is difluprednate treatment. "Dexamethasone" means dexamethasone and generic dexamethasone and pharmaceutical compositions comprising dexamethasone or generic dexamethasone. Pharmaceutical compositions comprising dexamethasone include but are not limited to Ozurdex TM 、Maxidex TM 、Decadron TM 、Dexamethasone Intensol TM 、Ocu-Dex TM 、Dexycu TM 、Dextenza TM and Zodex TM Ozurdex TM is a pharmaceutical composition comprising dexamethasone. "Difluprednate" means difluprednate, generic difluprednate, and pharmaceutical compositions comprising difluprednate or generic difluprednate. Pharmaceutical compositions comprising difluprednate include, but are not limited to, Durezol TM and difluprednate emulsion. "Triamcinolone" means triamcinolone, generic triamcinolone, and pharmaceutical compositions containing triamcinolone or generic triamcinolone. Pharmaceutical compositions containing triamcinolone include, but are not limited to, Triesence TM 、Xipere TM and Trivaris TM. In some embodiments, steroid therapy is administered before, during, and / or after administration of a unit dose of rAAV particles. In some embodiments, steroid therapy is administered before administration of a unit dose of rAAV particles. In some embodiments, steroid therapy is administered during administration of a unit dose of rAAV particles. In some embodiments, steroid therapy is administered after administration of a unit dose of rAAV particles. In some embodiments, steroid therapy is administered before and during administration of a unit dose of rAAV particles. In some embodiments, steroid therapy is administered before and after administration of a unit dose of rAAV particles. In some embodiments, steroid therapy is administered during and after administration of a unit dose of rAAV particles. In some embodiments, steroid therapy is administered before, during, and after administration of a unit dose of rAAV particles.

[0145] In some embodiments, the steroid treatment is an ophthalmic steroid treatment (e.g., difluprednate). In some embodiments, the ophthalmic steroid treatment (e.g., difluprednate) is a daily topical steroid treatment that lasts up to about 4 weeks, about 6 weeks, or about 8 weeks from the administration of a unit dose of rAAV particles. In some embodiments, the topical steroid treatment includes about four applications of the topical steroid in about week 1, about three applications of the topical steroid in about week 2, about two applications of the topical steroid in about week 3, and about one application of the topical steroid in about week 4; timing is from the administration of the unit dose of rAAV particles and thereafter. In some embodiments, topical steroid treatment comprises administering a topical steroid about four times a day (i.e., QID) after administering a unit dose of rAAV particles for about 3 weeks, followed by administering a topical steroid about 3 times a day (i.e., TID) for about 1 week, followed by administering a topical steroid about 2 times a day (i.e., BID) for about 1 week, and then administering a topical steroid about once a day (i.e., QD) for about 1 week. In some embodiments, the topical steroid comprises difluprednate 0.05% at a dose of about 1 μg to about 3 μg. In some embodiments, the topical steroid comprises difluprednate 0.05% at a dose of about 2.5 μg. In some embodiments, the topical steroid is about 0.005% to about 0.5% difluprednate. In some embodiments, the topical steroid is about 0.005%, about 0.006%, about 0.007%, about 0.008%, about 0.009%, about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, or about 0.1% difluprednate. In some embodiments, the topical steroid is difluprednate 0.05%. In some embodiments, the dose of difluprednate 0.05% is one drop of ophthalmic solution. In some embodiments, one drop is about 50 μl (e.g., about 25 μl to about 50 μl, about 50 μl to about 100 μl). In some embodiments, the dose of difluprednate comprises about 1 μg to about 5 μg, or about 2 μg to about 3 μg, or about 2.5 μg difluprednate. In some embodiments, the dose of difluprednate comprises about 2.5 μg difluprednate.

[0146] In some embodiments, after administering a unit dose of rAAV particles to an eye and / or a fellow eye of the individual, the retinal fluid (e.g., SRF and / or IRF) in the eye of the individual is reduced by more than any of about 5%, about 10%, about 15%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100%. In some embodiments, after administering a unit dose of rAAV particles to an eye and / or a fellow eye of the individual, the retinal fluid (e.g., SRF and / or IRF) in the eye of the individual is reduced by more than any of about 5%, about 10%, about 15%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100% compared to the level of retinal fluid in the eye of the individual before administration of the unit dose of rAAV particles. In some embodiments, retinal fluid (e.g., SRF and / or IRF) in an eye of the individual is reduced by about 100% after administering a unit dose of rAAV particles to the individual's eye and / or the contralateral eye, compared to the retinal fluid level in the eye of the individual before administration of the unit dose of rAAV particles.

[0147] In some embodiments, the methods provided herein also include monitoring the level of retinal fluid (e.g., SRF and / or IRF) in one eye and / or the contralateral eye of an individual after administering a unit dose of rAAV particles. In some embodiments, a decrease in retinal fluid (e.g., SRF and / or IRF) is observed for the first time in any of about 1 day, about 3 days, about 8 days, about 2 weeks, about 4 weeks, about 6 weeks, about 8 weeks, about 12 weeks, about 16 weeks, about 20 weeks, about 24 weeks, about 28 weeks, about 32 weeks, about 36 weeks, about 40 weeks, about 44 weeks, about 48 weeks, about 52 weeks, about 56 weeks, about 60 weeks, about 64 weeks, about 68 weeks, about 72 weeks, about 76 weeks, about 80 weeks, about 84 weeks, about 88 weeks, about 92 weeks, about 96 weeks, about 100 weeks, about 104 weeks, or more after administering a unit dose of rAAV particles. In some embodiments, the reduction in retinal fluid (e.g., SRF and / or IRF) in the eye is sustained or maintained for at least 1 week, at least 2 weeks, at least 4 weeks, at least 6 weeks, at least 8 weeks, at least 12 weeks, at least 16 weeks, at least 20 weeks, at least 24 weeks, at least 28 weeks, at least 32 weeks, at least 36 weeks, at least 40 weeks, at least 44 weeks, at least 48 weeks, at least 52 weeks, at least 56 weeks, at least 60 weeks, at least 64 weeks, at least 68 weeks, at least 72 weeks, at least 76 weeks, at least 80 weeks, at least 84 weeks, at least 88 weeks, at least 92 weeks, at least 96 weeks, at least 100 weeks, at least 104 weeks, or longer following administration of a unit dose of rAAV particles.

[0148] In some embodiments, the reduction of retinal fluid (e.g., SRF and / or IRF) in the eye is determined by any method known in the art. In some embodiments, the reduction of retinal fluid (e.g., SRF and / or IRF) in the eye is determined by optical coherence tomography (OCT), spectral domain OCT (SD-OCT), OCT angiography, fluorescein angiography, or by direct retinal observation. In some embodiments, the reduction of retinal fluid (e.g., SRF and / or IRF) in the eye is determined by optical coherence tomography (OCT). In some embodiments, the reduction of retinal fluid (e.g., SRF and / or IRF) in the eye is determined by spectral domain OCT (SD-OCT). In some embodiments, the reduction of retinal fluid (e.g., SRF and / or IRF) in the eye is determined by OCT angiography. In some embodiments, the reduction of retinal fluid (e.g., SRF and / or IRF) in the eye is determined by fluorescein angiography. In some embodiments, the reduction of retinal fluid (e.g., SRF and / or IRF) in the eye is determined by direct retinal observation.

[0149] In some embodiments, treatment of an ocular neovascular disease in an individual following administration of a unit dose of rAAV particles to one eye and / or the contralateral eye is assessed based on the level of retinal fluid (e.g., subretinal fluid (SRF) and / or intraretinal fluid (IRF)) compared to the level of retinal fluid (e.g., IRF and / or SRF) before administration of a unit dose of rAAV particles (e.g., as described herein) to the one eye and / or the contralateral eye. In some embodiments, the retinal fluid is subretinal fluid (SRF) or intraretinal fluid (IRF). In some embodiments, the retinal fluid is subretinal fluid (SRF). In some embodiments, the retinal fluid is intraretinal fluid (IRF). In some embodiments, treatment of an ocular neovascular disease in an individual following administration of a unit dose of rAAV particles to the eye and / or the fellow eye is determined if a decrease in retinal fluid (e.g., IRF and / or SRF) is observed after administration of a unit dose of rAAV particles to the eye and / or the fellow eye compared to the level of retinal fluid (e.g., IRF and / or SRF) before administration of the unit dose of rAAV particles (e.g., as described above) in the eye and / or the fellow eye. In some embodiments, the ocular neovascular disease is wAMD.

[0150] In some embodiments, administration of a unit dose of rAAV particles to an eye and / or a fellow eye of an individual results in maintenance or reduction of retinal thickness compared to retinal thickness prior to administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to an eye and / or a fellow eye of an individual results in reduction of retinal thickness compared to retinal thickness prior to administration of the unit dose of rAAV particles. In some embodiments, retinal thickness is central subfield thickness (CST) or central retinal thickness (CRT). In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in retinal thickness of greater than about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 99%, or about 100% compared to the retinal thickness before administration of the unit dose of rAAV particles. In some embodiments, retinal thickness (e.g., CST or CRT) is determined by OCT or SD-OCT.

[0151] In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) by about 10 μm to about 100 μm (e.g., more than any of about 10 μm, about 15 μm, about 20 μm, about 25 μm, about 30 μm, about 35 μm, about 40 μm, about 45 μm, about 50 μm, about 55 μm, about 60 μm, about 65 μm, about 70 μm, about 75 μm, about 80 μm, about 85 μm, about 90 μm, about 95 μm, about 100 μm, or more). In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) of about 5 μm to about 50 μm (e.g., any of about 5 μm, about 10 μm, about 15 μm, about 20 μm, about 25 μm, about 30 μm, about 35 μm, about 40 μm, about 45 μm, or about 50 μm). In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) of about 5 μm to about 40 μm (e.g., any of about 5 μm, about 10 μm, about 15 μm, about 20 μm, about 25 μm, about 30 μm, about 35 μm, or about 40 μm). In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) by about 5 μm to about 30 μm (e.g., any of about 5 μm, about 6 μm, about 7 μm, about 8 μm, about 9 μm, about 10 μm, about 11 μm, about 12 μm, about 13 μm, about 14 μm, about 15 μm, about 16 μm, about 17 μm, about 18 μm, about 19 μm, about 20 μm, about 21 μm, about 22 μm, about 23 μm, about 24 μm, about 25 μm, about 26 μm, about 27 μm, about 28 μm, about 29 μm, or about 30 μm). In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) by about 5 μm to about 25 μm (e.g., any of about 5 μm, about 6 μm, about 7 μm, about 8 μm, about 9 μm, about 10 μm, about 11 μm, about 12 μm, about 13 μm, about 14 μm, about 15 μm, about 16 μm, about 17 μm, about 18 μm, about 19 μm, about 20 μm, about 21 μm, about 22 μm, about 23 μm, about 24 μm, or about 25 μm).In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) of about 5 μm to about 20 μm (e.g., any of about 5 μm, about 6 μm, about 7 μm, about 8 μm, about 9 μm, about 10 μm, about 11 μm, about 12 μm, about 13 μm, about 14 μm, about 15 μm, about 16 μm, about 17 μm, about 18 μm, about 19 μm, or about 20 μm). In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) of between about 18 μm and about 75 μm. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central sub-field thickness (CST) by about 18.5 μm. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central sub-field thickness (CST) by about 21.0 μm. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central sub-field thickness (CST) by about 8.3 μm. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central sub-field thickness (CST) by about 25.5 μm. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central sub-field thickness (CST) by about 24.8 μm. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central sub-field thickness (CST) by about 75 μm. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central sub-field thickness (CST) by about 100 μm or more (e.g., about 100 μm or more, about 110 μm or more, about 120 μm or more, about 130 μm or more, about 140 μm or more, about 150 μm or more, about 160 μm or more, about 170 μm or more, about 180 μm or more, about 190 μm or more, or about 200 μm or more).In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) of between about 10 μm and about 200 μm (e.g., any of about 10 μm, about 20 μm, about 30 μm, about 40 μm, about 50 μm, about 60 μm, about 70 μm, about 80 μm, about 90 μm, about 100 μm, about 110 μm, about 120 μm, about 130 μm, about 140 μm, about 150 μm, about 160 μm, about 170 μm, about 180 μm, about 190 μm, or about 200 μm). In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) of between about 50 μm and about 200 μm (e.g., any of about 50 μm, about 60 μm, about 70 μm, about 80 μm, about 90 μm, about 100 μm, about 110 μm, about 120 μm, about 130 μm, about 140 μm, about 150 μm, about 160 μm, about 170 μm, about 180 μm, about 190 μm, or about 200 μm). In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) of between about 60 μm and about 200 μm (e.g., any of about 60 μm, about 70 μm, about 80 μm, about 90 μm, about 100 μm, about 110 μm, about 120 μm, about 130 μm, about 140 μm, about 150 μm, about 160 μm, about 170 μm, about 180 μm, about 190 μm, or about 200 μm). In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) of between about 70 μm and about 200 μm (e.g., any of about 70 μm, about 80 μm, about 90 μm, about 100 μm, about 110 μm, about 120 μm, about 130 μm, about 140 μm, about 150 μm, about 160 μm, about 170 μm, about 180 μm, about 190 μm, or about 200 μm). In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) of between about 80 μm and about 200 μm (e.g., any of about 80 μm, about 90 μm, about 100 μm, about 110 μm, about 120 μm, about 130 μm, about 140 μm, about 150 μm, about 160 μm, about 170 μm, about 180 μm, about 190 μm, or about 200 μm).In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) of between about 90 μm and about 200 μm (e.g., any of about 90 μm, about 100 μm, about 110 μm, about 120 μm, about 130 μm, about 140 μm, about 150 μm, about 160 μm, about 170 μm, about 180 μm, about 190 μm, or about 200 μm). In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) by between about 100 μm and about 200 μm (e.g., any of about 100 μm, about 110 μm, about 120 μm, about 130 μm, about 140 μm, about 150 μm, about 160 μm, about 170 μm, about 180 μm, about 190 μm, or about 200 μm). In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) of between about 110 μm and about 200 μm (e.g., any of about 110 μm, about 120 μm, about 130 μm, about 140 μm, about 150 μm, about 160 μm, about 170 μm, about 180 μm, about 190 μm, or about 200 μm). In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) of between about 115 μm and about 200 μm (e.g., any of about 115 μm, about 120 μm, about 125 μm, about 130 μm, about 135 μm, about 140 μm, about 145 μm, about 150 μm, about 155 μm, about 160 μm, about 165 μm, about 170 μm, about 175 μm, about 180 μm, about 185 μm, about 190 μm, about 195 μm, or about 200 μm). In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) of between about 120 μm and about 200 μm (e.g., any of about 120 μm, about 125 μm, about 130 μm, about 135 μm, about 140 μm, about 145 μm, about 150 μm, about 155 μm, about 160 μm, about 165 μm, about 170 μm, about 175 μm, about 180 μm, about 185 μm, about 190 μm, about 195 μm, or about 200 μm).In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) of between about 125 μm and about 200 μm (e.g., any of about 125 μm, about 130 μm, about 135 μm, about 140 μm, about 145 μm, about 150 μm, about 155 μm, about 160 μm, about 165 μm, about 170 μm, about 175 μm, about 180 μm, about 185 μm, about 190 μm, about 195 μm, or about 200 μm). In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) of between about 130 μm and about 200 μm (e.g., any of about 130 μm, about 135 μm, about 140 μm, about 145 μm, about 150 μm, about 155 μm, about 160 μm, about 165 μm, about 170 μm, about 175 μm, about 180 μm, about 185 μm, about 190 μm, about 195 μm, or about 200 μm). In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) of between about 135 μm and about 200 μm (e.g., any of about 135 μm, about 140 μm, about 145 μm, about 150 μm, about 155 μm, about 160 μm, about 165 μm, about 170 μm, about 175 μm, about 180 μm, about 185 μm, about 190 μm, about 195 μm, or about 200 μm). In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) of between about 140 μm and about 200 μm (e.g., any of about 140 μm, about 145 μm, about 150 μm, about 155 μm, about 160 μm, about 165 μm, about 170 μm, about 175 μm, about 180 μm, about 185 μm, about 190 μm, about 195 μm, or about 200 μm). In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) of between about 145 μm and about 200 μm (e.g., any of about 145 μm, about 150 μm, about 155 μm, about 160 μm, about 165 μm, about 170 μm, about 175 μm, about 180 μm, about 185 μm, about 190 μm, about 195 μm, or about 200 μm).In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) of between about 150 μm and about 200 μm (e.g., any of about 150 μm, about 155 μm, about 160 μm, about 165 μm, about 170 μm, about 175 μm, about 180 μm, about 185 μm, about 190 μm, about 195 μm, or about 200 μm). In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) of between about 155 μm and about 200 μm (e.g., any of about 155 μm, about 160 μm, about 165 μm, about 170 μm, about 175 μm, about 180 μm, about 185 μm, about 190 μm, about 195 μm, or about 200 μm). In some embodiments, administration of a unit dose of rAAV particles to an eye and / or a fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) of between about 160 μm to about 200 μm (e.g., any one of about 160 μm, about 165 μm, about 170 μm, about 175 μm, about 180 μm, about 185 μm, about 190 μm, about 195 μm, or about 200 μm). In some embodiments, administration of a unit dose of rAAV particles to an eye and / or a fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) of between about 165 μm to about 200 μm (e.g., any one of about 165 μm, about 170 μm, about 175 μm, about 180 μm, about 185 μm, about 190 μm, about 195 μm, or about 200 μm). In some embodiments, administration of a unit dose of rAAV particles to an eye and / or a fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) of between about 170 μm to about 200 μm (e.g., any one of about 170 μm, about 175 μm, about 180 μm, about 185 μm, about 190 μm, about 195 μm, or about 200 μm). In some embodiments, administration of a unit dose of rAAV particles to an eye and / or a fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) of between about 175 μm to about 200 μm (e.g., any one of about 175 μm, about 180 μm, about 185 μm, about 190 μm, about 195 μm, or about 200 μm).In some embodiments, administration of a unit dose of rAAV particles to an eye and / or a fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) of between about 180 μm and about 200 μm (e.g., any one of about 180 μm, about 185 μm, about 190 μm, about 195 μm, or about 200 μm). In some embodiments, administration of a unit dose of rAAV particles to an eye and / or a fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) of about 21.0 μm, as compared to the central retinal thickness (CRT) or central subfield thickness (CST) before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central subvisual field thickness (CST) by about 8.3 μm, compared to the central retinal thickness (CRT) or central subvisual field thickness (CST) before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central subvisual field thickness (CST) by about 26.2 μm, compared to the central retinal thickness (CRT) or central subvisual field thickness (CST) before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central subvisual field thickness (CST) by about 24.8 μm, compared to the central retinal thickness (CRT) or central subvisual field thickness (CST) before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central subvisual field thickness (CST) by about 40.8 μm, compared to the central retinal thickness (CRT) or central subvisual field thickness (CST) before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central subvisual field thickness (CST) by about 30.0 μm, compared to the central retinal thickness (CRT) or central subvisual field thickness (CST) before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central subvisual field thickness (CST) by about 118.6 μm, compared to the central retinal thickness (CRT) or central subvisual field thickness (CST) before administration of the unit dose of rAAV particles.In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central subvisual field thickness (CST) by about 119.0 μm, compared to the central retinal thickness (CRT) or central subvisual field thickness (CST) before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central subvisual field thickness (CST) by about 137.8 μm, compared to the central retinal thickness (CRT) or central subvisual field thickness (CST) before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central subvisual field thickness (CST) by about 152.7 μm, compared to the central retinal thickness (CRT) or central subvisual field thickness (CST) before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to an eye and / or a fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central sub-visual field thickness (CST) by about 153.3 μm, compared to the central retinal thickness (CRT) or central sub-visual field thickness (CST) before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to an eye and / or a fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central sub-visual field thickness (CST) by about 149.8 μm, compared to the central retinal thickness (CRT) or central sub-visual field thickness (CST) before administration of the unit dose of rAAV particles.

[0152] In some embodiments, administration of a unit dose of rAAV particles to an eye and / or the contralateral eye of an individual results in a change in central retinal thickness (CRT) or central subfield thickness (CST) of between about -200 μm and about +40 μm (e.g., any of about -200 μm, about -180 μm, about -160 μm, about -140 μm, about -120 μm, about -100 μm, about -80 μm, about -60 μm, about -40 μm, about -20 μm, about 0 μm, about +5 μm, about +10 μm, about +15 μm, about +20 μm, about +25 μm, about +30 μm, about +35 μm, or about +40 μm) compared to the retinal thickness before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) by about 8 μm, about 11 μm, about 16 μm, about 29 μm, about 33 μm, about 38 μm, about 55 μm, about 61 μm, or about 117 μm. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) by about 27.8 μm or about 30.8 μm. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in an increase in central retinal thickness (CRT) or central subfield thickness (CST) by about 4 μm, about 12 μm, or about 32 μm. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a change in central retinal thickness (CRT) or central subvisual field thickness (CST) of approximately -21.0 μm, compared to the central retinal thickness (CRT) or central subvisual field thickness (CST) before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a change in central retinal thickness (CRT) or central subvisual field thickness (CST) of approximately -8.3 μm, compared to the central retinal thickness (CRT) or central subvisual field thickness (CST) before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a change in central retinal thickness (CRT) or central subvisual field thickness (CST) of approximately -26.2 μm, compared to the central retinal thickness (CRT) or central subvisual field thickness (CST) before administration of the unit dose of rAAV particles.In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a change in central retinal thickness (CRT) or central subvisual field thickness (CST) of approximately -24.8 μm, compared to the central retinal thickness (CRT) or central subvisual field thickness (CST) before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a change in central retinal thickness (CRT) or central subvisual field thickness (CST) of approximately -40.8 μm, compared to the central retinal thickness (CRT) or central subvisual field thickness (CST) before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a change in central retinal thickness (CRT) or central subvisual field thickness (CST) of approximately -30.0 μm, compared to the central retinal thickness (CRT) or central subvisual field thickness (CST) before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a change in central retinal thickness (CRT) or central subvisual field thickness (CST) of approximately -118.6 μm, compared to the central retinal thickness (CRT) or central subvisual field thickness (CST) before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a change in central retinal thickness (CRT) or central subvisual field thickness (CST) of approximately -119.0 μm, compared to the central retinal thickness (CRT) or central subvisual field thickness (CST) before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a change in central retinal thickness (CRT) or central subvisual field thickness (CST) of approximately -137.8 μm, compared to the central retinal thickness (CRT) or central subvisual field thickness (CST) before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to an eye and / or a fellow eye of an individual results in a change in central retinal thickness (CRT) or central sub-visual field thickness (CST) of approximately -152.7 μm, compared to the central retinal thickness (CRT) or central sub-visual field thickness (CST) before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to an eye and / or a fellow eye of an individual results in a change in central retinal thickness (CRT) or central sub-visual field thickness (CST) of approximately -153.3 μm, compared to the central retinal thickness (CRT) or central sub-visual field thickness (CST) before administration of the unit dose of rAAV particles.In some embodiments, administration of a unit dose of rAAV particles to an eye and / or the contralateral eye of an individual results in a change in central retinal thickness (CRT) or central subfield thickness (CST) of approximately -149.8 μm compared to central retinal thickness (CRT) or central subfield thickness (CST) before administration of the unit dose of rAAV particles.

[0153] In some embodiments, the change (e.g., decrease) in central retinal thickness (CRT) or central subfield thickness (CST) is present at any of about 1 day, about 1 week, about 2 weeks, about 4 weeks, about 8 weeks, about 16 weeks, about 24 weeks, about 30 weeks, about 32 weeks, about 34 weeks, about 40 weeks, about 44 weeks, about 48 weeks, about 52 weeks, or longer after administration of a unit dose of rAAV particles to the eye and / or the contralateral eye of the individual, compared to the central retinal thickness (CRT) or central subfield thickness (CST) before administration of the unit dose of rAAV particles. In some embodiments, the change (e.g., decrease) in central retinal thickness (CRT) or central subfield thickness (CST) is present at any of about 1 day, about 1 week, about 2 weeks, about 4 weeks, about 8 weeks, about 12 weeks, about 16 weeks, about 20 weeks, about 24 weeks, about 28 weeks, about 32 weeks, about 36 weeks, about 40 weeks, about 44 weeks, about 48 weeks, about 52 weeks, about 56 weeks, about 60 weeks, about 64 weeks, about 68 weeks, about 72 weeks, about 76 weeks, about 80 weeks, about 84 weeks, about 88 weeks, about 92 weeks, about 96 weeks, about 100 weeks, about 104 weeks, about 108 weeks, or longer after administration of a unit dose of rAAV particles to the eye and / or the contralateral eye of the individual, as compared to the central retinal thickness (CRT) or central subfield thickness (CST) before administration of the unit dose of rAAV particles.

[0154] In some embodiments, administration of a unit dose of rAAV particles to an eye and / or the fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) by more than about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 99%, or about 100% compared to the retinal thickness before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to an eye and / or the fellow eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) by at least about 10% compared to the retinal thickness before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to an eye and / or the contralateral eye of an individual results in a decrease in central retinal thickness (CRT) or central subfield thickness (CST) by about 15% or more compared to the retinal thickness before administration of the unit dose of rAAV particles.

[0155] In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in an increase in central retinal thickness (CRT) or central subfield thickness (CST) of less than about 40 μm (e.g., any of less than about 40 μm, less than about 35 μm, less than about 30 μm, less than about 25 μm, less than about 20 μm, less than about 15 μm, less than about 10 μm, less than about 5 μm, less than about 1 μm, or less) compared to the retinal thickness before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in an increase in central retinal thickness (CRT) or central subfield thickness (CST) of about 32 μm or less compared to the retinal thickness before administration of the unit dose of rAAV particles.

[0156] In some embodiments, the maintenance, reduction, or increase in retinal thickness, compared to the retinal thickness before administration of the unit dose of rAAV particles, occurs for about 30 weeks or more after administration of the unit dose of rAAV particles to the individual's eye and / or the fellow eye. In some embodiments, the maintenance, reduction, or increase in retinal thickness, compared to the retinal thickness before administration of the unit dose of rAAV particles, occurs for any of about 30 weeks, about 34 weeks, about 44 weeks, about 6 months, about 1 year, about 1.5 years, about 2 years, about 3 years, about 5 years, about 10 years, or more after administration of the unit dose of rAAV particles to the individual's eye and / or the fellow eye.

[0157] In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in maintenance or reduction of macular volume compared to the macular volume before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a reduction in macular volume compared to the macular volume before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a reduction in macular volume by more than about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50%, compared to the macular volume before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a reduction in macular volume by at least about 10%, compared to the macular volume before administration of the unit dose of rAAV particles. In some embodiments, macular volume is determined by OCT or SD-OCT. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in macular volume of at least about 10% compared to the macular volume before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a decrease in macular volume of about 15% or more compared to the macular volume before administration of the unit dose of rAAV particles. In some embodiments, macular volume is determined by OCT or SD-OCT.

[0158] In some embodiments, the maintenance or reduction in macular volume, compared to the macular volume before administration of the unit dose of rAAV particles, occurs for about 30 weeks or more after administration of a unit dose of rAAV particles to the individual's eye and / or the fellow eye. In some embodiments, the maintenance or reduction in macular volume, compared to the macular volume before administration of the unit dose of rAAV particles, occurs for any of about 30 weeks, about 34 weeks, about 44 weeks, about 6 months, about 1 year, about 1.5 years, about 2 years, about 3 years, about 5 years, about 10 years, or more after administration of a unit dose of rAAV particles to the individual's eye and / or the fellow eye.

[0159] In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in maintenance or improvement of visual acuity compared to the visual acuity before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in improvement of visual acuity compared to the visual acuity before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in improvement of visual acuity by more than about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 125%, about 150%, about 175%, about 200%, about 225%, about 250%, about 275%, about 300% or more compared to the visual acuity before administration of the unit dose of rAAV particles. In some embodiments, the visual acuity is best corrected visual acuity (BCVA). In some embodiments, administering a unit dose of rAAV particles to an eye and / or the contralateral eye of an individual results in an improvement in BCVA compared to the BCVA before administration of the unit dose of rAAV particles. In some embodiments, BCVA is expressed as an ETDRS score, which corresponds to the number of letters read correctly (Vitale et al., (2016) JAMA Opthalmol 134(9):1041:1047).

[0160] In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in an improvement in BCVA of at least 15 ETDRS letters (Vitale et al., (2016) JAMA Opthalmol 134(9):1041:1047) (e.g., at least about 15, at least about 20, at least about 30, at least about 40, at least about 50, at least about 60, or about 70 letters) compared to BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in an improvement in BCVA of between about 1 to about 15 (e.g., any of about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, or about 15) ETDRS letters compared to BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in an improvement in BCVA of about 5 ETDRS letters, compared to BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in an improvement in BCVA of about 1, about 2, about 3, about 4, about 5, about 6, or about 7 ETDRS letters, compared to BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in an improvement in BCVA of about 3 ETDRS letters or more, compared to BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in an improvement in BCVA of about 4 ETDRS letters or more, compared to BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in an improvement in BCVA of about 5.1 ETDRS letters or more, compared to BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in an improvement in BCVA of about 6.4 ETDRS letters or more, compared to BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in an improvement in BCVA of about 6.8 ETDRS letters, compared to BCVA before administration of the unit dose of rAAV particles.In some embodiments, administration of a unit dose of rAAV particles to an eye and / or the fellow eye of an individual results in an improvement in BCVA of about 8.8 ETDRS letters compared to BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to an eye and / or the fellow eye of an individual results in an improvement in BCVA of about 2.3 ETDRS letters compared to BCVA before administration of the unit dose of rAAV particles.

[0161] In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in maintenance of BCVA, compared to BCVA before administration of the unit dose of rAAV particles, wherein the individual loses less than 15 ETDRS letters (Vitale et al., (2016) JAMA Opthalmol 134(9):1041:1047) (e.g., any of 15 or less, 14 or less, 13 or less, 12 or less, 11 or less, 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, 2 or less, 1 or 0 letters). In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in maintenance of BCVA, compared to BCVA before administration of the unit dose of rAAV particles, wherein the individual loses about 2 letters. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in maintenance of BCVA, wherein the individual loses any of about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, or about 9 ETDRS letters, as compared to the BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in maintenance of BCVA, wherein the individual loses 0 letters, as compared to the BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in maintenance of BCVA, wherein the individual loses about 1 letter, as compared to the BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in maintenance of BCVA, wherein the individual loses about 2.7 letters, as compared to the BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to an eye and / or the fellow eye of an individual results in maintenance of BCVA, wherein the individual has lost about 2.8 letters, as compared to BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to an eye and / or the fellow eye of an individual results in maintenance of BCVA, wherein the individual has lost about 2 letters or less, as compared to BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to an eye and / or the fellow eye of an individual results in maintenance of BCVA, wherein the individual has lost about 3.2 letters or less, as compared to BCVA before administration of the unit dose of rAAV particles.In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in maintenance of BCVA, wherein the individual loses between about 15 and about 0 letters (e.g., any one of about 15, about 14, about 13, about 12, about 11, about 10, about 9, about 8, about 7, about 6, about 5, about 4, about 3, about 2, about 1, or 0 letters), as compared to BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in maintenance of BCVA, wherein the individual loses between about 10 and about 0 letters (e.g., any one of about 10, about 9, about 8, about 7, about 6, about 5, about 4, about 3, about 2, about 1, or 0 letters), as compared to BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in maintenance of BCVA, wherein the individual loses between about 5 and about 0 letters (e.g., any one of about 5, about 4, about 3, about 2, about 1, or 0 letters), compared to the BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in maintenance of BCVA, wherein the individual loses between about 4 and about 0 letters (e.g., any one of about 4, about 3, about 2, about 1, or 0 letters), compared to the BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in maintenance of BCVA, wherein the individual loses between about 3 and about 0 letters (e.g., any one of about 3, about 2, about 1, or 0 letters), compared to the BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to an eye and / or the contralateral eye of an individual results in maintenance of BCVA, wherein the individual loses between about 2 and about 0 letters (e.g., any of about 2, about 1, or 0 letters), compared to BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to an eye and / or the contralateral eye of an individual results in maintenance of BCVA, wherein the individual loses between about 1 and about 0 letters, compared to BCVA before administration of the unit dose of rAAV particles.

[0162] In some embodiments, administration of a unit dose of rAAV particles to an eye and / or the contralateral eye of an individual results in a change in BCVA of between about -20 and +7 or more (e.g., any of -20, -19, -18, -17, -16, -15, -14, -13, -12, -11, -10, -9, -8, -7, -6, -5, -4, -3, -2, -1, 0, +1, +2, +3, +4, +5, +6, +7, +8, +9, +10, +11, +12, +13, +14, +15, +16, +17, +18, +19, +20 or more) compared to the BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in an increase in BCVA of about any of 16, 7, or 5 ETDRS letters compared to BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a decrease in BCVA of about any of 19, 14, 7, 6, 5, 4, 3, 2, or 1 ETDRS letters compared to BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a decrease in BCVA of about 4.8 or about 0.8 ETDRS letters compared to BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of an individual results in a decrease in BCVA of about 2 ETDRS letters or less compared to BCVA before administration of the unit dose of rAAV particles. In some embodiments, administering a unit dose of rAAV particles to an eye and / or the contralateral eye of an individual results in a decrease in BCVA of about 3.2 ETDRS letters or less compared to BCVA before administration of the unit dose of rAAV particles.

[0163] In some embodiments, administration of a unit dose of rAAV particles to an eye and / or the contralateral eye of an individual results in a change in BCVA of between about -15 and +7 or more (e.g., any of -15, -14, -13, -12, -11, -10, -9, -8, -7, -6, -5, -4, -3, -2, -1, 0, +1, +2, +3, +4, +5, +6, +7, +8, +9, +10, +11, +12, +13, +14, +15, +16, +17, +18, +19, +20 or more) ETDRS letters compared to the BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in a change in BCVA of between about -10 and +7 or more (e.g., any of -10, -9, -8, -7, -6, -5, -4, -3, -2, -1, 0, +1, +2, +3, +4, +5, +6, +7, +8, +9, +10, +11, +12, +13, +14, +15, +16, +17, +18, +19, +20 or more) ETDRS letters compared to the BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to an eye and / or the contralateral eye of an individual results in a change in BCVA of between about -5 and +7 or more (e.g., any of -5, -4, -3, -2, -1, 0, +1, +2, +3, +4, +5, +6, +7, +8, +9, +10, +11, +12, +13, +14, +15, +16, +17, +18, +19, +20 or more) ETDRS letters compared to the BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to an eye and / or the contralateral eye of an individual results in a change in BCVA of between about -4 and +7 or more (e.g., any of -4, -3, -2, -1, 0, +1, +2, +3, +4, +5, +6, +7, +8, +9, +10, +11, +12, +13, +14, +15, +16, +17, +18, +19, +20 or more) ETDRS letters compared to BCVA before administration of the unit dose of rAAV particles.In some embodiments, administration of a unit dose of rAAV particles to an eye and / or the contralateral eye of an individual results in a change in BCVA of between about -3 and +7 or more (e.g., any of -3, -2, -1, 0, +1, +2, +3, +4, +5, +6, +7, +8, +9, +10, +11, +12, +13, +14, +15, +16, +17, +18, +19, +20 or more) ETDRS letters compared to the BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to an eye and / or the contralateral eye of an individual results in a change in BCVA of between about -2 and +7 or more (e.g., any of -2, -1, 0, +1, +2, +3, +4, +5, +6, +7, +8, +9, +10, +11, +12, +13, +14, +15, +16, +17, +18, +19, +20 or more) ETDRS letters compared to the BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to an eye and / or the contralateral eye of an individual results in a change in BCVA of between about -1 and +7 or more (e.g., any of -1, 0, +1, +2, +3, +4, +5, +6, +7, +8, +9, +10, +11, +12, +13, +14, +15, +16, +17, +18, +19, +20, or more) ETDRS letters compared to BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to an eye and / or the contralateral eye of an individual results in a change in BCVA of between about 0 and +7 or more (e.g., any of 0, +1, +2, +3, +4, +5, +6, +7, +8, +9, +10, +11, +12, +13, +14, +15, +16, +17, +18, +19, +20, or more) ETDRS letters compared to BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to an eye and / or the contralateral eye of an individual results in a change in BCVA of between about +1 and +7 or more (e.g., any of +1, +2, +3, +4, +5, +6, +7, +8, +9, +10, +11, +12, +13, +14, +15, +16, +17, +18, +19, +20 or more) ETDRS letters compared to BCVA before administration of the unit dose of rAAV particles.In some embodiments, administration of a unit dose of rAAV particles to an eye and / or the contralateral eye of an individual results in a change in BCVA of between about +2 and +7 or more (e.g., any of +2, +3, +4, +5, +6, +7, +8, +9, +10, +11, +12, +13, +14, +15, +16, +17, +18, +19, +20 or more) ETDRS letters compared to BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to an eye and / or the contralateral eye of an individual results in a change in BCVA of between about +3 and +7 or more (e.g., any of +3, +4, +5, +6, +7, +8, +9, +10, +11, +12, +13, +14, +15, +16, +17, +18, +19, +20 or more) ETDRS letters compared to BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to an eye and / or the contralateral eye of an individual results in a change in BCVA of between about +4 and +7 or more (e.g., any of +4, +5, +6, +7, +8, +9, +10, +11, +12, +13, +14, +15, +16, +17, +18, +19, +20 or more) ETDRS letters compared to BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to an eye and / or the contralateral eye of an individual results in a change in BCVA of between about +5 and +7 or more (e.g., any of +5, +6, +7, +8, +9, +10, +11, +12, +13, +14, +15, +16, +17, +18, +19, +20 or more) ETDRS letters compared to BCVA before administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to an eye and / or the contralateral eye of an individual results in a change in BCVA of about +6 or about +7 ETDRS letters compared to BCVA before administration of the unit dose of rAAV particles.

[0164] In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in transient inflammation (e.g., inflammation driven by aqueous humor cells and / or vitreous cells, aqueous flare, posterior synechiae, poor pupil dilation). In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in inflammation (e.g., inflammation driven by aqueous humor cells and / or vitreous cells, aqueous flare, posterior synechiae, poor pupil dilation) that improves after administration of oral and / or topical steroid treatment and / or mydriatic agents. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual results in inflammation (e.g., inflammation driven by aqueous humor cells and / or vitreous cells) that resolves after administration of oral and / or topical steroid treatment. Inflammation (eg, inflammation driven by aqueous humor cells and / or vitreous cells, aqueous flare, posterior synechiae, poor pupil dilation) can be measured using any method known in the art, such as slit lamp examination.

[0165] In some embodiments, the maintenance or improvement in visual acuity (e.g., BCVA) compared to the visual acuity before administration of the unit dose of rAAV particles occurs for any of about 1 day, about 1 week, about 2 weeks, about 4 weeks, about 8 weeks, about 12 weeks, about 16 weeks, about 20 weeks, about 24 weeks, about 28 weeks, about 32 weeks, about 36 weeks, about 40 weeks, about 44 weeks, about 48 weeks, about 52 weeks, about 56 weeks, about 60 weeks, about 64 weeks, about 68 weeks, about 72 weeks, about 76 weeks, about 80 weeks, about 84 weeks, about 88 weeks, about 92 weeks, about 96 weeks, about 100 weeks, about 104 weeks, about 108 weeks, or longer after administration of a unit dose of rAAV particles to the individual's eye and / or the contralateral eye. In some embodiments, the maintenance or improvement of visual acuity (e.g., BCVA) is maintained or improved for about 30 weeks or longer after administering a unit dose of rAAV particles to an eye and / or the fellow eye of an individual, compared to the visual acuity before administering the unit dose of rAAV particles. In some embodiments, the maintenance or improvement of visual acuity (e.g., BCVA) is maintained or improved for about 30 weeks, about 34 weeks, about 44 weeks, about 6 months, about 1 year, about 1.5 years, about 2 years, about 3 years, about 5 years, about 10 years, or longer after administering a unit dose of rAAV particles to an eye and / or the fellow eye of an individual, compared to the visual acuity before administering the unit dose of rAAV particles.

[0166] In some embodiments, treatment of an ocular neovascular disease in an individual following administration of a unit dose of rAAV particles in one eye and / or the fellow eye is assessed based on the best corrected visual acuity (BCVA) of the eye and / or the fellow eye. In some embodiments, BCVA is expressed as an ETDRS score, which corresponds to the number of letters read correctly (Vitale et al., (2016) JAMA Opthalmol 134(9):1041:1047). In some embodiments, the individual's vision and / or visual acuity is determined to be maintained if the individual loses less than 15 letters (e.g., any of 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, 1, or 0 letters) in the ETDRS score compared to before administration of the unit dose of rAAV particles in one eye and / or the fellow eye. In some embodiments, the individual's vision and / or visual acuity is determined to be improved if the individual gains at least 15 letters (e.g., any of at least about 15, at least about 20, at least about 30, at least about 40, at least about 50, at least about 60, or about 70 letters) compared to before administration of the unit dose of rAAV particles in one eye and / or the fellow eye.

[0167] In some embodiments, treatment of an ocular neovascular disease in an individual following administration of a unit dose of rAAV particles in one eye and / or the fellow eye is assessed based on central subfield thickness (CST) or central retinal thickness (CRT) in the one eye and / or the fellow eye. In some embodiments, CST or CRT is determined by SD-OCT. In some embodiments, treatment of an ocular neovascular disease in an individual following administration of a unit dose of rAAV particles in the one eye and / or the fellow eye is determined if CST or CRT assessed by SD-OCT is reduced after administration of a unit dose of rAAV particles in the one eye and / or the fellow eye compared to before administration of the unit dose of rAAV particles in the one eye and / or the fellow eye. In some embodiments, treatment of the ocular neovascular disease in the individual following administration of the unit dose of rAAV particles in the one eye and / or the fellow eye is determined if CST or CRT assessed by SD-OCT is maintained after administration of the unit dose of rAAV particles in the one eye and / or the fellow eye compared to before administration of the unit dose of rAAV particles in the one eye and / or the fellow eye.

[0168] In some embodiments, treatment of an ocular neovascular disease in an individual after administration of a unit dose of rAAV particles in one eye and / or the fellow eye is assessed based on macular volume in the one eye and / or the fellow eye. In some embodiments, macular volume is determined by SD-OCT. In some embodiments, if the macular volume assessed by SD-OCT after administration of a unit dose of rAAV particles in the one eye and / or the fellow eye is reduced compared to before administration of the unit dose of rAAV particles in the one eye and / or the fellow eye, treatment of an ocular neovascular disease in the individual after administration of the unit dose of rAAV particles in the one eye and / or the fellow eye is determined. In some embodiments, if the macular volume assessed by SD-OCT after administration of a unit dose of rAAV particles in the one eye and / or the fellow eye is maintained compared to before administration of the unit dose of rAAV particles in the one eye and / or the fellow eye, treatment of an ocular neovascular disease in the individual after administration of the unit dose of rAAV particles in the one eye and / or the fellow eye is determined.

[0169] In some embodiments, treatment of an ocular neovascular disease in an individual following administration of a unit dose of rAAV particles in one eye and / or the fellow eye is assessed based on retinal thickness (e.g., central retinal thickness (CRT) or central subfield thickness (CST)) and macular volume in one eye and / or the fellow eye. In some embodiments, CST and macular volume are determined by SD-OCT. In some embodiments, treatment of an ocular neovascular disease in an individual following administration of a unit dose of rAAV particles in one eye and / or the fellow eye is determined if CST and macular volume assessed by SD-OCT are reduced after administration of a unit dose of rAAV particles in one eye and / or the fellow eye compared to before administration of the unit dose of rAAV particles in the one eye and / or the fellow eye. In some embodiments, treatment of an ocular neovascular disease in an individual following administration of a unit dose of rAAV particles in the one eye and / or the fellow eye is determined if CST and macular volume assessed by SD-OCT are maintained after administration of a unit dose of rAAV particles in the one eye and / or the fellow eye compared to before administration of the unit dose of rAAV particles in the one eye and / or the fellow eye.

[0170] In some embodiments, treatment of an ocular neovascular disease in an individual following administration of a unit dose of rAAV particles in one eye and / or the fellow eye is assessed based on the number of rescue therapy treatments (e.g., aflibercept injections) that the individual required following administration of the unit dose of rAAV particles in the one eye and / or the fellow eye. In some embodiments, treatment of an ocular neovascular disease in an individual following administration of a unit dose of rAAV particles in the one eye and / or the fellow eye is determined if the individual required less than one rescue therapy treatment (e.g., aflibercept injection) every 4 weeks, every 5 weeks, every 6 weeks, every 7 weeks, every 8 weeks, every 9 weeks, every 10 weeks, or more following administration of the unit dose of rAAV particles in the one eye and / or the fellow eye.

[0171] In some embodiments, treatment of an ocular neovascular disease in an individual following administration of a unit dose of rAAV particles in the one eye and / or the contralateral eye is determined if the individual does not require any rescue therapy treatment (e.g., aflibercept injection) for any of at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 7 weeks, at least 8 weeks, at least 9 weeks, at least 10 weeks, at least 15 weeks, at least 20 weeks, at least 30 weeks, at least 40 weeks, at least 50 weeks, at least 60 weeks, at least 70 weeks, at least 80 weeks, at least 90 weeks, at least 100 weeks, at least 110 weeks, or more following administration of the unit dose of rAAV particles in the one eye and / or the contralateral eye.

[0172] In some embodiments, the individual does not require any rescue therapy treatment (e.g., an aflibercept injection) for at least about 24 months, at least about 23 months, at least about 22 months, at least about 21 months, at least about 20 months, at least about 19 months, at least about 18 months, at least about 17 months, at least about 16 months, at least about 15 months, at least about 14 months, at least about 13 months, at least about 12 months, at least about 11 months, at least about 10 months, at least about 9 months, at least about 8 months, at least about 7 months, at least about 6 months, at least about 5 months, at least about 4 months, at least about 3 months, at least about 2 months, at least about 1 month, at least about 3 weeks, at least about 2 weeks, or at least about 1 week after administration of a unit dose of rAAV particles in one eye and / or the fellow eye. In some embodiments, the individual does not require any rescue therapy treatment (e.g., an aflibercept injection) for at least about 12 months after administration of a unit dose of rAAV particles in one eye and / or the fellow eye. In some embodiments, the individual does not require any rescue therapy treatment (e.g., an aflibercept injection) for at least about 10 months after administering a unit dose of rAAV particles in one eye and / or the fellow eye. In some embodiments, the individual does not require any rescue therapy treatment (e.g., an aflibercept injection) for at least about 7 months after administering a unit dose of rAAV particles in one eye and / or the fellow eye. In some embodiments, the individual does not require any rescue therapy treatment (e.g., an aflibercept injection) for at least about 6 months after administering a unit dose of rAAV particles in one eye and / or the fellow eye. In some embodiments, the individual does not require any rescue therapy treatment (e.g., an aflibercept injection) for at least about 2 months after administering a unit dose of rAAV particles in one eye and / or the fellow eye. In some embodiments, the individual does not require any rescue therapy treatment (e.g., an aflibercept injection) for at least about 1 month after administering a unit dose of rAAV particles in one eye and / or the fellow eye.

[0173] In some embodiments, administration of a single unit dose of rAAV particles to one eye and / or the contralateral eye of a plurality of individuals results in at least about 50% (e.g., any one of at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100%) of the individuals in the plurality of individuals not requiring anti-VEGF rescue therapy (e.g., an aflibercept injection). In some embodiments, administration of a single unit dose of rAAV particles to one eye and / or the contralateral eye of a plurality of individuals results in at least about 67% (e.g., any one of at least about 67%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100%) of the individuals in the plurality of individuals not requiring anti-VEGF rescue therapy (e.g., an aflibercept injection). In some embodiments, administration of a single unit dose of rAAV particles to one eye and / or the fellow eye of a plurality of individuals results in at least about 50% of the individuals in the plurality of individuals not requiring anti-VEGF rescue therapy (e.g., an aflibercept injection). In some embodiments, administration of a single unit dose of rAAV particles to one eye and / or the fellow eye of a plurality of individuals results in at least about 78% of the individuals in the plurality of individuals not requiring anti-VEGF rescue therapy (e.g., an aflibercept injection). In some embodiments, administration of a single unit dose of rAAV particles to one eye and / or the fellow eye of a plurality of individuals results in at least about 80% of the individuals in the plurality of individuals not requiring anti-VEGF rescue therapy (e.g., an aflibercept injection). In some embodiments, administration of a single unit dose of rAAV particles to one eye and / or the fellow eye of a plurality of individuals results in at least about 82% of the individuals in the plurality of individuals not requiring anti-VEGF rescue therapy (e.g., an aflibercept injection). In some embodiments, administration of a single unit dose of rAAV particles to one eye and / or the contralateral eye of a plurality of individuals results in 100% of the individuals in the plurality of individuals not requiring anti-VEGF rescue therapy (eg, aflibercept injection).

[0174] In some embodiments, administration of a single unit dose of rAAV particles to one eye and / or the contralateral eye of a plurality of individuals results in at least about 50% (e.g., any of at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100%) of the individuals in the plurality having a positive response to the rAAV particles at least about 4 weeks after administration of the rAAV particles (e.g., at least about 4 weeks, at least about 8 weeks, at least about 12 weeks, at least about 15 weeks, at least about 20 weeks, at least about 30 weeks, at least about 45 weeks, at least about 50% of the individuals in the plurality having a positive response to the rAAV particles at least about 4 weeks after administration of the rAAV particles). In some embodiments, administration of a single unit dose of rAAV particles to one eye and / or the contralateral eye of a plurality of individuals results in at least about 50% of the plurality of individuals not requiring anti-VEGF rescue therapy (e.g., aflibercept injection) for about 52 weeks or more or about 56 weeks or more after administration of the rAAV particles. In some embodiments, administration of a single unit dose of rAAV particles to one eye and / or the contralateral eye of a plurality of individuals results in at least about 67% (e.g., any of at least about 67%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100%) of the individuals in the plurality of individuals not requiring anti-VEGF rescue therapy (e.g., aflibercept injection) for at least about 20 weeks after administration of the rAAV particles (e.g., any of at least about 20 weeks, at least about 24 weeks, at least about 28 weeks, at least about 32 weeks, at least about 36 weeks, at least about 40 weeks, at least about 44 weeks, at least about 48 weeks, at least about 52 weeks, at least about 56 weeks, at least about 60 weeks, at least about 64 weeks, at least about 66 weeks, or more after administration of the rAAV particles).In some embodiments, administration of a single unit dose of rAAV particles to one eye and / or the contralateral eye of a plurality of individuals results in at least about 78% of the individuals in the plurality not requiring anti-VEGF rescue therapy (e.g., aflibercept injection) for at least about 4 weeks after administration of the rAAV particles (e.g., any of at least about 4 weeks, at least about 8 weeks, at least about 12 weeks, at least about 16 weeks, at least about 20 weeks, at least about 24 weeks, at least about 28 weeks, at least about 32 weeks, at least about 36 weeks, at least about 40 weeks, at least about 44 weeks, at least about 48 weeks, at least about 52 weeks, at least about 56 weeks, at least about 60 weeks, at least about 64 weeks, at least about 68 weeks, at least about 72 weeks, at least about 76 weeks, at least about 80 weeks, at least about 84 weeks, at least about 88 weeks, at least about 92 weeks, at least about 96 weeks, at least about 100 weeks, at least about 104 weeks, at least about 108 weeks, or more after administration of the rAAV particles). In some embodiments, administration of a single unit dose of rAAV particles to one eye and / or the contralateral eye of a plurality of individuals results in at least about 78% of the individuals in the plurality of individuals not requiring anti-VEGF rescue therapy (e.g., an aflibercept injection) for about 20 weeks or more or about 36 weeks or more after administration of the rAAV particles. In some embodiments, administration of a single unit dose of rAAV particles to one eye and / or the contralateral eye of a plurality of individuals results in at least about 80% of the individuals in the plurality of individuals not requiring anti-VEGF rescue therapy (e.g., an aflibercept injection) for at least about 20 weeks (e.g., any of at least about 20 weeks, at least about 24 weeks, at least about 28 weeks, at least about 32 weeks, at least about 36 weeks, at least about 40 weeks, at least about 44 weeks, at least about 48 weeks, at least about 52 weeks, at least about 56 weeks, at least about 60 weeks, at least about 64 weeks, at least about 66 weeks, or more after administration of the rAAV particles). In some embodiments, administration of a single unit dose of rAAV particles to one eye and / or the contralateral eye of a plurality of individuals results in at least about 82% of the plurality of individuals not requiring anti-VEGF rescue therapy (e.g., aflibercept injection) for at least about 20 weeks after administration of the rAAV particles (e.g., any of at least about 20 weeks, at least about 24 weeks, at least about 28 weeks, at least about 32 weeks, at least about 36 weeks, at least about 40 weeks, at least about 44 weeks, at least about 48 weeks, at least about 52 weeks, at least about 56 weeks, at least about 60 weeks, at least about 64 weeks, at least about 66 weeks, or more after administration of the rAAV particles).In some embodiments, administration of a single unit dose of rAAV particles to one eye and / or the contralateral eye of a plurality of individuals results in 100% of the individuals in the plurality not requiring anti-VEGF rescue therapy (e.g., aflibercept injection) for at least about 20 weeks after administration of the rAAV particles (e.g., any of at least about 20 weeks, at least about 24 weeks, at least about 28 weeks, at least about 32 weeks, at least about 36 weeks, at least about 40 weeks, at least about 44 weeks, at least about 48 weeks, at least about 52 weeks, at least about 56 weeks, at least about 60 weeks, at least about 64 weeks, at least about 66 weeks, or more after administration of the rAAV particles). In some embodiments, administration of a single unit dose of rAAV particles to one eye and / or the contralateral eye of a plurality of individuals results in 100% of the individuals in the plurality not requiring anti-VEGF rescue therapy (e.g., aflibercept injection) for at least about 4 weeks after administration of the rAAV particles (e.g., any of at least about 4 weeks, at least about 8 weeks, at least about 12 weeks, at least about 16 weeks, at least about 20 weeks, at least about 24 weeks, at least about 28 weeks, at least about 32 weeks, at least about 36 weeks, at least about 40 weeks, at least about 44 weeks, at least about 48 weeks, at least about 52 weeks, at least about 56 weeks, at least about 60 weeks, at least about 64 weeks, at least about 68 weeks, at least about 72 weeks, at least about 76 weeks, at least about 80 weeks, at least about 84 weeks, at least about 88 weeks, at least about 92 weeks, at least about 96 weeks, at least about 100 weeks, at least about 104 weeks, at least about 108 weeks, or more after administration of the rAAV particles). In some embodiments, administration of a single unit dose of rAAV particles to one eye and / or the contralateral eye of a plurality of individuals results in 100% of the individuals in the plurality not requiring anti-VEGF rescue therapy (e.g., aflibercept injection) for any of about 64 weeks or longer, 72 weeks or longer, or 84 weeks or longer after administration of the rAAV particles.

[0175] In some embodiments, administration of a unit dose of rAAV particles in one eye and / or the fellow eye of a plurality of individuals results in about 78% or less (e.g., any of about 78% or less, about 75% or less, about 70% or less, about 65% or less, about 60% or less, about 55% or less, about 50% or less, about 45% or less, about 40% or less, about 35% or less, about 30% or less, about 25% or less, about 20% or less, about 15% or less, about 10% or less, about 5% or less, about 2.5% or less, about 1% or less, or about 0.5% or less) of the individuals in the plurality of individuals requiring any rescue therapy (e.g., aflibercept injection) in the one eye and / or the fellow eye. In some embodiments, administration of a unit dose of rAAV particles in one eye and / or the fellow eye of a plurality of individuals results in about 50% or less (e.g., any of about 50% or less, about 45% or less, about 40% or less, about 35% or less, about 30% or less, about 25% or less, about 20% or less, about 15% or less, about 10% or less, about 5% or less, about 2.5% or less, about 1% or less, or about 0.5% or less) of the individuals in the plurality of individuals requiring any rescue therapy (e.g., aflibercept injection) in the one eye and / or the fellow eye. In some embodiments, administration of a unit dose of rAAV particles in one eye and / or the fellow eye of a plurality of individuals results in less than about 30% (e.g., less than any of about 30%, about 25%, about 20%, about 15%, about 10%, about 5%, about 2.5%, about 1%, or about 0.5%) of the individuals in the plurality of individuals requiring any rescue treatment (e.g., an aflibercept injection) in one eye and / or the fellow eye. In some embodiments, administration of a unit dose of rAAV particles in one eye and / or the fellow eye of a plurality of individuals results in less than about 30% of the individuals in the plurality of individuals requiring any rescue treatment (e.g., an aflibercept injection) in one eye and / or the fellow eye. In some embodiments, administration of a unit dose of rAAV particles in one eye and / or the fellow eye of a plurality of individuals results in less than about 20% of the individuals in the plurality of individuals requiring any rescue treatment (e.g., an aflibercept injection) in one eye and / or the fellow eye. In some embodiments, administering the unit dose of rAAV particles in one eye and / or the fellow eye of the plurality of individuals results in 0% of the individuals in the plurality of individuals requiring any rescue therapy (e.g., aflibercept injection) in the one eye and / or the fellow eye.

[0176] In some embodiments, administration of a unit dose of rAAV particles in one eye and / or the contralateral eye of a plurality of individuals results in about 78% or less (e.g., any of about 78% or less, about 75% or less, about 70% or less, about 65% or less, about 60% or less, about 55% or less, about 50% or less, about 45% or less, about 40% or less, about 35% or less, about 30% or less, about 25% or less, about 20% or less, about 15% or less, about 10% or less, about 5% or less, about 2.5% or less, about 1% or less, or about 0.5% or less) of the individuals in the plurality of individuals experiencing at least about 4 days after administration of the rAAV particles. weeks (e.g., any of at least about 4 weeks, at least about 8 weeks, at least about 12 weeks, at least about 16 weeks, at least about 20 weeks, at least about 24 weeks, at least about 28 weeks, at least about 32 weeks, at least about 36 weeks, at least about 40 weeks, at least about 44 weeks, at least about 48 weeks, at least about 52 weeks, at least about 56 weeks, at least about 60 weeks, at least about 64 weeks, at least about 68 weeks, at least about 72 weeks, at least about 76 weeks, at least about 80 weeks, at least about 84 weeks, at least about 88 weeks, at least about 92 weeks, at least about 96 weeks, at least about 100 weeks, at least about 104 weeks, at least about 108 weeks, or more after administration of the rAAV particles). In some embodiments, administration of a unit dose of rAAV particles in one eye and / or the contralateral eye of a plurality of individuals results in less than about 30% (e.g., less than any of about 30%, about 25%, about 20%, about 15%, about 10%, about 5%, about 2.5%, about 1%, or about 0.5%) of the individuals in the plurality of individuals requiring any rescue therapy (e.g., aflibercept injection) for at least about 20 weeks after administration of the rAAV particles (e.g., any of at least about 20 weeks, at least about 24 weeks, at least about 28 weeks, at least about 32 weeks, at least about 36 weeks, at least about 40 weeks, at least about 44 weeks, at least about 48 weeks, at least about 52 weeks, at least about 56 weeks, at least about 60 weeks, at least about 64 weeks, at least about 66 weeks, or more after administration of the rAAV particles). In some embodiments, administration of a unit dose of rAAV particles in one eye and / or the fellow eye of a plurality of individuals results in less than about 30% of the individuals in the plurality of individuals requiring any rescue therapy (e.g., aflibercept injection) in the one eye and / or the fellow eye at least about 20 weeks after administration of the rAAV particles (e.g., any of at least about 20 weeks, at least about 24 weeks, at least about 28 weeks, at least about 32 weeks, at least about 36 weeks, at least about 40 weeks, at least about 44 weeks, at least about 48 weeks, at least about 52 weeks, at least about 56 weeks, at least about 60 weeks, at least about 64 weeks, at least about 66 weeks, or more after administration of the rAAV particles).In some embodiments, administration of a unit dose of rAAV particles in one eye and / or the fellow eye of a plurality of individuals results in less than about 20% of the individuals in the plurality of individuals requiring any rescue therapy (e.g., aflibercept injection) in the one eye and / or the fellow eye at least about 20 weeks after administration of the rAAV particles (e.g., any of at least about 20 weeks, at least about 24 weeks, at least about 28 weeks, at least about 32 weeks, at least about 36 weeks, at least about 40 weeks, at least about 44 weeks, at least about 48 weeks, at least about 52 weeks, at least about 56 weeks, at least about 60 weeks, at least about 64 weeks, at least about 66 weeks, or more after administration of the rAAV particles). In some embodiments, administration of a unit dose of rAAV particles in one eye and / or the fellow eye of a plurality of individuals results in 0% of the individuals in the plurality of individuals requiring any rescue therapy (e.g., aflibercept injection) in the one eye and / or the fellow eye at least about 20 weeks after administration of the rAAV particles (e.g., any of at least about 20 weeks, at least about 24 weeks, at least about 28 weeks, at least about 32 weeks, at least about 36 weeks, at least about 40 weeks, at least about 44 weeks, at least about 48 weeks, at least about 52 weeks, at least about 56 weeks, at least about 60 weeks, at least about 64 weeks, at least about 66 weeks, or more after administration of the rAAV particles). In some embodiments, administration of a single unit dose of rAAV particles in one eye and / or the contralateral eye of a plurality of individuals results in 0% of the individuals in the plurality having a negative outcome at least about 4 weeks after administration of the rAAV particles (e.g., at least about 4 weeks, at least about 8 weeks, at least about 12 weeks, at least about 16 weeks, at least about 20 weeks, at least about 24 weeks, at least about 28 weeks, at least about 32 weeks, at least about 36 weeks, at least about 40 weeks, at least about 44 weeks after administration of the rAAV particles). , at least about 48 weeks, at least about 52 weeks, at least about 56 weeks, at least about 60 weeks, at least about 64 weeks, at least about 68 weeks, at least about 72 weeks, at least about 76 weeks, at least about 80 weeks, at least about 84 weeks, at least about 88 weeks, at least about 92 weeks, at least about 96 weeks, at least about 100 weeks, at least about 104 weeks, at least about 108 weeks, or longer) in one eye and / or the fellow eye without requiring any rescue treatment (e.g., aflibercept injection).

[0177] In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of a plurality of individuals results in a reduction in the average annualized anti-VEGF injection rate of at least about 80%, at least about 85%, at least about 87%, at least about 90%, at least about 95%, at least about 99%, or 100% compared to the average annualized anti-VEGF injection rate prior to administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of a plurality of individuals results in a reduction in the average annualized anti-VEGF injection rate of about 87% or more compared to the average annualized anti-VEGF injection rate prior to administration of the unit dose of rAAV particles. In some embodiments, administration of a unit dose of rAAV particles to one eye and / or the fellow eye of a plurality of individuals results in a reduction in the average annualized anti-VEGF injection rate of 100% compared to the average annualized anti-VEGF injection rate prior to administration of the unit dose of rAAV particles.

[0178] In some embodiments, the average annualized anti-VEGF injection rate prior to administration of a unit dose of rAAV particles is calculated according to the following formula:

[0179] Annualized rate before administration of a unit dose of rAAV particles=(number of anti-VEGF injections in the 12 months before administration of a unit dose of rAAV particles) / (number of days from the first anti-VEGF injection in the past 12 months before administration of a unit dose of rAAV particles to administration of a unit dose of rAAV particles / 365.25).

[0180] In some embodiments, the average annualized anti-VEGF injection rate following administration of a unit dose of rAAV particles is calculated according to the following formula:

[0181] Annualized rate after administration of a unit dose of rAAV particles=(number of anti-VEGF injections from administration of a unit dose of rAAV particles) / (number of days from administration of a unit dose of rAAV particles / 365.25).

[0182] In some embodiments, the individual is determined to require rescue therapy (e.g., an intravitreal injection of an anti-VEGF, such as an aflibercept injection) after administration of rAAV particles if the individual exhibits a loss of 10 or more letters in BCVA in the eye to which the rAAV particles were administered and / or the fellow eye (attributable to intraretinal fluid or subretinal fluid (e.g., as determined by SD-OCT) as compared to the BCVA of the eye to which the rAAV particles were administered and / or the fellow eye prior to administration of the rAAV particles. In some embodiments, the individual is determined to require rescue therapy (e.g., an intravitreal injection of an anti-VEGF, such as an aflibercept injection) after administration of rAAV particles if the individual exhibits an increase in central subfield thickness (e.g., CST or CRT) of greater than 75 μm in the eye to which the rAAV particles were administered and / or the fellow eye as compared to the central subfield thickness (e.g., as determined by SD-OCT) of the eye to which the rAAV particles were administered and / or the fellow eye prior to administration of the rAAV particles. In some embodiments, the individual is determined to require rescue therapy (e.g., anti-VEGF intravitreal injection, such as aflibercept injection) following administration of rAAV particles if the individual exhibits vision-threatening hemorrhage due to AMD in the eye to which the rAAV particles were administered and / or in the contralateral eye.

[0183] In some embodiments, rescue treatment comprises administration of a standard of care anti-VEGF therapy. Such standard of care anti-VEGF therapy includes one or more anti-VEGF therapies (e.g., intravitreal anti-VEGF injections). In some embodiments, rescue treatment comprises one or more aflibercept IVT injections. In some embodiments, rescue treatment comprises one or more aflibercept IVT injections containing about 2 mg of aflibercept.

[0184] In some embodiments, treatment of an ocular neovascular disease in an individual following administration of a unit dose of rAAV particles in one eye and / or the fellow eye is assessed based on the level of retinal fluid compared to the level of retinal fluid before administration of the unit dose of rAAV particles in the one eye and / or the fellow eye. In some embodiments, treatment of an ocular neovascular disease in an individual following administration of a unit dose of rAAV particles in the one eye and / or the fellow eye is determined if a decrease in retinal fluid is observed after administration of the unit dose of rAAV particles in the one eye and / or the fellow eye as compared to the level of retinal fluid before administration of the unit dose of rAAV particles in the one eye and / or the fellow eye. In some embodiments, the ocular neovascular disease is wAMD.

[0185] In some embodiments, treatment of an ocular neovascular disease in an individual following administration of a unit dose of rAAV particles in one eye and / or the fellow eye is assessed based on resolution of pigment epithelial detachment (PED) as compared to PED before administration of the unit dose of rAAV particles in the one eye and / or the fellow eye. In some embodiments, treatment of an ocular neovascular disease in an individual following administration of a unit dose of rAAV particles in the one eye and / or the fellow eye is determined if resolution of PED is observed after administration of the unit dose of rAAV particles in the one eye and / or the fellow eye as compared to PED before administration of the unit dose of rAAV particles in the one eye and / or the fellow eye. In some embodiments, the ocular neovascular disease is wAMD.

[0186] In some embodiments, treatment of an ocular neovascular disease in an individual following administration of a unit dose of rAAV particles in one eye and / or the fellow eye is assessed based on growth of choroidal neovascularization (CNV) lesions as determined by fluorescein angiography. In some embodiments, treatment of an ocular neovascular disease in an individual following administration of a unit dose of rAAV particles in one eye and / or the fellow eye is determined if the CNV lesion is reduced (e.g., by more than any of about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or 100%) after administration of the unit dose of rAAV particles in the one eye and / or the fellow eye as compared to the CNV lesion that existed before administration of the unit dose of rAAV particles in the one eye and / or the fellow eye. In some embodiments, treatment of an ocular neovascular disease in an individual following administration of a unit dose of rAAV particles in one eye and / or the fellow eye is determined if the CNV lesion does not grow (e.g., grows by less than any of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, or about 20%) after administration of a unit dose of rAAV particles in one eye and / or the fellow eye compared to the CNV lesion that existed before administration of the unit dose of rAAV particles in the one eye and / or the fellow eye. In some embodiments, the ocular neovascular disease is wAMD.

[0187] In some embodiments, the treatment of an ocular neovascular disease in an individual following administration of a unit dose of rAAV particles in one eye and / or the contralateral eye is assessed based on the anatomical features of the eye and / or the contralateral eye, based on any method known in the art (e.g., SD-OCT, OCT, fluorescein angiography, digital color fundus photography, etc.). In some embodiments, treatment of an ocular neovascular disease in an individual following administration of a unit dose of rAAV particles in one eye and / or the contralateral eye is determined if an improvement in the anatomical features of the eye and / or the contralateral eye is observed following administration of a unit dose of rAAV particles in the eye and / or the contralateral eye. In some embodiments, the ocular neovascular disease is wAMD.

[0188] In some embodiments, treatment of an ocular neovascular disease in an individual following administration of a unit dose of rAAV particles in one eye and / or the fellow eye is assessed based on an ophthalmological examination, intraocular pressure (e.g., using a Goldmann applanation tonometer or Tono-Pen), indirect ophthalmoscopy, examination of one eye and / or the fellow eye and adnexa, eyelid and / or pupil reactivity, ptosis, abnormal pupil shape, anisocoria, abnormal reaction to light, afferent pupillary defects, slit lamp examination (including eyelids, conjunctiva, cornea, lens, iris, and anterior chamber), abnormalities of the posterior vitreous segment, optic nerve, peripheral retina, and retinal vasculature, SD-OCT, fluorescein angiography, digital color fundus photography (including images of the retina, optic disc, and / or macula), aqueous humor sampling, vitreous humor sampling, OCT-angiography (OCT-A), refraction, and / or visual acuity (BCVA). In some embodiments, SD-OCT is performed to assess retinal thickness (e.g., central retinal thickness or central subfield thickness), macular volume, and / or the presence of fluid (e.g., subretinal fluid or intraretinal fluid). In some embodiments, the ocular neovascular disease is wAMD.

[0189] A unit dose of rAAV particles can be administered to one eye and / or the contralateral eye of an individual by any method known in the art. For example, a unit dose of rAAV particles can be administered to one eye and / or the contralateral eye of an individual via intraocular or intravitreal injection. In some embodiments, administering a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual is performed intraocularly. In some embodiments, administering a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual is performed by intravitreal injection (IVT) or subretinal injection. In some embodiments, administering a unit dose of rAAV particles to one eye and / or the contralateral eye of an individual is performed by IVT injection. In some embodiments, a unit dose of rAAV particles is administered by intravitreal injection using aseptic technique. In some embodiments, a unit dose of rAAV particles is administered by intravitreal injection using aseptic technique using povidone-iodine.

[0190] In some embodiments, the individual has not received prior treatment for an ocular neovascular disease. In some embodiments, the individual has not received prior treatment for an ocular neovascular disease in one eye and / or the contralateral eye. In some embodiments, the individual has not received prior treatment with an anti-VEGF agent (e.g., bevacizumab, brucella, ranibizumab, fareximab, abispiracept, conbercept, OPT-302, KSI-301, injectable sunitinib maleate (GB-102), PAN-90806 (PanOptica), and / or aflibercept). In some embodiments, the subject has not received prior treatment with an anti-VEGF agent (e.g., bevacizumab, brolucizumab, ranibizumab, farecximab, abispiracept, conbercept, OPT-302, KSI-301, injectable sunitinib maleate (GB-102), PAN-90806 (PanOptica), and / or aflibercept) in one eye and / or the fellow eye. In some embodiments, the subject has not received prior treatment with aflibercept. In some embodiments, the subject has not received prior treatment with aflibercept in one eye and / or the fellow eye.

[0191] Steroid treatment

[0192] In some embodiments, the unit dose of rAAV particles is administered in combination with a steroid therapy. In some embodiments, the steroid therapy is a corticosteroid therapy. Exemplary corticosteroids include, but are not limited to, aclometasone, amcinomide, beclomethasone, betamethasone, budesonide, ciclesonide, clobetasol, clobetasone, clocortolone, cloprednol, cortivazol, deflazacort, deoxycorticosterone, desonide desoximetasone, dexamethasone, diflorasone, diflucortolone, difluprednate, fluclorolone, fludrocortisone, fludroxycortide, flumetasone, flunisolide, fluocinolone acetonide), fluocinonide, fluocortin, fluocortolone, fluorometholone, fluperolone, fluticasone, fluprednidene, formocortal, halcinonide, halometasone, hydrocortisone aceponate, hydrocortisone buteprate, hydrocortisone butyrate In some embodiments, the steroid therapy is systemic steroid therapy. In some embodiments, the steroid therapy is oral steroid therapy. In some embodiments, the steroid therapy is ophthalmic steroid therapy.In some embodiments, the ophthalmic steroid treatment is a topical steroid treatment (e.g., drops), periocular steroid treatment (e.g., sub-Tenon's capsule, subconjunctival), intravitreal steroid treatment, or suprachoroidal steroid treatment. In some embodiments, the topical steroid treatment is difluprednate treatment, medrysone treatment, loteprednol treatment, prednisolone treatment, fluocinolone treatment, triamcinolone treatment, rimexolone treatment, dexamethasone treatment, fluorometholone treatment, fluocinolone treatment, rimexolone treatment, or prednisone treatment. In some embodiments, the ophthalmic steroid treatment is difluprednate treatment. In some embodiments, the steroid treatment is prednisone treatment. In some embodiments, the steroid treatment is difluprednate treatment.

[0193] In some embodiments, steroid therapy includes systemic steroid therapy and topical steroid therapy. In some embodiments, systemic steroid therapy is oral steroid therapy. In some embodiments, systemic steroid therapy is prednisone therapy. In some embodiments, topical steroid therapy is difluprednate therapy. In some embodiments, systemic steroid therapy and topical steroid therapy are applied simultaneously (for example, on the same day). In some embodiments, systemic steroid therapy and topical steroid therapy are applied separately (for example, on different days).

[0194] In some embodiments, the steroid is administered before, during, and / or after the administration of a unit dose of rAAV particles. In some embodiments, the steroid is administered before, during, and after the administration of a unit dose of rAAV particles. In some embodiments, the steroid is administered during and after the administration of a unit dose of rAAV particles. In some embodiments, the steroid is administered before the administration of a unit dose of rAAV particles. In some embodiments, the steroid is administered during the administration of a unit dose of rAAV particles. In some embodiments, the steroid is administered before and during the administration of a unit dose of rAAV particles. In some embodiments, the steroid is administered after the administration of a unit dose of rAAV particles. In some embodiments, the steroid is administered during and after the administration of a unit dose of rAAV particles. In some embodiments, the steroid is administered before and / or after the administration of a unit dose of rAAV particles. In some embodiments, the steroid is administered before and after the administration of a unit dose of rAAV particles.

[0195] In some embodiments, the steroid therapy is systemic steroid therapy. In some embodiments, the systemic steroid therapy is oral steroid therapy.

[0196] In some embodiments, steroid treatment is oral prednisone treatment. In some embodiments, oral prednisone treatment is started before administering a unit dose of rAAV particles. In some embodiments, about 7 days, about 6 days, about 5 days, about 4 days, about 3 days, about 2 days, about 1 day or 0 days before administering a unit dose of rAAV particles, with a dosage of about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg or about 70 mg of prednisone per day, initial oral prednisone treatment is administered, and continues for about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days or about 10 days or longer. In some embodiments, about 3 days before administering a unit dose of rAAV, initial oral prednisone treatment is administered at a dosage of about 60 mg of prednisone per day, and continues for about 3 days.

[0197] In some embodiments, the initial oral prednisone treatment is followed by a gradual reduction in the oral prednisone treatment dose. In some embodiments, the gradually decreasing oral prednisone treatment dose is administered as follows: a dose of any of about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, or about 50 mg of prednisone per day for any of about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days, followed by a dose of about 10 mg, about 15 mg, about 20 mg, or about 25 mg of prednisone per day for any of about 1 day, about 2 days, about 3 days, or about 4 days, followed by a dose of about 5 mg, about 10 mg, or about 15 mg of prednisone per day for about 1 day, about 2 days, about 3 days, or about 4 days. In some embodiments, the tapering prednisone dose is administered as follows: a dose of either prednisone of about 40 mg per day for 3 days, followed by a dose of about 20 mg per day for 2 days, followed by a dose of about 10 mg per day for 2 days.

[0198] In some embodiments, initial oral prednisone therapy is initiated 3 days prior to administration of the unit dose of rAAV particles as follows: a dose of 60 mg of prednisone per day for 6 days, followed by a dose of 40 mg of prednisone per day for 3 days, followed by a dose of 20 mg of prednisone per day for 2 days, followed by a dose of 10 mg of prednisone per day for 2 days.

[0199] In some embodiments, the steroid treatment is an ophthalmic steroid treatment. In some embodiments, the ophthalmic steroid treatment is difluprednate treatment. In some embodiments, the steroid treatment is administered before, during, and / or after the administration of a unit dose of rAAV particles. In some embodiments, the steroid treatment is administered before the administration of a unit dose of rAAV particles. In some embodiments, the steroid treatment is administered during the administration of a unit dose of rAAV particles. In some embodiments, the steroid treatment is administered after the administration of a unit dose of rAAV particles. In some embodiments, the steroid treatment is administered before and during the administration of a unit dose of rAAV particles. In some embodiments, the steroid treatment is administered before and after the administration of a unit dose of rAAV particles. In some embodiments, the steroid treatment is administered during and after the administration of a unit dose of rAAV particles. In some embodiments, the steroid treatment is administered before, during, and after the administration of a unit dose of rAAV particles.

[0200] In some embodiments, the steroid treatment is an ophthalmic steroid treatment, such as a topical steroid treatment. In some embodiments, the ophthalmic steroid treatment, such as a topical steroid treatment, is a daily steroid treatment for up to 4 weeks, up to 6 weeks, up to 8 weeks, up to 3 months, up to 4 months, up to 5 months, or up to 6 months after the administration of the unit dose of rAAV particles. In some embodiments, the topical steroid treatment comprises about four applications of the topical steroid in about week 1, about three applications of the topical steroid in about week 2, about two applications of the topical steroid in about week 3, and about one application of the topical steroid in about week 4; timed from and after the administration of the unit dose of rAAV particles. In some embodiments, topical steroid treatment comprises administering topical steroids about four times a day (i.e., QID) for about 3 weeks following administration of a unit dose of rAAV particles, followed by administering topical steroids about 3 times a day (i.e., TID) for about 1 week, followed by administering topical steroids about 2 times a day (i.e., BID) for about 1 week, and then administering topical steroids about once a day (i.e., QD) for about 1 week. In some embodiments, extended ophthalmic steroid treatment is at the discretion of the treating physician.

[0201] In some embodiments, the ophthalmic steroid is about 0.005% to about 0.5% difluprednate. In some embodiments, the ophthalmic steroid is about 0.005%, about 0.006%, about 0.007%, about 0.008%, about 0.009%, about 0.01%, about 0.02%, about 0.03%, about 0.4%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09% or about 0.1% difluprednate. In some embodiments, the ophthalmic steroid is difluprednate 0.05%. In some embodiments, the dose of difluprednate 0.05% is one drop of ophthalmic solution. In some embodiments, one drop is about 50 μl (e.g., about 25 μl to about 50 μl, or about 50 μl to about 100 μl). In some embodiments, the dose of difluprednate comprises about 1 μg to about 5 μg, or about 2 μg to about 3 μg, or about 2.5 μg difluprednate. In some embodiments, the dose of difluprednate comprises about 2.5 μg difluprednate.

[0202] In some embodiments, the topical steroid treatment comprises 7 weeks of topical steroid treatment, e.g., 0.05% difluprednate. In some embodiments, the topical steroid treatment comprises administering the topical steroid about four times a day (i.e., QID) for about four weeks, followed by administering the topical steroid about three times a day (i.e., TID) for about one week, followed by administering the topical steroid about twice a day (i.e., BID) for about one week, and then administering the topical steroid about once a day (i.e., QD) for about one week; the timing begins about one week prior to administering the unit dose of rAAV particles. In some embodiments, the topical steroid treatment comprises administering the topical steroid about four times a day (i.e., QID) for about 28 days, followed by administering the topical steroid about three times a day (i.e., TID) for about 7 days, followed by administering the topical steroid about twice a day (i.e., BID) for about 7 days, and then administering the topical steroid about once a day (i.e., QD) for about 7 days; the countdown begins about 7 days before the administration of the unit dose of rAAV particles. In some embodiments, the topical steroid treatment comprises administering the topical steroid about four times a day (i.e., QID) on day 1 to about day 28, followed by administering the topical steroid about three times a day (i.e., TID) on day 29 to about day 35, followed by administering the topical steroid about twice a day (i.e., BID) on day 36 to about day 42, and then administering the topical steroid about once a day (i.e., QD) on day 43 to about day 49; the countdown begins on day 1. In some embodiments, if inflammation is present, topical steroid treatment is continued.

[0203] In some embodiments, the treatment methods provided herein include administering an anti-VEGF agent (e.g., aflibercept IVT injection) to one eye of the individual before administering a unit dose of rAAV particles to the individual. In some embodiments, the anti-VEGF agent is administered about 7 days or about 1 week before administering a unit dose of rAAV particles. In some embodiments, the anti-VEGF agent is administered on about day 1, and the unit dose of rAAV particles is administered on about day 8. In some embodiments, topical steroid treatment includes 7 weeks of topical steroid treatment, for example, 0.05% difluprednate. In some embodiments, topical steroid treatment includes administering topical steroids about four times a day (i.e., QID) for about four weeks, followed by administering topical steroids about three times a day (i.e., TID) for about one week, followed by administering topical steroids about twice a day (i.e., BID) for about one week, and then administering topical steroids about once a day (i.e., QD) for about one week; timing from the start and after administration of the anti-VEGF agent. In some embodiments, topical steroid treatment includes applying topical steroids about four times a day (i.e., QID) for about 28 days, followed by applying topical steroids about three times a day (i.e., TID) for about 7 days, followed by applying topical steroids about twice a day (i.e., BID) for about 7 days, and then applying topical steroids about once a day (i.e., QD) for about 7 days; timing is started from and after the application of the anti-VEGF agent. In some embodiments, topical steroid treatment includes applying topical steroids about four times a day (i.e., QID) from day 1 to about day 28, followed by applying topical steroids about three times a day (i.e., TID) from day 29 to about day 35, followed by applying topical steroids about twice a day (i.e., BID) from day 36 to about day 42, and then applying topical steroids about once a day (i.e., QD) from day 43 to about day 49; timing is started on day 1. In some embodiments, if inflammation is present, topical steroid treatment is continued.

[0204] In some embodiments, the topical steroid treatment comprises 4 months of topical steroid treatment, e.g., 0.05% difluprednate. In some embodiments, the topical steroid treatment comprises administering the topical steroid about four times a day (i.e., QID) for about one month, followed by administering the topical steroid about three times a day (i.e., TID) for about one month, followed by administering the topical steroid about twice a day (i.e., BID) for about one month, and then administering the topical steroid about once a day (i.e., QD) for about one month; the timing begins about one week prior to administering the unit dose of rAAV particles. In some embodiments, the topical steroid treatment comprises administering the topical steroid about four times a day (i.e., QID) for about 30 days, followed by administering the topical steroid about three times a day (i.e., TID) for about 30 days, followed by administering the topical steroid about twice a day (i.e., BID) for about 30 days, and then administering the topical steroid about once a day (i.e., QD) for about 30 days; the countdown begins about 7 days before the administration of the unit dose of rAAV particles. In some embodiments, the topical steroid treatment comprises administering the topical steroid about four times a day (i.e., QID) on day 1 to about day 30, followed by administering the topical steroid about three times a day (i.e., TID) on day 31 to about day 60, followed by administering the topical steroid about twice a day (i.e., BID) on day 61 to about day 90, and then administering the topical steroid about once a day (i.e., QD) on day 91 to about day 120; the countdown begins on day 1. In some embodiments, if inflammation is present, topical steroid treatment is continued.

[0205] In some embodiments, the treatment methods provided herein include administering an anti-VEGF agent (e.g., aflibercept IVT injection) to one eye of the individual before administering a unit dose of rAAV particles to the individual. In some embodiments, the anti-VEGF agent is administered about 7 days or about 1 week before administering a unit dose of rAAV particles. In some embodiments, the anti-VEGF agent is administered on about day 1, and the unit dose of rAAV particles is administered on about day 8. In some embodiments, topical steroid treatment includes 4 months of topical steroid treatment, for example, 0.05% difluprednate. In some embodiments, topical steroid treatment includes administering topical steroids about four times a day (i.e., QID) for about one month, followed by administering topical steroids about three times a day (i.e., TID) for about one month, followed by administering topical steroids about twice a day (i.e., BID) for about one month, and then administering topical steroids about once a day (i.e., QD) for about one month; timing from the start of and after the administration of the anti-VEGF agent. In some embodiments, topical steroid treatment includes applying topical steroids about four times a day (i.e., QID) for about 30 days, followed by applying topical steroids about three times a day (i.e., TID) for about 30 days, followed by applying topical steroids about twice a day (i.e., BID) for about 30 days, and then applying topical steroids about once a day (i.e., QD) for about 30 days; timing is started from and after the administration of the anti-VEGF agent. In some embodiments, topical steroid treatment includes applying topical steroids about four times a day (i.e., QID) on day 1 to about day 30, followed by applying topical steroids about three times a day (i.e., TID) on day 31 to about day 60, followed by applying topical steroids about twice a day (i.e., BID) on day 61 to about day 90, and then applying topical steroids about once a day (i.e., QD) on day 91 to about day 120; timing is started on day 1. In some embodiments, if inflammation is present, topical steroid treatment is continued.

[0206] Vectors for delivering transgenes to target cells

[0207] In some embodiments, the recombinant adeno-associated virus (rAAV) particle comprises a recombinant viral vector derived from an adeno-associated virus (AAV) that has been altered so that it is replication-defective in a subject (e.g., a human or non-human primate). In some embodiments, the adeno-associated virus (AAV) is a recombinant AAV (rAAV).

[0208] AAV or rAAV is a small, non-enveloped, single-stranded DNA virus. rAAV is a non-pathogenic human parvovirus and can be made dependent on helper viruses (including adenovirus, herpes simplex virus, vaccinia virus, and CMV) for replication.

[0209] Exposure to wild-type (wt) AAV is not associated with or known to cause any human pathology and is common in the general population, making AAV or rAAV a suitable delivery system for gene therapy. AAV and rAAV used for gene therapy to deliver anti-VEGF agents (e.g., aflibercept) can be of any serotype. In some embodiments, the methods of the present disclosure provide for the use of any suitable AAV serotype, including AAV1, AAV2, AAV2.5, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, rh10, AAV-DJ, and any hybrid or chimeric AAV thereof. In some embodiments, the serotype used is based on the tropism of the virus or the infectivity of the target cell of interest. In some embodiments, several AAV vectors can be generated to allow selection of the optimal serotype for use with the anti-VEGF agent transgene (e.g., aflibercept transgene).

[0210] In some embodiments, the methods of the present disclosure provide for the use of pseudotyped AAVs. Pseudotyped AAV particles comprise an AAV genome inverted terminal repeat (ITR) of one AAV serotype encapsidated by an AAV capsid of another AAV serotype. Typically, pseudotyped AAVs are designated "AAV# / #," where the first "#" indicates the AAV ITR serotype and the second "#" indicates the capsid serotype. For example, an AAV particle comprising an AAV2 ITR and an AAV1 capsid would be referred to as "AAV2 / 1."

[0211] In some embodiments, the rAAV particles comprise nucleic acids, such as heterologous nucleic acids. In some embodiments, the nucleic acid encodes a transgene, such as an anti-VEGF agent (e.g., aflibercept). In some embodiments, the encoded transgene (e.g., an anti-VEGF agent) is under the transcriptional control of a promoter that initiates nucleic acid transcription. In some embodiments, the promoter is a "ubiquitous" promoter. In some embodiments, the promoter is a "strong" or constitutively active promoter, such as a cytomegalovirus (CMV) promoter, an elongation factor 1α (EF1a) promoter, a glyceraldehyde 3-phosphate dehydrogenase (GAPDH) promoter, or a connexin 36 (or "Cx36") promoter. In some embodiments, the promoter is a tissue-specific promoter that is activated in specific tissues or cells, such as retinal cells, to reduce potential toxicity or undesirable effects on non-target cells. In some aspects, several AAV vectors can be generated to allow selection of the best serotype and promoter for use with an anti-VEGF agent transgene (e.g., aflibercept transgene). In some embodiments, the nucleic acid is flanked by AAV inverted terminal repeats (ITRs). In some embodiments, the nucleic acid is flanked by AAV2 ITRs.

[0212] In some embodiments, the AAV vector comprises a polynucleotide cassette for enhanced expression of a transgene (e.g., an anti-VEGF agent, such as aflibercept) in target cells (e.g., retinal cells). In some embodiments, the polynucleotide cassette comprises, in 5' to 3' order: (a) a first enhancer region comprising a CMV sequence (SEQ ID NO: 22); (b) a promoter region comprising a CMV sequence (SEQ ID NO: 23); (c) a 5'UTR region comprising, in 5' to 3' order, a TPL sequence and an eMLP sequence (SEQ ID NO: 24 and SEQ ID NO: 25, respectively); (d) a coding sequence encoding a peptide or polypeptide (e.g., an anti-VEGF agent, such as aflibercept); (e) a second enhancer region comprising an entire EES sequence (SEQ ID NO: 26); and (f) an HGH polyadenylation site (SEQ ID NO: 27). In certain of these embodiments, the polynucleotide cassette comprises one or more sequences selected from SEQ ID NOs: 28-32, or a sequence having at least 85% identity thereto. In some of these embodiments, the 5' arm of the polynucleotide cassette comprises or consists of SEQ ID NO: 33 or a sequence having at least 85% identity thereto. In some of these embodiments, the 3' arm of the polynucleotide cassette comprises or consists of SEQ ID NO: 34 or a sequence having at least 85% identity thereto. The nucleic acid sequences of SEQ ID NOs: 22-34 are provided below:

[0213]

[0214]

[0215] In some embodiments, the polynucleotide cassette comprises or consists of SEQ ID NO: 39, or a sequence at least 85% identical thereto.

[0216]

[0217] SEQ ID NO:39, shown above, comprises, in a 5' to 3' orientation, the inverted terminal repeat (ITR) of AAV serotype 2, comprising nucleotides 1-145 of SEQ ID NO:39; a CMV promoter comprising nucleotides 180-693 of SEQ ID NO:39; a 5' untranslated region (UTR) including an adenoviral tripartite leader sequence and a synthetic intron, and comprising nucleotides 694-1314 of SEQ ID NO:39; a Kozak sequence comprising nucleotides 1329-1340 of SEQ ID NO:39; a codon-optimized aflibercept cDNA sequence comprising nucleotides 1338-2714 of SEQ ID NO:39; a 3' UTR including a human scaffold attachment region and comprising nucleotides 2717-3527 of SEQ ID NO:39; and a human growth hormone polyadenylation / transcription termination signal comprising nucleotides 1340-1352 of SEQ ID NO:39. NO: 39 nucleotides 3546-3748; and AAV serotype 2 inverted terminal repeats (ITRs) comprising nucleotides 3772-3916 of SEQ ID NO: 39. See, e.g. Figure 1C .

[0218] Additional polynucleotide cassettes for enhanced expression of a transgene (e.g., a transgene encoding an anti-VEGF agent such as aflibercept) in target cells (such as retinal cells) are disclosed in WO 2018 / 170473, the contents of which are incorporated herein by reference with respect to polynucleotide cassettes for enhanced expression of a transgene in target cells.

[0219] In some embodiments, rAAV particles include variant capsid proteins with enhanced target cell (e.g., retinal cell) infectivity for increasing transduction of retinal cells or increasing targeting of gene delivery to retinal cells in individuals. In some embodiments, rAAV particles include amino acid modifications in the capsid protein GH loop / loop IV of the AAV capsid protein. In some embodiments, the modification site is a solvent accessible portion of the GH loop / loop IV of the AAV capsid protein. For description of the GH loop / loop IV of the AAV capsid, see, for example, van Vliet et al. (2006) Mol. Ther. 14: 809; Padron et al. (2005) J. Virol. 79: 5047; and Shen et al. (2007) Mol. Ther. 15: 1955. Several AAV capsid variants are known, including the 7m8 variant. In some embodiments, the rAAV particles comprise a variant AAV capsid protein comprising an insertion of 5 to 11 amino acids (e.g., a 7 amino acid sequence) in the GH loop of the capsid protein relative to the corresponding parental AAV capsid protein, and wherein the variant capsid protein confers increased infectivity to retinal cells compared to the infectivity of AAV particles comprising the corresponding parental or unmodified AAV capsid protein to retinal cells. In some embodiments, any of the following amino acid sequences can be inserted into the GH loop of the capsid protein: LALGETTRPA (SEQ ID NO: 1); LANETITRPA (SEQ ID NO: 2), LAKAGQANNA (SEQ ID NO: 3), LAKDPKTTNA (SEQ ID NO: 4), KDTDTTR (SEQ ID NO: 5), RAGGSVG (SEQ ID NO: 6), AVDTTKF (SEQ ID NO: 7), STGKVPN (SEQ ID NO: 8), LAKDTDTTRA (SEQ ID NO: 9), LARAGGSVGA (SEQ ID NO: 10), LAAVDTTKFA (SEQ ID NO: 11), and LASTGKVPNA (SEQ ID NO: 12), LGETTRP (SEQ ID NO: 14), NETITRP (SEQ ID NO: 15), KAGQANN (SEQ ID NO: 16), KDPKTTN (SEQ ID NO: 17), KDTDTTR (SEQ ID NO: 18), RAGGSVG (SEQ ID NO: 19), AVDTTKF (SEQ ID NO: 20), STGKVPN (SEQ ID NO: 21), LAKDTDTTRA (SEQ ID NO: 22), LARAGGSVGA (SEQ ID NO: 23), LAAVDTTKFA (SEQ ID NO: 24), and LASTGKVPNA (SEQ ID NO: 25). NO:19), AVDTTKF (SEQ ID NO:20), and STGKVPN (SEQ ID NO:21).In some embodiments, any one of the amino acid sequences set forth in SEQ ID NOs: 1-12 and 14-21 is inserted into the solvent-exposed GH loop of the VP1 capsid protein in rAAV. Additional details regarding amino acid sequences that can be inserted into the GH loop of a capsid protein (e.g., to facilitate transduction of a target nucleic acid into retinal cells following IVT injection) are provided in WO2012145601, US9587282, US10202657, and US10214785, which are incorporated herein by reference with respect to amino acid sequences that can be inserted into the GH loop of a capsid protein.

[0220] In some embodiments, the rAAV particle comprises an AAV capsid protein, such as an AAV2 capsid protein, comprising any of the following amino acid sequences: LALGETTRPA (SEQ ID NO: 1); LANETITRPA (SEQ ID NO: 2), LAKAGQANNA (SEQ ID NO: 3), LAKDPKTTNA (SEQ ID NO: 4), KDTDTTR (SEQ ID NO: 5), RAGGSVG (SEQ ID NO: 6), AVDTTKF (SEQ ID NO: 7), STGKVPN (SEQ ID NO: 8), LAKDTDTTRA (SEQ ID NO: 9), LARAGGSVGA (SEQ ID NO: 10), LAAVDTTKFA (SEQ ID NO: 11), and LASTGKVPNA (SEQ ID NO: 12), LGETTRP (SEQ ID NO: 14), NETITRP (SEQ ID NO: 15), KAGQANN (SEQ ID NO: 16), KDPKTTN (SEQ ID NO: 17), KDTDTTR (SEQ ID NO: 18), RAGGSVG (SEQ ID NO: 19), AVDTTKF (SEQ ID NO: 20), STGKVPN (SEQ ID NO: 21), LAKDTDTTRA (SEQ ID NO: 22), LARAGGSVGA (SEQ ID NO: 23), LAAVDTTKFA (SEQ ID NO: 24), and LASTGKVPNA (SEQ ID NO: 25). NO:18), RAGGSVG (SEQ ID NO:19), AVDTTKF (SEQ ID NO:20), and STGKVPN (SEQ ID NO:21), wherein the amino acid sequence is inserted between positions 587 and 588 of the AAV2 capsid protein; between amino acids 590 and 591 of the AAV1 capsid protein; between amino acids 575 and 576 of the AAV5 capsid protein; between amino acids 590 and 591 of the AAV6 capsid protein; between amino acids 589 and 590 of the AAV7 capsid protein; between amino acids 590 and 591 of the AAV8 capsid protein; between amino acids 588 and 589 of the AAV9 capsid protein; or between amino acids 589 and 590 of the AAV10 capsid protein. In some embodiments, the rAAV particle comprises an AAV2 capsid protein comprising the amino acid sequence LALGETTRPA (SEQ ID NO: 1) inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to that of the AAV2 VP1 capsid protein. In some embodiments, the rAAV particle comprises an AAV2 capsid protein comprising the amino acid sequence LALGETTRPA (SEQ ID NO: 1) inserted between positions 587 and 588 of AAV2 VP1 comprising the sequence of SEQ ID NO: 13.

[0221] In some embodiments, the rAAV particle comprises a 7m8 variant capsid protein from AAV2 comprising the amino acid sequence LALGETTRPA (SEQ ID NO: 1) inserted into the GH loop of the AAV2 VP1 protein between positions 587 and 588 of AAV2 VP1. In some embodiments, the rAAV particle comprises an AAV2 VP1 capsid protein comprising a GH loop comprising the amino acid sequence of SEQ ID NO: 38 or an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 38. In some embodiments, the rAAV particle comprises an AAV2 VP1 capsid protein comprising a GH loop comprising an amino acid sequence having any of at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 38.

[0222] FSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTNTPSGTTTQSRLQFSQAGASDIRDQSRNWLPGPCYRQQRVSKTSADNNNSEYSWTGATKYHLNGRDSLVNPGPAMASHKDDEEKFFPQS GVLIFGKQGSEKTNVDIEKVMITDEEEIRTTNPVATEQYGSVSTNLQRGNLALGETTRPARQAATADVNTQGVLPGMVWQDRDVYLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKN(SEQ ID NO:38)

[0223] In some embodiments, the rAAV particle comprises a 7m8 variant capsid protein from AAV2 comprising the amino acid sequence LALGETTRPA (SEQ ID NO: 1) inserted between positions 587 and 588 of AAV2 VP1. The sequence of the 7m8 variant capsid protein from AAV2 comprising the amino acid sequence LALGETTRPA (SEQ ID NO: 1) inserted between positions 587 and 588 of AAV2 VP1 is provided below:

[0224] (SEQ ID NO:37)

[0225] In some embodiments, the rAAV particle comprises a capsid protein VP1 comprising the amino acid sequence LGETTRP (SEQ ID NO: 14) inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to the AAV2 VP1 capsid protein. In some embodiments, the rAAV particle comprises a capsid protein VP2 comprising the amino acid sequence LGETTRP (SEQ ID NO: 14) inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to the AAV2 VP1 capsid protein. In some embodiments, the rAAV particle comprises a capsid protein VP3 comprising the amino acid sequence LGETTRP (SEQ ID NO: 14) inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to the AAV2 VP1 capsid protein. In some embodiments, the rAAV particle comprises capsid proteins VP1, VP2, and VP3, wherein each of VP1, VP2, and VP3 comprises the amino acid sequence LGETTRP (SEQ ID NO: 14) inserted between positions 587 and 588 of said capsid protein, wherein the amino acid residue numbering corresponds to that of the AAV2 VP1 capsid protein.

[0226] In some embodiments, the rAAV particle comprises a capsid protein VP1 comprising the amino acid sequence LALGETTRPA (SEQ ID NO: 1) inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to the AAV2 VP1 capsid protein. In some embodiments, the rAAV particle comprises a capsid protein VP2 comprising the amino acid sequence LALGETTRPA (SEQ ID NO: 1) inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to the AAV2 VP1 capsid protein. In some embodiments, the rAAV particle comprises a capsid protein VP3 comprising the amino acid sequence LALGETTRPA (SEQ ID NO: 1) inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to the AAV2 VP1 capsid protein. In some embodiments, the rAAV particle comprises capsid proteins VP1, VP2, and VP3, wherein each of VP1, VP2, and VP3 comprises the amino acid sequence LALGETTRPA (SEQ ID NO: 1) inserted between positions 587 and 588 of said capsid protein, wherein the amino acid residue numbering corresponds to that of the AAV2 VP1 capsid protein.

[0227] In some embodiments, the recombinant virus and / or plasmid used to generate rAAV virus comprises other transcriptional or regulatory elements, such as poly A (polyadenylation) sequences, untranslated regions (UTRs), 3'UTRs, or termination sequences. In some embodiments, an internal ribosome entry site (IRES) or similar element is used to express more than one gene from a vector or plasmid, which allows for the co-expression of two or more proteins or the generation of multi-gene or multi-cistronic mRNAs.

[0228] In some embodiments, rAAV and / or a plasmid used to generate rAAV comprises one or more of the following nucleic acid elements: a first ITR sequence; a promoter sequence; an intron sequence; a first UTR sequence; a heterologous nucleic acid encoding an anti-VEGF agent (e.g., aflibercept); a second UTR sequence; a polyA sequence; and a second ITR sequence. In some embodiments, a linker sequence is inserted between two or more nucleic acid elements. In some embodiments, the heterologous nucleic acid encodes a therapeutic polypeptide, e.g., aflibercept (or a functional fragment or functional variant thereof).

[0229] In some embodiments, the vector is a targeted vector, particularly a targeted rAAV (e.g., AAV2.7m8) that exhibits higher infectivity to specific cells such as retinal cells (e.g., photoreceptors, retinal ganglion cells, Müller cells, bipolar cells, amacrine cells, horizontal cells, or retinal pigment epithelial cells). The viral vectors used in the present disclosure may include those that exhibit low toxicity and / or low immunogenicity in an individual and express a therapeutically effective amount of an anti-VEGF agent (e.g., aflibercept) in an individual (e.g., a human). Any suitable method known in the art can be used for the biochemical purification of recombinant viruses (e.g., rAAV), for example, for the preparation of pharmaceutical compositions described elsewhere herein. The recombinant AAV virus can be harvested directly from the cells or from a culture medium containing the cells. The virus can be purified using various biochemical methods, such as gel filtration, filtration, chromatography, affinity purification, gradient ultracentrifugation, or size exclusion methods. In some embodiments, the virus is lyophilized.

[0230] In some embodiments, the rAAV particles comprise a 7m8 variant capsid protein, such as rAAV2.7m8, and a nucleic acid sequence encoding an anti-VEGF agent (e.g., aflibercept, or a functional fragment or functional variant thereof). In some embodiments, the retinal cell infectivity of the rAAV particles (e.g., 7m8 variant) is increased by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 100% compared to AAV particles comprising the corresponding parental or unmodified AAV capsid protein. In some embodiments, the increase in retinal cell infectivity is any of between 5% and 100%, between 5% and 95%, between 5% and 90%, between 5% and 85%, between 5% and 80%, between 5% and 75%, between 5% and 70%, between 5% and 65%, between 5% and 60%, between 5% and 55%, between 5% and 50%, between 5% and 45%, between 5% and 40%, between 5% and 35%, between 5% and 30%, between 5% and 25%, between 5% and 20%, between 5% and 15%, or between 5% and 10%, compared to AAV particles comprising the corresponding parental or unmodified AAV capsid protein.

[0231] In some embodiments, the retinal cell infectivity of a rAAV variant (e.g., rAAV2.7m8) is increased by any of at least 1-fold, at least 1.1-fold, at least 1.2-fold, at least 1.3-fold, at least 1.4-fold, at least 1.5-fold, at least 1.6-fold, at least 1.7-fold, at least 1.8-fold, at least 1.9-fold, or at least 2-fold compared to an AAV particle comprising the corresponding parental or unmodified AAV capsid protein. In some embodiments, the infectivity is increased by any of at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, or at least 10-fold compared to an AAV particle comprising the corresponding parental AAV capsid protein. In some embodiments, the increase in infectivity is any of at least 15-fold, at least 20-fold, at least 25-fold, at least 30-fold, at least 35-fold, at least 40-fold, at least 45-fold, at least 50-fold, at least 55-fold, at least 60-fold, at least 65-fold, at least 70-fold, at least 75-fold, at least 80-fold, at least 85-fold, at least 90-fold, or at least 100-fold compared to AAV particles comprising the corresponding parental or unmodified AAV capsid protein.

[0232] In some embodiments, the retinal cell infectivity of a rAAV variant (e.g., rAAV2.7m8) is increased by between 10-fold and 100-fold, between 10-fold and 95-fold, between 10-fold and 90-fold, between 10-fold and 85-fold, between 10-fold and 80-fold, between 10-fold and 75-fold, between 10-fold and 70-fold, between 10-fold and 65-fold, between 10-fold and 60-fold, between 10-fold and 55-fold, between 10-fold and 50-fold, between 10-fold and 45-fold, between 10-fold and 40-fold, between 10-fold and 35-fold, between 10-fold and 30-fold, between 10-fold and 25-fold, between 10-fold and 20-fold, or between 10-fold and 15-fold compared to an AAV particle comprising the corresponding parental or unmodified AAV capsid protein.

[0233] In some embodiments, the increase in retinal cell infectivity is between 2-fold and 20-fold, between 2-fold and 19-fold, between 2-fold and 18-fold, between 2-fold and 17-fold, between 2-fold and 16-fold, between 2-fold and 15-fold, between 2-fold and 14-fold, between 2-fold and 13-fold, between 2-fold and 12-fold, between 2-fold and 11-fold, between 2-fold and 10-fold, between 2-fold and 9-fold, between 2-fold and 8-fold, between 2-fold and 7-fold, between 2-fold and 6-fold, between 2-fold and 5-fold, between 2-fold and 4-fold, or between 2-fold and 3-fold compared to AAV particles comprising the corresponding parental or unmodified AAV capsid protein.

[0234] In some embodiments, the amino acid modifications of the capsid proteins described herein can confer an improved ability to cross the inner limiting membrane (ILM) in the eye of an individual (e.g., a human) compared to the ability of AAV particles comprising the corresponding parental or unmodified AAV capsid protein to cross the ILM in the eye of the subject. In some embodiments, the improvement in the ability of a rAAV variant (e.g., rAAV2.7m8) to cross the ILM compared to AAV particles comprising the corresponding parental or unmodified AAV capsid protein is an increase of at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 100%. In some embodiments, the improvement in the ability to cross the ILM is any one of an increase of between 5% and 100%, between 5% and 95%, between 5% and 90%, between 5% and 85%, between 5% and 80%, between 5% and 75%, between 5% and 70%, between 5% and 65%, between 5% and 60%, between 5% and 55%, between 5% and 50%, between 5% and 45%, between 5% and 40%, between 5% and 35%, between 5% and 30%, between 5% and 25%, between 5% and 20%, between 5% and 15%, or between 5% and 10%, compared to the parent or unmodified AAV capsid protein.

[0235] In some embodiments, the ability of a rAAV variant (e.g., rAAV2.7m8) to cross the ILM is improved by at least 1-fold, at least 1.1-fold, at least 1.2-fold, at least 1.3-fold, at least 1.4-fold, at least 1.5-fold, at least 1.6-fold, at least 1.7-fold, at least 1.8-fold, at least 1.9-fold, or at least 2-fold compared to an AAV particle comprising the corresponding parental AAV capsid protein. In some embodiments, the ability to cross the ILM is improved by at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, or at least 10-fold compared to an AAV particle comprising the corresponding parental AAV capsid protein. In some embodiments, the improvement in the ability to cross the ILM is any of at least 15-fold, at least 20-fold, at least 25-fold, at least 30-fold, at least 35-fold, at least 40-fold, at least 45-fold, at least 50-fold, at least 55-fold, at least 60-fold, at least 65-fold, at least 70-fold, at least 75-fold, at least 80-fold, at least 85-fold, at least 90-fold, or at least 100-fold compared to an AAV particle comprising a corresponding parental or unmodified AAV capsid protein.

[0236] In some embodiments, the rAAV variant (e.g., rAAV2.7m8) has an improvement in the ability to cross the ILM of between 10-fold and 100-fold, between 10-fold and 95-fold, between 10-fold and 90-fold, between 10-fold and 85-fold, between 10-fold and 80-fold, between 10-fold and 75-fold, between 10-fold and 70-fold, between 10-fold and 65-fold, between 10-fold and 60-fold, between 10-fold and 55-fold, between 10-fold and 50-fold, between 10-fold and 45-fold, between 10-fold and 40-fold, between 10-fold and 35-fold, between 10-fold and 30-fold, between 10-fold and 25-fold, between 10-fold and 20-fold, or between 10-fold and 15-fold compared to an AAV particle comprising the corresponding parental or unmodified AAV capsid protein.

[0237] In some embodiments, the improvement in the ability of a rAAV variant (e.g., rAAV2.7m8) to cross the ILM is between 2-fold and 20-fold, 2-fold and 19-fold, 2-fold and 18-fold, 2-fold and 17-fold, 2-fold and 16-fold, 2-fold and 15-fold, 2-fold and 14-fold, 2-fold and 13-fold, 2-fold and 12-fold, 2-fold and 11-fold, 2-fold and 10-fold, 2-fold and 9-fold, 2-fold and 8-fold, 2-fold and 7-fold, 2-fold and 6-fold, 2-fold and 5-fold, 2-fold and 4-fold, or 2-fold and 3-fold compared to AAV particles comprising the corresponding parental or unmodified AAV capsid protein.

[0238] In some embodiments, rAAV.7m8 comprising a nucleic acid encoding aflibercept is used for gene therapy. In some embodiments, a nucleic acid sequence encoding an anti-VEGF agent (e.g., aflibercept) is delivered to the eye or retinal cells of a subject via intravitreal or subretinal injection using AAV2 or rAAV2. In some embodiments, a nucleic acid sequence encoding an anti-VEGF agent (e.g., aflibercept) is delivered to the eye or retinal cells of a subject via intravitreal injection using AAV2 or rAAV2. In some embodiments, a nucleic acid sequence encoding an anti-VEGF agent (e.g., aflibercept) is delivered to the eye or retinal cells of a subject using rAAV2.7m8. In some embodiments, a heterologous nucleic acid (e.g., a nucleic acid encoding an anti-VEGF agent such as aflibercept) is integrated into the target cell genome (e.g., the retinal cell genome), resulting in, for example, long-term expression of an anti-VEGF agent (such as aflibercept) in the target cell. In some embodiments, a viral vector delivers a plasmid or other extrachromosomal genetic element comprising a heterologous nucleic acid (eg, a nucleic acid encoding an anti-VEGF agent such as aflibercept) to a target cell (eg, a retinal cell).

[0239] In some embodiments, the rAAV particle comprises a nucleic acid encoding a polypeptide flanked by AAV2 inverted terminal repeats (ITRs), the polypeptide comprising an amino acid sequence that is at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% identical to the amino acid sequence of SEQ ID NO: 35. In some embodiments, the rAAV particle comprises a nucleic acid encoding a polypeptide flanked by AAV2 inverted terminal repeats (ITRs), the polypeptide comprising an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO: 35. In some embodiments, the rAAV particle comprises a nucleic acid encoding a polypeptide flanked by AAV2 inverted terminal repeats (ITRs), the polypeptide comprising the amino acid sequence of SEQ ID NO: 35. In some embodiments, the rAAV particle comprises a nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 35. In some embodiments, the rAAV particle comprises a nucleic acid encoding aflibercept flanked by AAV2 inverted terminal repeats (ITRs). The sequence of SEQ ID NO:35 is provided below:

[0240] SDTGPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSP SHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAP ELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG(SEQ ID NO:35)

[0241] In some embodiments, the rAAV particle comprises a nucleic acid having any of at least about 75%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.9%, or at least about 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 36, and wherein the nucleic acid is flanked by AAV2 inverted terminal repeats (ITRs). The sequence of SEQ ID NO: 36 is provided at Figure 5In some embodiments, the rAAV particle comprises a nucleic acid having at least about 75%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.9%, or at least about 100% sequence homology to the nucleic acid sequence of aflibercept (e.g., SEQ ID NO: 36), and wherein the nucleic acid is flanked by AAV2 inverted terminal repeats (ITRs). In some embodiments, the nucleic acid sequence of aflibercept is derived from its amino acid sequence. In some embodiments, the nucleic acid sequence of aflibercept is codon-optimized to improve its expression in a subject. In some embodiments, the rAAV particle comprises a nucleic acid having any of at least about 75%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.9%, or 100% sequence homology to the nucleic acid sequence of SEQ ID NO: 40, and wherein the nucleic acid is flanked by AAV2 inverted terminal repeats (ITRs). In some embodiments, the rAAV particle comprises a nucleic acid comprising the nucleic acid sequence of SEQ ID NO: 40. In some embodiments, the rAAV particle comprises a nucleic acid comprising the nucleic acid sequence of SEQ ID NO: 40, and wherein the nucleic acid is flanked by AAV2 inverted terminal repeats (ITRs).

[0242]

[0243] In some embodiments, the rAAV particle comprises a nucleic acid encoding a polypeptide flanked by AAV2 inverted terminal repeats (ITRs), the polypeptide comprising an amino acid sequence that is at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 41. In some embodiments, the rAAV particle comprises a nucleic acid encoding a polypeptide flanked by AAV2 inverted terminal repeats (ITRs), the polypeptide comprising an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO: 41. In some embodiments, the rAAV particle comprises a nucleic acid encoding a polypeptide flanked by AAV2 inverted terminal repeats (ITRs), the polypeptide comprising the amino acid sequence of SEQ ID NO: 41. In some embodiments, the rAAV particle comprises a nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 41.

[0244] MVSYWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYK TNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:41)

[0245] In some embodiments, the nucleic acid sequence of aflibercept is codon-optimized for expression in primates or human subjects. Construction of a synthetic gene corresponding to the amino acid sequence of aflibercept has been described in the literature, for example, Kanda A, Noda K, Saito W, Ishida S. Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy. Scientific Reports 5:17946 (2015) (describing “Transduction of VEGF-Trap into VEGF-Trap by IDT (Coralville, IA)”). R1R2 cDNA (corresponding to aflibercept) was generated as a synthetic gene ("a synthetic gene"). Given the available amino acid sequence of aflibercept, any method known in the art can be used to generate cDNA for aflibercept for use in gene therapy or rAAV as described herein.

[0246] Codon optimization can be achieved using any method known in the art. Codon optimization refers to the process of modifying a nucleic acid sequence for enhancing the expression of a gene in a target cell or host cell (e.g., human retinal cells) by replacing at least one codon of a native sequence with a codon that is more frequently used or most frequently used in a host cell while maintaining the native amino acid sequence. Codon usage tables are readily available, including, for example, GenScript codon usage frequency table tools (www (dot) genscript (dot) com / tools / codon-frequency-table); codon usage databases (www (dot) kazusa (dot) or (dot) jp / codon / ); and Nakamura, Y. et al. "Codon usage tabulated from the international DNA sequence databases: status for the year 2000" Nucl. Acids Res. 28: 292 (2000).

[0247] Homology refers to the percentage of conservation of aligned residues between two sequences, including but not limited to functional fragments, sequences containing insertions, deletions, substitutions, pseudo fragments, pseudo genes, splice variants or artificially optimized sequences.

[0248] In some embodiments, the rAAV particle comprises a nucleic acid encoding aflibercept. In some embodiments, the polypeptide is aflibercept.

[0249] As used herein, "aflibercept" refers to a polypeptide or protein sequence having at least 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more, or 100% homology to the aflibercept amino acid sequence identified above (SEQ ID NO: 35), or a functional fragment, variant, or mutant thereof. Homology refers to the percentage conservation of residues between two aligned sequences, including but not limited to functional fragments, sequences containing insertions, deletions, substitutions, pseudofragments, pseudogenes, splice variants, or artificially optimized sequences.

[0250] In some embodiments, the amino acid sequence of aflibercept is at least any of 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% homologous to the amino acid sequence of aflibercept of SEQ ID NO: 35. In some embodiments, the nucleic acid sequences encoding aflibercept disclosed herein are compared to the corresponding cDNA sequences of the aflibercept amino acid sequences identified above and show at least any of 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9% or 100% sequence homology between the nucleic acid sequence of aflibercept (e.g., SEQ ID NO: 36). In some embodiments, aflibercept has at least any of 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% spatial homology to aflibercept (e.g., with respect to its secondary, tertiary, and quaternary structure or conformation). In some embodiments, aflibercept has at most any of 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% spatial homology to aflibercept used in standard of care (e.g., with respect to its secondary, tertiary, and quaternary structure or conformation).

[0251] In some embodiments, the aflibercept gene product or aflibercept transgene (e.g., as included in an rAAV-based gene therapy) comprises a capsid variant as disclosed herein (e.g., a 7m8 variant), encoding a protein, fusion protein, or polypeptide having at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% homology to the amino acid sequence of SEQ ID NO: 35 above, or to the corresponding cDNA sequence of aflibercept (e.g., the cDNA of the aflibercept sequence used in gene therapy compared to SEQ ID NO: 36). In some embodiments, the method compositions disclosed herein comprise a functional fragment of aflibercept or a variant or mutant thereof. In some embodiments, the nucleic acid sequence of aflibercept is modified or codon-optimized to enhance its in vivo activity, expression, stability, and / or solubility.

[0252] Aflibercept is a 115 kDa fusion protein that can be glycosylated. Aflibercept comprises an IgG backbone fused to the extracellular VEGF receptor sequences of human VEGFR-1 and VEGFR-2 and acts like a soluble decoy receptor by binding to VEGF-A with a higher affinity than its native or endogenous receptor. See, e.g., Stewart MW. Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug. Br. J. Ophthalmol. 2012 Sep;96(9):1157-8. Aflibercept's high affinity for VEGF interferes with or disrupts subsequent binding and activation of native or endogenous VEGF receptors. Reduced VEGF activity can lead to angiogenesis and reduced vascular permeability. Aflibercept's inhibition of placental growth factors PIGF and VEGF-B may also be useful in treating ocular diseases or conditions characterized by abnormal (e.g., excessive) angiogenesis and / or neovascularization. PlGF is associated with angiogenesis, and certain ocular diseases or conditions, such as wet AMD, may be associated with elevated PlGF levels. Overexpression of VEGF-B may be associated with disruption of the blood-retinal barrier and retinal angiogenesis. Therefore, inhibition of VEGF-A, VEGF-B, and PlGF may all contribute to the efficacy of aflibercept.

[0253] Method for preparing vector for delivering transgene to target cells

[0254] In some embodiments, rAAV particles are manufactured using any method known in the art. In some embodiments, rAAV particles are manufactured using a baculovirus expression vector system in Sf9 cells. Sf9 cells are an insect cell culture cell line commonly used for recombinant protein production using baculovirus. In some embodiments, two baculoviruses are used to manufacture rAAV particles in Sf9 cells. In some embodiments, two baculoviruses are used to manufacture rAAV particles in Sf9 cells, wherein the first baculovirus encodes the genes for AAV2 Rep and AAV2.7m8 Cap proteins, and the second baculovirus encodes an anti-VEGF agent. In some embodiments, two baculoviruses are used to manufacture rAAV particles in Sf9 cells, wherein the first baculovirus encodes the genes for AAV2 Rep and AAV2.7m8 Cap proteins, and the second baculovirus encodes an aflibercept (e.g., human aflibercept) cDNA expression cassette. In some embodiments, rAAV particles are produced in Sf9 cells using two baculoviruses, wherein the first baculovirus encodes genes for the AAV2 Rep and AAV2.7m8 Cap proteins, and the second baculovirus comprises a nucleic acid encoding a polypeptide flanked by AAV2 inverted terminal repeats (ITRs), the polypeptide comprising an amino acid sequence at least about 95% identical to the amino acid sequence of SEQ ID NO: 35. In some embodiments, the polypeptide comprises the amino acid sequence of SEQ ID NO: 35. In some embodiments, the polypeptide is aflibercept.

[0255] dose

[0256] In some embodiments, a unit dose of rAAV particles is administered to one eye of an individual. In some embodiments, the one eye of an individual is a right eye or a left eye. In some embodiments, the one eye of an individual is a right eye. In some embodiments, the one eye of an individual is a left eye. In some embodiments, the methods provided herein further comprise administering a unit dose of rAAV particles to the contralateral eye of an individual. In some embodiments, the one eye of an individual is a right eye, and the contralateral eye is a left eye. In some embodiments, the one eye of an individual is a left eye, and the contralateral eye is a right eye.

[0257] In some embodiments, administration of the unit dose of rAAV particles to the contralateral eye is at least about 2 weeks (e.g., at least about 2 weeks, at least about 3 weeks, at least about 4 weeks, at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 1 year, at least about 2 years, at least about 3 years, at least about 4 years, at least about 5 years, or longer) after administration of the unit dose of rAAV particles to one eye. In some embodiments, the unit dose of rAAV particles is administered to the contralateral eye at least about 2 weeks after the unit dose of rAAV particles is administered to one eye, and the unit dose of rAAV particles administered to the individual's contralateral eye is higher (e.g., any of about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 125%, about 150%, about 175%, about 200%, about 225%, about 250%, about 275%, about 300% or more higher) than the unit dose of rAAV particles administered to the individual's one eye.

[0258] In some embodiments, the unit dose of rAAV particles is administered to the contralateral eye of the individual at most about 1 week, at most about 2 weeks, at most about 3 weeks, or at most about 4 weeks after the unit dose of rAAV particles is administered to one eye. In some embodiments, the unit dose of rAAV particles is administered to the contralateral eye of the individual at most about 2 weeks (e.g., about 0 days, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, or 14 days) after the unit dose of rAAV particles is administered to one eye. In some embodiments, the unit dose of rAAV particles is administered to the individual's contralateral eye up to about 2 weeks (e.g., about 0 days, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, or 14 days) after the unit dose of rAAV particles is administered to one eye, and the unit dose of rAAV particles administered to the individual's contralateral eye is approximately the same (e.g., less than 1% higher or lower, less than 5% higher or lower, less than 10% higher or lower, or less than 20% higher or lower) or lower (e.g., about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% lower) as compared to the unit dose of rAAV particles administered to the individual's one eye. In some embodiments, the unit dose of rAAV particles is administered to the contralateral eye of the individual up to about 2 weeks after the unit dose of rAAV particles is administered to one eye, and the unit dose of rAAV particles administered to the contralateral eye of the individual is approximately the same as the unit dose of rAAV particles administered to the one eye of the individual (e.g., less than 1% higher or lower, less than 5% higher or lower, less than 10% higher or lower, or less than 20% higher or lower). In some embodiments, the unit dose of rAAV particles is administered to the contralateral eye of the individual up to about 2 weeks after the unit dose of rAAV particles is administered to one eye, and the unit dose of rAAV particles administered to the contralateral eye of the individual is lower (e.g., about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% lower) than the unit dose of rAAV particles administered to the one eye of the individual.

[0259] In some embodiments, a unit dose of rAAV particles is administered to one eye and / or the contralateral eye of an individual. In some embodiments, a unit dose of rAAV particles is expressed as the number of vector genomes (vg). In some embodiments, a unit dose is about 6×10 11 In some embodiments, the unit dose is about 1×10 10 to about 2×10 10 vg, about 2×10 10 to about 3×1010 vg, about 3×10 10 to about 4×10 10 vg, about 4×10 10 to about 5×10 10 vg, about 5×10 10 to about 6×10 10 vg, about 6×10 10 to about 7×10 10 vg, about 7×10 10 to about 8×10 10 vg, about 8×10 10 to about 9×10 10 vg, about 9×10 10 to about 10×10 10 vg, about 1×10 11 to about 2×10 11 vg, about 2×10 11 to about 3×10 11 vg, about 3×10 11 to about 4×10 11 vg, about 4×10 11 to about 5×10 11 vg or about 5×10 11 to about 6×10 11 In some embodiments, the unit dose is about 6×10 10 vector genomes (vg) to approximately 2 × 10 11 In some embodiments, the unit dose is about 6×10 10 vg is about 2×10 11 vg, about 7×10 10 vg is about 2×10 11 vg, about 8×10 10 vg is about 2×10 11 vg, about 9×10 10 vg is about 2×10 11 vg, about 10×10 10 vg is about 2×10 11 vg or about 1×10 11 vg is about 2×10 11 In some embodiments, the unit dose is about 6×10 10 vg is about 2×10 11 In some embodiments, the unit dose is about 6×10 10 vg is about 7×1010 vg, about 7×10 10 vg is about 8×10 10 vg, about 8×10 10 vg to about 9×10 10 vg, about 9×10 10 vg to about 10×10 10 vg, about 10×10 10 vg is about 1×10 11 vg or about 1×10 11 vg is about 2×10 11 In some embodiments, the unit dose is about 6×10 10 vg, about 7×10 10 vg, about 8×10 10 vg, about 9×10 10 vg, about 10×10 10 vg, about 1×10 11 vg or about 2×10 11 In some embodiments, the unit dose is about 6×10 10 vg or about 2×10 11 In some embodiments, the unit dose is about 6×10 10 In some embodiments, the unit dose is about 6×10 10 vg, about 2×10 11 vg or about 6×10 11 In some embodiments, the unit dose is about 6×10 10 In some embodiments, the unit dose is about 2×10 11 In some embodiments, the unit dose is about 6×10 11 vg.

[0260] In some embodiments, a unit dose of rAAV particles is administered to one eye and / or the contralateral eye of an individual. In some embodiments, the unit dose is expressed as the number of vector genomes (vg) per eye (vg / eye). In some embodiments, the unit dose is approximately 6×10 11 vg / eye or less rAAV particles. In some embodiments, the unit dose is about 1×10 10 to about 2×10 10 vg, about 2×10 10 to about 3×10 10 vg, about 3×10 10 to about 4×10 10 vg, about 4×10 10to about 5×10 10 vg, about 5×10 10 to about 6×10 10 vg, about 6×10 10 to about 7×10 10 vg, about 7×10 10 to about 8×10 10 vg, about 8×10 10 to about 9×10 10 vg, about 9×10 10 to about 10×10 10 vg, about 1×10 11 to about 2×10 11 vg, about 2×10 11 to about 3×10 11 vg, about 3×10 11 to about 4×10 11 vg, about 4×10 11 to about 5×10 11 vg or about 5×10 11 to about 6×10 11 vg / eye, including any value within these ranges. In some embodiments, the unit dose is about 6×10 10 vg / eye is about 2×10 11 vg / eye of rAAV particles. In some embodiments, the unit dose is about 6×10 10 vg / eye is about 2×10 11 vg / eye, about 7×10 10 vg / eye is about 2×10 11 vg / eye, about 8×10 10 vg / eye is about 2×10 11 vg / eye, about 9×10 10 vg / eye is about 2×10 11 vg / eye, about 10×10 10 vg / eye is about 2×10 11 vg / eye or about 1×10 11 vg / eye is about 2×10 11 vg / eye of rAAV particles. In some embodiments, the unit dose is about 6×10 10 vg / eye is about 2×10 11 vg / eye of rAAV particles. In some embodiments, the unit dose is about 6×10 10 vg / eye is about 7×10 10 vg / eye, about 7×10 10vg / eye is about 8×10 10 vg / eye, about 8×10 10 vg / eye is about 9×10 10 vg / eye, about 9×10 10 vg / eye is about 10×10 10 vg / eye, about 10×10 10 vg / eye is about 1×10 11 vg / eye or about 1×10 11 vg / eye is about 2×10 11 vg / eye of rAAV particles. In some embodiments, the unit dose is about 6×10 10 vg / eye, about 7×10 10 vg / eye, about 8×10 10 vg / eye, about 9×10 10 vg / eye, about 10×10 10 vg / eye, about 1×10 11 vg / eye or about 2×10 11 vg / eye of rAAV particles. In some embodiments, the unit dose is about 6×10 10 vg / eye or about 2×10 11 vg / eye of rAAV particles. In some embodiments, the unit dose is about 6×10 10 vg / eye of rAAV particles. In some embodiments, the unit dose is about 6×10 10 vg / eye, about 2×10 11 vg / eye or about 6×10 11 vg / eye. In some embodiments, the unit dose is about 6×10 10 vg / eye. In some embodiments, the unit dose is about 2×10 11 vg / eye. In some embodiments, the unit dose is about 6×10 11 vg / eyes.

[0261] In some embodiments, a unit dose of rAAV particles is administered to one eye and / or the contralateral eye of an individual. In some embodiments, E is an abbreviation for a decimal power, and xEy refers to x multiplied by the y power / exponent of a decimal number. In some embodiments, the unit dose is expressed as the number of vector genomes (vg). In some embodiments, the unit dose is about 6E 11 In some embodiments, the unit dose is about 1E 10 to about 2E 10 vg, about 2E 10 to about 3E10 Between vg, about 3E 10 to about 4E 10 Between vg, about 4E 10 to about 5E 10 Between vg, about 5E 10 to about 6E 10 Between vg, about 6E 10 to about 7E 10 Between vg, about 7E 10 to about 8E 10 Between vg, about 8E 10 to about 9E 10 Between vg, about 9E 10 to about 10E 10 Between vg, about 1E 11 to about 2E 11 Between vg, about 2E 11 to about 3E 11 Between vg, about 3E 11 to about 4E 11 Between vg, about 4E 11 to about 5E 11 vg or about 5E 11 to about 6E 11 In some embodiments, the unit dose is about 6E 10 vector genomes (vg) to approximately 2E 11 In some embodiments, the unit dose is about 6E 10 vg to about 2E 11 vg, about 7E 10 vg to about 2E 11 vg, about 8E 10 vg to about 2E 11 vg, about 9E 10 vg to about 2E 11 vg, about 10E 10 vg to about 2E 11 vg or about 1E 11 vg to about 2E 11 In some embodiments, the unit dose is about 6E 10 vg to about 2E 11 In some embodiments, the unit dose is about 6E 10 vg to about 7E 10 vg, about 7E 10 vg to about 8E 10 vg, about 8E10 vg to about 9E 10 vg, about 9E 10 vg to about 10E 10 vg, about 10E 10 vg to about 1E 11 vg or about 1E 11 vg to about 2E 11 In some embodiments, the unit dose is about 6E 10 vg, about 7E 10 vg, about 8E 10 vg, about 9E 10 vg, about 10E 10 vg, about 1E 11 vg or about 2E 11 In some embodiments, the unit dose is about 6E 10 vg or about 2E 11 In some embodiments, the unit dose is about 6E 10 In some embodiments, the unit dose is about 6E 10 vg, about 2E 11 vg or about 6E 11 In some embodiments, the unit dose is about 6E 10 In some embodiments, the unit dose is about 2E 1...

Claims

1. A method for reducing fluctuations in central subfield thickness (CST) or central retinal thickness (CRT) in an eye of an individual suffering from an ocular neovascular disease, the method comprising administering a unit dose of rAAV particles to one eye of the individual, wherein the individual is a human, and wherein the rAAV particles comprise: a) a nucleic acid encoding a polypeptide flanked by AAV2 inverted terminal repeats (ITRs), the polypeptide comprising an amino acid sequence having at least about 95% identity to the amino acid sequence of SEQ ID NO: 35, and b) an AAV2 capsid protein comprising the amino acid sequence LGETTRP (SEQ ID NO: 14) inserted between positions 587 and 588 of said capsid protein, wherein said amino acid residue numbering corresponds to that of the AAV2 VP1 capsid protein.

2. The method of claim 1, wherein the individual has been treated with at least one anti-VEGF agent within about 1 to 12 weeks prior to administration of the unit dose of rAAV particles.

3. The method of claim 1 or claim 2, wherein the fluctuating levels of CST or CRT in the one eye of the individual are refractory to previous treatment with an anti-VEGF agent.

4. The method of claim 2 or claim 3, wherein the anti-VEGF agent is aflibercept.

5. The method of claim 1, wherein the fluctuating level of CST or CRT in the one eye of the individual is reduced by about 40% to about 90% after administering the rAAV particles in the one eye compared to the fluctuating level of CST or CRT in the one eye of the individual before administering the rAAV to the individual.

6. The method of claim 5, wherein the reduction is from about 45% to about 85%.

7. The method of claim 5, wherein the reduction is from about 50 to about 90%.

8. The method of any one of claims 1-7, wherein the unit dose of rAAV particles is about 6 x 10 10 About 6 x 10 11 vector genomes / eye (vg / eye) or less.

9. The method of claim 10, wherein the rAAV particles are about 2 x 10 11 vg / eye or 6x 10 11 .

10. A method for improving visual acuity in an individual suffering from an ocular neovascular disease, the method comprising: (a) administering an anti-VEGF agent to one eye of the individual; as well as (b) administering approximately 6×10 10 About 6×10 11 A unit dose of a recombinant adeno-associated virus (rAAV) particle containing 1 vector genome (vg) or less, wherein the individual is a human, and wherein the rAAV particle comprises: (i) a nucleic acid encoding a polypeptide flanked by AAV2 inverted terminal repeats (ITRs), the polypeptide comprising an amino acid sequence having at least about 95% identity to the amino acid sequence of SEQ ID NO: 35, and (ii) an AAV2 capsid protein comprising the amino acid sequence LGETTRP (SEQ ID NO: 14) inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to the AAV2 VP1 capsid protein.

11. The method of claim 10, comprising administering the unit dose of rAAV particles to the one eye of the individual about 1 to about 12 weeks after administration of the anti-VEGF agent.

12. The method of claim 10 or claim 11, comprising administering the anti-VEGF agent to the one eye of the individual on day 1, and administering the unit dose of rAAV particles to the one eye of the individual on day 8.

13. The method of any one of claims 10-12, wherein the anti-VEGF agent comprises aflibercept.

14. The method of claim 13, wherein the aflibercept is administered by intravitreal injection at a dose of about 2 mg.

15. The method of any one of claims 1-14, wherein the unit dose of rAAV particles is about 6×10 10 About 6×10 11 between vector genomes / eye (vg / eye).

16. The method of any one of claims 1-15, wherein the unit dose of rAAV particles is about 6×10 10 About 2×10 11 between vector genomes / eye (vg / eye).

17. The method of any one of claims 1-16, wherein the unit dose of rAAV particles is about 2×10 11 About 6×10 11 between vector genomes / eye (vg / eye).

18. The method of claim 17, wherein the unit dose of rAAV particles is about 2×10 11 or about 6×10 11 vector genomes / eye (vg / eye).

19. The method of claim 18, wherein the unit dose of rAAV particles is about 2×10 11 vector genomes / eye (vg / eye).

20. The method of claim 18, wherein the unit dose of rAAV particles is about 6×10 11 vector genomes / eye (vg / eye).

21. The method of any one of claims 1-20, wherein the individual has one or more symptoms of an ocular neovascular disease in the fellow eye.

22. The method of any one of claims 1-21, further comprising administering a unit dose of rAAV particles to the contralateral eye of the individual.

23. The method of claim 22, wherein administering the unit dose of rAAV particles to the fellow eye is at most about 2 weeks after administering the unit dose of rAAV particles to the one eye.

24. The method of claim 23, wherein: (a) administering the unit dose of rAAV particles to the fellow eye on the same day as administering the unit dose of rAAV particles to the one eye; or (b) administering the unit dose of rAAV particles to the fellow eye is between about 1 day and about 14 days after administering the unit dose of rAAV particles to the one eye.

25. The method of claim 23 or claim 24, wherein the unit dose of rAAV particles administered to the contralateral eye of the individual comprises the same or fewer vector genomes / eye (vg / eye) than the unit dose of rAAV particles administered to the one eye of the individual.

26. The method of claim 22, wherein administering the unit dose of rAAV particles to the fellow eye is at least about 2 weeks after administering the unit dose of rAAV particles to the one eye.

27. The method of claim 26, wherein the unit dose of rAAV particles administered to the contralateral eye of the individual comprises more vector genomes / eye (vg / eye) than the unit dose of rAAV particles administered to one eye of the individual.

28. The method of any one of claims 1-27, wherein the nucleic acid comprises the nucleic acid sequence of SEQ ID NO: 40 or a sequence at least 85% identical thereto.

29. The method of any one of claims 1-28, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:

35.

30. The method of any one of claims 1-29, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:

41.

31. The method of any one of claims 1-30, wherein the polypeptide is aflibercept.

32. The method of any one of claims 1-31, wherein the nucleic acid further comprises a first enhancer region, a promoter region, a 5'UTR region, a second enhancer region, and a polyadenylation site.

33. The method of any one of claims 1 to 32, wherein the nucleic acid comprises, in 5' to 3' order: (a) the first enhancer region; (b) promoter region; (c) 5'UTR region; (d) a nucleic acid encoding a polypeptide comprising an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO: 35; (e) a second enhancer region; and (f) polyadenylation site; and flanked by AAV2 inverted terminal repeats (ITRs).

34. The method of claim 32 or claim 33, wherein the first enhancer region comprises a CMV sequence comprising the sequence of SEQ ID NO: 22 or a sequence at least 85% identical thereto.

35. The method of any one of claims 32-34, wherein the promoter region comprises a CMV sequence comprising the sequence of SEQ ID NO: 23 or a sequence at least 85% identical thereto.

36. The method of any one of claims 33-35, wherein the polypeptide-encoding nucleic acid comprises the nucleic acid sequence of SEQ ID NO: 40 or a sequence at least 85% identical thereto.

37. The method of any one of claims 33-36, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 35, or a sequence at least 95% identical thereto.

38. The method of any one of claims 33-37, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 41, or a sequence at least 95% identical thereto.

39. The method of any one of claims 33-38, wherein the polypeptide is aflibercept.

40. The method of any one of claims 32-39, wherein the 5'UTR region comprises, in 5' to 3' order, a TPL sequence comprising a sequence of SEQ ID NO: 24 or a sequence having at least 85% identity thereto, and an eMLP sequence comprising a sequence of SEQ ID NO: 25 or a sequence having at least 85% identity thereto.

41. The method of any one of claims 32-40, wherein the second enhancer region comprises a complete EES sequence comprising the sequence of SEQ ID NO: 26 or a sequence at least 85% identical thereto.

42. The method of any one of claims 32-41, wherein the polyadenylation site comprises an HGH polyadenylation site comprising the sequence of SEQ ID NO: 27 or a sequence at least 85% identical thereto.

43. The method of any one of claims 1-31, wherein the nucleic acid further comprises (a) a first enhancer region comprising a CMV sequence comprising a sequence of SEQ ID NO:22, or a sequence at least 85% identical thereto; (b) a promoter region comprising a CMV sequence comprising a sequence of SEQ ID NO:23, or a sequence at least 85% identical thereto; (c) a 5'UTR region comprising, in 5' to 3' order, a TPL sequence comprising a sequence of SEQ ID NO:24, or a sequence at least 85% identical thereto, and an eMLP sequence comprising a sequence of SEQ ID NO:25, or a sequence at least 85% identical thereto; (d) a second enhancer region comprising a complete EES sequence comprising a sequence of SEQ ID NO:26, or a sequence at least 85% identical thereto; and (e) an HGH polyadenylation site comprising a sequence of SEQ ID NO:27, or a sequence at least 85% identical thereto.

44. The method of any one of claims 1-43, wherein the nucleic acid comprises the sequence of SEQ ID NO: 39 or a sequence at least 85% identical thereto.

45. The method of any one of claims 1-44, wherein the AAV2 capsid protein comprises the amino acid sequence LALGETTRPA (SEQ ID NO: 1) inserted between positions 587 and 588 of the capsid protein, wherein the amino acid residue numbering corresponds to the AAV2 VP1 capsid protein.

46. ​​The method of any one of claims 1-45, wherein the AAV2 capsid protein comprises the amino acid sequence LGETTRP (SEQ ID NO: 14) inserted between positions 587 and 588 of the AAV2 VP1 comprising the sequence of SEQ ID NO:

13.

47. The method of any one of claims 1-46, wherein the AAV2 capsid protein comprises the amino acid sequence LALGETTRPA (SEQ ID NO: 1) inserted between positions 587 and 588 of the AAV2 VP1 comprising the sequence of SEQ ID NO:

13.

48. The method of any one of claims 1-45, wherein the rAAV particle comprises an AAV2 VP1 capsid protein comprising a GH loop comprising the amino acid sequence of SEQ ID NO:38 or an amino acid sequence having at least 90% sequence identity to SEQ ID NO:

38.

49. The method of any one of claims 1-48, wherein administering the unit dose of rAAV particles to the one eye and / or the fellow eye is performed by intravitreal administration.

50. The method of any one of claims 1-49, wherein the unit dose of rAAV particles is in a pharmaceutical formulation.

51. The method of claim 50, wherein the pharmaceutical formulation comprises the rAAV particles, sodium chloride, sodium phosphate, and a surfactant.

52. The method of claim 51, wherein the pharmaceutical formulation comprises about 150 to about 200 mM sodium chloride, about 1 to about 10 mM sodium dihydrogen phosphate, about 1 to about 10 mM sodium dihydrogen phosphate, about 0.0005% (w / v) to about 0.005% (w / v) poloxamer 188, and about 6×10 13 About 6×10 10 The invention relates to rAAV particles comprising 1 vector genome (vg) / mL (vg / mL), wherein the pharmaceutical formulation has a pH of about 7.0 to about 7.

5.

53. The method of claim 52, wherein the pharmaceutical formulation comprises about 180 mM sodium chloride, about 5 mM sodium dihydrogen phosphate, about 5 mM sodium dihydrogen phosphate, about 6×10 12 vg / mL of the rAAV particles and about 0.001% (w / v) poloxamer 188, wherein the pharmaceutical formulation has a pH of about 7.

3.

54. The method of claim 52, wherein the pharmaceutical formulation comprises about 180 mM sodium chloride, about 5 mM sodium dihydrogen phosphate, about 5 mM sodium dihydrogen phosphate, about 2×10 12 vg / mL of the rAAV particles and about 0.001% (w / v) poloxamer 188, wherein the pharmaceutical formulation has a pH of about 7.

3.

55. The method of claim 52, wherein the pharmaceutical formulation comprises about 180 mM sodium chloride, about 5 mM sodium dihydrogen phosphate, about 5 mM sodium dihydrogen phosphate, about 6×10 11 vg / mL of the rAAV particles and about 0.001% (w / v) poloxamer 188, wherein the pharmaceutical formulation has a pH of about 7.

3.

56. The method of any one of claims 1-55, wherein the unit dose of rAAV particles administered to the one eye and / or the contralateral eye is in a volume of about 25 μL to about 250 μL.

57. The method of claim 56, wherein the unit dose of rAAV particles administered to the one eye and / or the contralateral eye comprises a volume of about 100 μL.

58. The method of claim 56, wherein the unit dose of rAAV particles administered to the one eye and / or the contralateral eye comprises a volume of about 30 μL.

59. The method of any one of claims 1-58, wherein the individual received prior treatment for the ocular neovascular disease with an anti-VEGF agent.

60. The method of claim 59, wherein the individual has received 1 or 2 injections of an anti-VEGF agent in the one eye and / or the fellow eye prior to administering the rAAV particles in the one eye and / or the fellow eye.

61. The method of any one of claims 1-60, wherein the individual has not received prior treatment for the ocular neovascular disease with an anti-VEGF agent.

62. The method of any one of claims 59-61, wherein the anti-VEGF agent is aflibercept.

63. The method of any one of claims 1-62, wherein the ocular neovascular disease is wet age-related macular degeneration (AMD), retinal neovascularization, choroidal neovascularization diabetic retinopathy, proliferative diabetic retinopathy, retinal vein occlusion, central retinal vein occlusion, branch retinal vein occlusion, diabetic macular edema, diabetic retinal ischemia, ischemic retinopathy, diabetic retinal edema, or any combination thereof.

64. The method of any one of claims 1-63, wherein the unit dose of rAAV particles is administered in combination with steroid therapy.

65. The method of claim 64, wherein the steroid therapy is corticosteroid therapy.

66. The method of claim 64 or claim 65, wherein the steroid therapy is systemic steroid therapy.

67. The method of any one of claims 64-66, wherein the steroid therapy is oral steroid therapy.

68. The method of any one of claims 64-67, wherein the steroid therapy is prednisone therapy.

69. The method of claim 64 or claim 65, wherein the steroid treatment is a topical steroid treatment.

70. The method of claim 69, wherein the steroid therapy is difluprednate therapy.

71. The method of any one of claims 64-70, wherein the steroid is administered before, during, and / or after administration of the unit dose of rAAV particles to the one eye and / or the contralateral eye.

72. The method of any one of claims 69-71, wherein the steroid treatment is a topical steroid treatment, and the topical steroid treatment is a daily steroid treatment for up to about 4 weeks, up to about 6 weeks, or up to about 8 weeks from administration of the unit dose of rAAV particles.

73. The method of claim 72, wherein the topical steroid treatment comprises applying the topical steroid about four times per day in about week 1, about three times per day in about week 2, about twice per day in about week 3, and about once per day in about week 4; timed from and after administration of the unit dose of rAAV particles.

74. The method of claim 72, wherein the topical steroid treatment comprises applying the topical steroid about four times a day for about 3 weeks, followed by applying the topical steroid about 3 times a day for about 1 week, followed by applying the topical steroid about 2 times a day for about 1 week, and followed by applying the topical steroid about once a day for about 1 week after administering the unit dose of rAAV particles.

75. The method of claim 72, wherein the topical steroid treatment comprises applying the topical steroid about four times a day for about four weeks, followed by applying the topical steroid about three times a day for about one week, followed by applying the topical steroid about twice a day for about one week, and followed by applying the topical steroid about once a day for about one week; starting about one week prior to administering the unit dose of rAAV particles.

76. The method of any one of claims 10-63, further comprising administering a topical steroid treatment.

77. The method of claim 76, wherein the topical steroid treatment is difluprednate treatment.

78. The method of claim 76 or claim 77, wherein the topical steroid treatment comprises applying the topical steroid about four times a day for about four weeks, followed by applying the topical steroid about three times a day for about one week, followed by applying the topical steroid about twice a day for about one week, and followed by applying the topical steroid about once a day for about one week; timing from and after administration of the anti-VEGF agent.

79. The method of any one of claims 70-78, wherein the topical steroid comprises difluprednate 0.05% in a dose of about 1 μg to about 3 μg.

80. The method of any one of claims 70-79, wherein the topical steroid comprises difluprednate 0.05% at a dose of about 2.5 μg.

81. The method of any one of claims 1-80, wherein administration of the unit dose of rAAV particles to the one eye and / or the fellow eye of the individual results in maintenance or reduction of the retinal thickness compared to the retinal thickness prior to administration of the unit dose of rAAV particles.

82. The method of claim 81, wherein administering the unit dose of rAAV particles to one eye and / or the contralateral eye of the individual results in a reduction in retinal thickness compared to retinal thickness prior to administration of the unit dose of rAAV particles.

83. The method of claim 82, wherein the retinal thickness is reduced by at least about 10% compared to the retinal thickness prior to administration of the unit dose of rAAV particles.

84. The method of any one of claims 81-83, wherein the retinal thickness is central subfield thickness (CST) or central retinal thickness (CRT).

85. The method of any one of claims 1-84, wherein administration of the unit dose of rAAV particles to the one eye and / or the fellow eye of the individual results in maintenance or reduction of the macular volume compared to the macular volume prior to administration of the unit dose of rAAV particles.

86. The method of claim 85, wherein administration of the unit dose of rAAV particles to the one eye and / or the fellow eye of the individual results in a reduction in the macular volume compared to the macular volume prior to administration of the unit dose of rAAV particles.

87. The method of claim 86, wherein the macular volume is reduced by at least about 10% compared to the macular volume prior to administration of the unit dose of rAAV particles.

88. The method of any one of claims 1-87, wherein administration of the unit dose of rAAV particles to the one eye and / or the fellow eye of the individual results in maintenance or improvement of the visual acuity compared to the visual acuity prior to administration of the unit dose of rAAV particles.

89. The method of claim 88, wherein administration of the unit dose of rAAV particles to the one eye and / or the fellow eye of the individual results in an improvement in the visual acuity compared to the visual acuity prior to administration of the unit dose of rAAV particles.

90. The method of claim 88 or claim 89, wherein the visual acuity is best corrected visual acuity (BCVA).

91. The method of any one of claims 1-90, wherein administering the unit dose of rAAV particles to the one eye and / or the fellow eye of a plurality of individuals results in at least about 50% of the plurality of individuals not requiring anti-VEGF rescue therapy.

92. The method of claim 91, wherein at least about 50% of the plurality of individuals do not require anti-VEGF rescue therapy for at least about 20 weeks, at least about 36 weeks, at least about 52 weeks, at least about 56 weeks, or longer after administration of the unit dose of rAAV particles.

93. The method of any one of claims 1-90, wherein administering the unit dose of rAAV particles to the one eye and / or the fellow eye of a plurality of individuals results in at least about 67% of the plurality of individuals not requiring anti-VEGF rescue therapy.

94. The method of claim 93, wherein at least about 67% of the plurality of individuals do not require anti-VEGF rescue therapy for at least about 20 weeks, at least about 36 weeks, at least about 52 weeks, at least about 60 weeks, at least about 64 weeks, or at least about 66 weeks after administration of the unit dose of rAAV particles.

95. The method of any one of claims 1-90, wherein administering the unit dose of rAAV particles to the one eye and / or the fellow eye of a plurality of individuals results in at least about 78% of the plurality of individuals not requiring anti-VEGF rescue therapy.

96. The method of claim 95, wherein at least about 78% of the plurality of individuals do not require anti-VEGF rescue therapy for at least about 20 weeks, at least about 36 weeks, or longer after administration of the unit dose of rAAV particles.

97. The method of any one of claims 1-90, wherein administering the unit dose of rAAV particles to the one eye and / or the fellow eye of a plurality of individuals results in 100% of the plurality of individuals not requiring anti-VEGF rescue therapy.

98. The method of claim 97, wherein 100% of the plurality of individuals do not require anti-VEGF rescue therapy for at least about 64 weeks, at least about 68 weeks, at least about 72 weeks, at least about 76 weeks, at least about 80 weeks, at least about 84 weeks, or longer after administration of the unit dose of rAAV particles.

99. The method of any one of claims 1-98, wherein administration of the unit dose of rAAV particles to the one eye and / or the fellow eye of the plurality of individuals results in a reduction in the annualized anti-VEGF injection rate by at least about 80%, at least about 85%, at least about 87%, at least about 90%, at least about 95%, at least about 99%, or 100%, compared to the annualized anti-VEGF injection rate prior to administration of the unit dose of rAAV particles.

100. The method of any one of claims 1-99, wherein the ocular neovascular disease is wet age-related macular degeneration (AMD).

101. The method of any one of claims 1-100, wherein the ocular neovascular disease is diabetic macular edema (DME).

102. The method of claim 101, wherein administration of the unit dose of rAAV particles to the one eye and / or the fellow eye of the individual results in a 2-step or 3-step improvement on the Diabetic Retinopathy Severity Scale (DRSS).

103. A method for treating an ocular neovascular disease in an individual comprising about 6×10 of a recombinant adeno-associated virus (rAAV) particle. 11 vector genomes (vg) or less, the method comprising administering the unit dose to one eye of the individual, wherein the individual is a human, and wherein the rAAV particle comprises: a) a nucleic acid encoding a polypeptide flanked by AAV2 inverted terminal repeats (ITRs), the polypeptide comprising an amino acid sequence having at least about 95% identity to the amino acid sequence of SEQ ID NO: 35, and b) an AAV2 capsid protein comprising the amino acid sequence LGETTRP (SEQ ID NO: 14) inserted between positions 587 and 588 of said capsid protein, wherein said amino acid residue numbering corresponds to that of the AAV2 VP1 capsid protein.

104. A unit dose of rAAV particles for use in a method for reducing fluctuations in CST or CRT in an eye of an individual suffering from an ocular neovascular disease, the method comprising administering the unit dose to an eye of the individual, wherein the individual is a human, and wherein the rAAV particles comprise: a) a nucleic acid encoding a polypeptide flanked by AAV2 inverted terminal repeats (ITRs), the polypeptide comprising an amino acid sequence having at least about 95% identity to the amino acid sequence of SEQ ID NO: 35, and b) an AAV2 capsid protein comprising the amino acid sequence LGETTRP (SEQ ID NO: 14) inserted between positions 587 and 588 of said capsid protein, wherein said amino acid residue numbering corresponds to that of the AAV2 VP1 capsid protein.

105. The unit dose for use according to claim 104 or claim 105, wherein the method further comprises administering an anti-VEGF agent to the one eye of the individual prior to administering the unit dose.